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2. Abbreviations  
 
 
ACTB  ?-actin 
AP-1   activator protein 1 
BSA    bovine serum albumin 
CCL   chemokine (C-C motif) ligand 
CD    cluster of differentiation 
cDNA  complementary DNA 
CTSK  cathepsin k 
CXCL  chemokine (C-X-C motif) ligand 
CX3CL  chemokine (C-X3-C motif) ligand 
DAMP  danger-associated molecular pattern 
DNA   deoxyribonucleic acid 
ECM   extracellular matrix 
EFG    epidermal growth factor 
FBS    fetal bovine serum 
Fc    fold change 
FGF    fibroblast growth factor 
FLT    fms-like tyrosine kinase 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
G-CSF  granulocyte colony-stimulating factor  
GM-CSF  granulocyte-macrophage colony-stimulating factor 
GO   gene ontology 
HMGB1  high-mobility group box 1 
HSP   heat-shock protein 
HXLPE   highly cross-linked polyethylene 
IFN    interferon 
IL    interleukin 
IL-1ra  interleukin-1 receptor antagonist 
IRF    interferon regulatory factor 
LPS   lipopolysaccharide 
LTA    lipoteichoic acid 
MAL   MyD88 adaptor-like 
MAPK   mitogen-activated protein kinases 
M-CSF  macrophage colony-stimulating factor 
MHC   major histocompatibility complex 
MMP   matrix metalloproteinase 
MyD88   myeloid differentiation factor 88 
NFAT  nuclear factor of activated T cells 
NF-?B   nuclear factor kappa-light-chain-enhancer of activated B cells 
NE     neutrophil elastase  
OPG    osteoprotegerin 
OSM   oncostatin M 
PAMP   pathogen-associated molecular pattern  
PBGD   porphobilinogen deaminase 
PBMC   peripheral blood mononuclear cells  
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PBS   phosphate-buffered saline 
PGE2  prostaglandin E2 
PI3K   phosphoinositide 3-kinase 
PMMA   polymethyl methacrylate 
PPAR?  peroxisome proliferator-activated receptor-? 
PRR   pattern recognition receptor 
qRT-PCR  quantitative real-time polymerase chain reaction 
RANK    receptor activator of nuclear factor kappa B 
RANKL   receptor activator of nuclear factor kappa B ligand 
RNA   ribonucleic acid  
RPLP0  large ribosomal protein P0 
sCD40L  soluble cluster of differentiation 40 ligand 
sIL-2r?  soluble interleukin-2 receptor alpha 
SPIA   signaling pathway impact analysis 
STAT  signal transducer and activator of transcription 
TGF    transforming growth factor 
Th    T helper cell 
THR   total hip replacement 
TIR    toll-interleukin 1 receptor 
TLR    toll-like receptor 
TNF    tumor necrosis factor 
TNFSF  tumor necrosis factor super family  
TRAM   TRIF-related adaptor molecule 
TRAP    tartrate-resistant acidic phosphatase 
TRIF   TIR domain–containing adaptor inducing interferon-? 
UHMWPE  ultra high molecular weight polyethylene  
VEGF  vascular endothelial growth factor 
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3. Abstract 
 
Treatment of patients suffering from end-stage hip arthritis was revolutionized in the 
late 1950s by the development of modern total hip replacement (THR). This operation 
effectively alleviates pain and improves function of these patients; unsurprisingly, the 
demand for THR surgery has been rapidly increasing.  Despite the fact that the clinical 
outcome of THR surgery is typically excellent and that THR is generally considered one 
of the most successful surgical interventions, THR is not without complications. Its two 
main complications are implant infection, also known as septic loosening, and long-term 
aseptic implant loosening. In both cases, the bone originally surrounding the implant is 
resorbed, and the implant loosens, necessitating revision operations which are costly, 
technically demanding, and are causes of morbidity and even mortality. Despite new, 
more durable implant materials and advances  in surgical technique, the THR revision 
numbers have been on a  steady increase, closely following the increase in  primary THR 
operation numbers and widening of the primary operation indications to include younger 
and more active patients. 
Traditionally, septic and aseptic joint replacement loosening has been considered 
two separate entities, in which septic loosening is due to chronic inflammation caused by 
bacterial infection of implant components, whereas aseptic loosening is driven by a 
foreign body reaction against about 1-µm biomaterial wear particles that are generated due 
to abrasion between THR components. According to this particle-disease hypothesis, these 
wear particles are released into peri-implant tissues where they are phagocytosed by 
macrophages. The macrophages respond to this foreign material by producing an array of 
inflammatory mediators causing the local micro-environment to favor formation of 
osteoclasts and active bone resorption which ultimately leads into implant loosening. The 
fundamental events in the pathogenesis of aseptic loosening thus are wear-particle 
recognition, phagocytosis, and subsequent macrophage activation to the inflammatory 
phenotype. The exact mechanisms by which biomaterial particles are recognized by 
macrophages and how their phagocytosis leads to macrophage activation have, however, 
remained elusive, as has the fundamental question of why implant loosening develops in 
only a relatively small proportion of patients, even though all hip replacements generate 
wear particles. 
During the last decade, the strict dichotomy between septic and aseptic loosening 
has been increasingly questioned. For instance, subclinical bacterial biofilms occur in at 
least in some cases of apparently aseptic impant loosening. Likewise, pro-inflammatory 
and osteolytic properties of wear particles depend at least partially on the presence of 
bacterial components adhering to their surfaces. These observations lead to the hypothesis 
that recognition of bacterial product-coated wear particles and subsequent activation of 
interface tissue macrophages into the inflammatory phenotype might be mediated by 
macrophages Toll-like receptors (TLRs).  
TLRs are a family of pattern recognition receptors that recognize various exo- and 
endogenous danger-signal molecules and mediate macrophage activation. We evaluated 
the extent to which the various TLRs occur and how they localize in the aseptic interface 
tissues by using immunohistochemistry and qRT-PCR. The direct effect of wear particles 
on TLR levels we then evaluated in an animal model of wear-particle-induced 
inflammation and in a macrophage culture system. In hopes of identifying cell populations 
potentially useful as diagnostic markers of subclinical implant-related infection, cell 
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populations occurring in typical septic and aseptic interface tissue were evaluated by use 
of cell-type specific antibodies and immunohistochemistry.  
Macrophages and foreign body giant cells of aseptic interface tissue expressed 
TLR1-9 and actively produced all of these, except TLR3 and TLR7. Based on the 
literature it seems likely that TLRs, especially TLR2, TLR2/1, TLR2/6, TLR4, and TLR9, 
are involved in wear-particle recognition and subsequent macrophage activation either by 
directly binding to the particles’ polymeric surfaces or to metal ions released from the 
implant but probably more likely via recognition of exo- or endogenous danger signal 
molecules adhering to particle surfaces. In a mouse model of particle-induced 
inflammation, wear particles led  to down-regulation rather than to up-regulation of TLR 
levels, and had no effect on TLR mRNA levels in the mouse macrophage culture system. 
Up-regulation of TLRs in aseptic interface tissue is thus likely mediated by factors other 
than a direct effect of wear particles on macrophages. Comparison of inflammatory cell 
populations present in septic and aseptic interface tissues revealed that, in addition to 
neutrophils, B lymphocytes and plasma cells might serve as useful marker cells in the 
diagnosis of low-grade implant-related infection. 
Macrophages are a functionally dynamic and adaptive population of cells that can 
assume various functional phenotypes as guided by signals from the local micro-
environment. Differing macrophage phenotypes express various levels of TLRs and other 
pattern-recognition receptors and have fundamentally differing abilities to produce pro-
inflammatory and chemotactic mediators. We thus further hypothesized that this 
macrophage phenotype, or macrophage polarization, may be an important determinant of 
the way that macrophages react to wear particles. To test this hypothesis, we differentiated 
M0, M1, and M2 macrophages from human monocytes and compared their responses to 
titanium-particle stimulus using genome-wide microarray analysis and a multiplex 
cytokine assay. 
In comparison to non-activated M0 macrophages, the overall chemotactic and 
inflammatory responses to wear particles was greatly enhanced in M1 macrophages and 
effectively suppressed in M2 macrophages, which effectively contained particles in 
intracellular compartment. Results suggest that in addition to wear-particle characteristics 
and biomolecules adhering to particle surfaces, the local cytokine milieu also determines 
the extent to which macrophages are activated by wear particles.This effect may have been 
due to differing expression of TLRs or other pattern-recognition receptors between these 
macrophage types. Limiting the action of M1-polarizing factors such as bacterial biofilm 
formation in the interface tissue and perhaps also promoting M2 macrophage polarization 
by biomaterial solutions or pharmacologically might thus limit osteolysis resulting from 
inevitably forming wear particles. Interesting is also the emerging hypothesis that the low-
grade inflammation at systemic level associated, for example, with obesity and 
atherosclerosis, might be a determinant in the general systemic M1-M2 balance of 
macrophages and thus in the susceptibility of an individual to develop aseptic osteolysis. 
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4. Introduction 
 
Since its development in the late 1950s, total hip replacement (THR) has been a 
successful  treatment  for  patients  suffering  from end-stage  hip  joint  arthritis.  The  clinical  
outcomes  of  the  operation  are  generally  excellent  and  the  demand  for  THR  surgery  has  
been rapidly increasing (Ethgen et al 2004, OECD Health data 2011, Skyttä et al 2011). 
The two main complications of THR are implant infection, also known as septic 
loosening, and aseptic loosening. In both cases, the bone originally surrounding the 
implant is resorbed, and the implant loosens, necessitating technically demanding revision 
operations. Despite the advances in implant materials and in surgical techniques, THR 
revision numbers have been on a steady increase (Kurtz et al 2005, Bozic et al 2009, 
National agency for Medicines 2009). 
Traditionally, septic and aseptic prosthesis loosening has been considered two 
separate entities, in which septic loosening is due to chronic inflammation caused by 
bacterial infection of joint replacement components (Zimmerli et al 2004). In contrast, 
aseptic loosening is driven by a foreign body reaction against biomaterial wear particles 
that are generated due to abrasion between THR components (Goodman et al 2009, Gallo 
et al 2012). These wear particles are in the peri-implant tissues phagocytosed by 
macrophages which are induced to produce an array of inflammatory mediators causing 
the local micro-environment to favor formation of osteoclasts and active bone resorption 
(Ingham and Fisher 2005, Konttinen et al 2005). Wear-particle-induced macrophage 
activation to the inflammatory phenotype is thus considered a fundamental event in the 
pathogenesis of aseptic loosening but the exact mechanisms of this wear-particle-induced 
macrophage activation have remained elusive. 
Toll-like  receptors  (TLRs)  are  a  family  of  ten  pattern  recognition  receptors  which  
recognize various pathogen-derived molecules such as lipoteichoic acid (LTA) and 
lipopolysaccharide (LPS, Kawai and Akira 2010). In addition, endogenous TLR ligands, 
released because of cell necrosis and extracellular matrix (ECM) damage, appear to exist 
(Bianchi 2007, Kono and Rock 2008). Collectively, these TLR ligands are known as 
danger-associated molecular patterns (DAMP); recognition of a DAMP molecule by TLR 
and subsequent TLR signaling mediates macrophage activation and production of 
inflammatory mediators (Gordon 2003). 
In addition to this TLR-mediated macrophage activation, macrophages can assume 
distinct activation phenotypes as a response to the local cytokine microenvironment (Ma 
et al 2003, Mosser and Edwards 2008). Reflecting the concept and following the 
nomenclature of CD4+ T helper (Th) lymphocyte polarization into Th1 and Th2 cells, a 
corresponding concept has been established of functional macrophage polarization into 
M1 and M2 macrophages, or “classically” and “alternatively” activated macrophages. M1 
macrophages are an inflammatory macrophage phenotype that is especially related to Th1 
response and immunity against intracellular pathogens, whereas M2 macrophages are 
related to a wide range of physiological and pathological processes such as allergy, 
parasite immunity, tissue healing, homeostasis, and fibrosis (Schroder et al 2004, Martinez 
et al 2009). 
During the last decade, the strict dichotomy between septic and aseptic joint 
replacement loosening has been increasingly questioned (Nelson et al 2005). For example, 
recent observations are that wear particles are relatively inert, cause only limited 
macrophage activation and osteolysis, and have their inflammatory properties largely 
dependent on bacterial structural components adhering to their surfaces (Greenfield et al 
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2005). These observations lead to the hypothesis that recognition of DAMP-coated wear 
particles and following activation of interface tissue macrophages into the inflammatory 
phenotype might be mediated by macrophages’ TLRs. Additionally, as M1 and M2 
macrophages express different levels of TLRs and have dissimilar abilities to produce 
inflammatory mediators, we further hypothesized that macrophage polarization might be 
an important determinant in the way that macrophages react to wear particles. 
The present study aimed to evaluate the possible presence and localization of 
various TLRs in the aseptic interface tissue and to discover whether wear particles directly 
regulate TLR levels in a mouse model of wear-particle-induced inflammation and in a 
macrophage culture system. In hopes of identifying cell populations potentially useful as 
diagnostic markers of subclinical implant-related infection, we characterized cell 
populations occurring in typical septic and aseptic interface tissue. Additionally, the aim 
was to discover whether macrophage polarization affects macrophage wear-particle 
responses. 
12 
 
 
5. Review of the literature 
 
5.1. Total hip replacement 
 
5.1.1. Hip replacement designs and materials   
Treatment of patients suffering from end-stage hip arthritis was revolutionized in the 
late 1950s and early 1960s by the development of modern THR by British orthopedic 
surgeon Sir John Charnley. The original Charnley THR was composed of a stainless-steel 
femoral component and an acetabular cup made of ulta high molecular-weight 
polyethylene (UHMWPE), that formed a low-friction and relatively durable articulation 
(Charnley 1961). Hip replacement components were firmly fixed to the surrounding bone 
with polymethyl methacrylate (PMMA, bone cement). Charney’s THR design was 
superior to other contemporary hip replacement solutions, which failed primarily due to 
poor design and unfortunate material choices; his THR design rapidly gained popularity 
(Learmonth et al 2007). Since then, some major improvements to original Charnley hip 
replacement design (such as more wear-resistant implant materials) and surgical 
techniques (such as modern cementing techniques) have been introduced and new hip 
replacement  designs  (such  as  uncemented  THR)  emerged.  The  basic  principles  of  
Charnley “low-frictional torque arthroplasty” have, however, remained largely the same 
for 50 years (Charnley 1970, Learmonth et al 2007). 
 A typical modern THR implant is composed of three separate parts: a cup, a head, 
and a stem. The head is attached to the femoral intramedullary stem, and the cup and the 
head articulate in a ball-and-socket fashion closely mimicking the normal hip joint 
anatomy  (Figure  1).  The  cup-part  is  either  a  single  component  or  a  composite  of  two  
separate parts, an outer metal shell facing the bony acetabulum and an inner liner forming 
the actual articulating surface of the implant (modular cup). The femoral component is 
also typically modular so that the intramedullary stem and the articulating head of the joint 
are separate components, possibly made of different materials. During the THR operation, 
the femoral head and part of the femoral neck are removed and the acetabulum and 
femoral medullary canal reamed and cleaned. The cup of the THR implant is then inserted 
into the acetabulum and the stem into the reamed medullary canal of the femur. Fixation 
of the components to the surrounding bone is achieved either with PMMA (cemented 
implants) or by friction and the eventual growth of bone tissue directly onto the implants 
surface (uncemented implants). Based on mode of fixation, THR implants are classified 
into these two broad categories: cemented and uncemented. 
In cemented implants, fixation to bone is achieved by an additional layer of bone 
cement placed between the bone and the implant (Charnley 1964, Scheerlinck et al 2006, 
Hernigou et al 2009). If appropriately inserted under constant pressure, PMMA effectively 
seeps between the trabeculae of endosteal spongy bone and functions as a mechanical 
interlock between hip replacement components and bone. Cemented hip replacement 
stems are further divided into two fundamentally different design categories depending on 
mode of attachment to bone cement, namely a highly polished taper-slip / force-closed 
design and a composite beam / shape-closed design (Scheerlinck et al 2006). The idea for 
the former is that there is no firm adhesion between hip replacement and PMMA mantle 
and that the femoral stem is firmly pressed, and even is slowly forced to migrate, deeper 
into the PMMA mantle and femoral canal by continuous axial loading. The composite 
beam-design, in contrast, aims at firm attachment of the implant to the PMMA mantle via 
surface roughening and modifications. 
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Figure 1. An uncemented total hip replacement composed of three parts: a stem, a head, 
and a modular cup. The head is attached to the intramedullary femoral stem. The rounded 
head articulates with the acetabular cup in a ball-and-socket fashion closely mimicking 
normal hip joint anatomy. The implant is well fixed to the surrounding bone with no signs 
of osteolysis. 
 
In uncemented hip replacements, fixation is achieved initially by mere friction 
between implant components and the bone bed (Learmonth et al 2007). In this “press fit” 
or “friction fit” technique, the slightly over-sized implant components are tightly fitted 
into their corresponding bony sockets to achieve firm mechanical locking to the bone. 
Additionally, the surfaces of uncemented hip replacements are typically trabecular or 
porous; a firm secondary stabilization of the implant components occurs over time as bone 
grows directly onto the micro- or macroporous implant surface,  or in case of a tantalum 
surface, even into the trabecular surface itself. In some uncemented THR designs, the 
porous surface is further coated with osteoconductive material such as hydroxylapatite. 
THR implants can be further classified based on the material of their bearing 
surfaces (Learmonth et al 2007). Following the principles of the original Charnley hip 
replacement design, the stainless-steel head on an UHMWPE cup was the gold standard 
for a bearing surface for several decades. However, since recognition that extensive wear 
of the UHMWPE acetabular cup is the leading cause of osteolysis and aseptic loosening, 
more wear-resistant bearing surfaces have been vigorously sought. 
During the last decade, this research has led to development of first and second 
generation highly cross-linked polyethylene (HXLPE) plastics produced by gamma 
irradiation of UHMWPE. Compared to UHMWPE, HXLPE acetabular liners have greatly 
reduced wear rates; accordingly, traditional UHMWPE, although still used in some hip 
replacement designs, has been largely replaced by HXPLE as the material of choice for 
acetabular liners (Muratoglu et al 2001).  
Stainless steel is a still widely used material for the femoral head and stem for 
cemented hip replacements, although alternative metal alloys have also emerged, such as 
cobalt-chromium-molybdenum. Titanium alloy, composed typically of titanium, 
aluminum, and vanadium, is the usual material of choice for femoral stems and the outer 
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shell of the acetabular cup in uncemented hip replacements, but due to its relative softness 
and low wear resistance, it is not suited for use as a bearing surface.  
The search for more wear-resistant bearing surfaces has also led to the development 
of metal-on-metal (typically various cobalt-chromium alloys), ceramic-on-ceramic 
(typically alumina or zirconia ceramics), and ceramic-on-HXLPE bearings, which have 
greatly reduced wear rates in comparison to traditional metal-on-UHMWPE bearings but 
which present other possible problems, such as fractures of brittle ceramic components 
(Jeffers and Walter 2012). In particular; the surprisingly high failure rates and the release 
of high and systemically detectable levels of metal ions and nano-sized metal particles 
from meta-on-metal implants, has recently led to much concern (Zywiel et al 2011, Cohen 
2012, Smith et al 2012).  
New, still more wear-resistant and biocompatible bearing-surface materials, such as 
amorphous diamond are being developed but have not yet reached clinical use (Alakoski 
et al 2008). 
 
5.1.2. Indications for THR operation 
About 60 to 80% of THR operations are performed for primary osteoarthritis of the 
hip joint and 5 to 10% for rheumatoid arthritis (Havelin et al 2000, Lucht 2000, Furnes et 
al 2001, Puolakka et al 2001, Pedersen et al 2005, National agency for Medicines 2009, 
Fevang et al 2010, Hailer et al 2010). Other less-common indications for THR surgery 
include trauma, tumors, and secondary osteoarthritis with various causes such as avascular 
necrosis of the femoral head or developmental dysplasia of the hip. The number of THRs 
performed for rheumatoid arthritis has been decreasing, likely due to the increased 
effectiveness of immunosuppressive therapies, whereas operation numbers for 
osteoarthritis have shown a steady increase (da Silva et al 2003, Weiss et al 2005, Fevang 
et al 2007).  Definitive indications for THR are not well established but often include, in 
addition to demonstration of typical degenerative changes in hip radiographs, continuous 
hip pain, loss of mobility, and considerable disability, all refractory to conservative 
treatment including adequate pain medication, physiotherapy and weight reduction (Zhang 
et al 2005, 2008, Malmivaara et al 2007).  
 
5.1.3. Incidence of THR operations 
The number of THR operations performed annually has been increasing steadily and 
quite rapidly during the past two decades in all western countries (Havelin et al 2000, 
Lucht 2000, Puolakka et al 2001, Ostendorf et al 2002, Wells et al 2002, Dixon et al 2004, 
Kurtz et al 2005, Pedersen et al 2005). In OECD countries, for example, a 25% increase in 
the incidence of THR operations occurred between 2000 and 2009 (OECD Health data 
2011).  Similarly in Finland, the number of THR operations performed annually increased 
from about 5000 in 1996 to over 8000 in 2006 (National agency for Medicines 2009). 
Since then, operation numbers in Finland have plateaued and even slightly declined, with 
7400 THR operations performed in 2010 (Perälä 2010). Especially noteworthy is the 
dramatic increase in the THR operation nubers done on relatively young patients; In the 
Finnish population, the incidence of THR opearions tripled (30 vs. 90 /100 000) between 
1980 and 2007 in patients aged 50 to 59, likely due to broadening indications for surgery 
(Skyttä et al 2011). 
Currently, the overall incidence of THR operations in western countries exceeds 
150/100 000, ranging from 93 in Spain to 296 in Germany (OECD Health data 2011). 
Based  on  these  figures,  estimates  are  that  the  impressive  number  of  1  million  THR  
operations are currently performed globally each year. The number of operations is 
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expected to continue to increase, partially due to population aging and a related increased 
prevalence of osteoarthritis, and also due to widening THR surgery indications (Birrell et 
al 1999). According to an estimate based on the US population, the demand for THR 
operations will increase as much as 174%, reaching almost 600 000 THR operations per 
year in the US alone, by 2030 (Kurtz et al 2007). 
 
5.1.4. Outcomes of THR operation  
Since its introduction, THR surgery has become hugely successful, and it can well 
be said that THR has revolutionized treatment of end-stage, disabling arthritis. The 
Finnish Medical Society Duodecim’s journal Duodecim recently highlighted artificial 
joints as one of the “twelve wondrous achievements of modern medicine” comparable to 
antibiotics, organ transplants, and x-rays (Ylikorkala el al 2011). Outcome studies over the 
years have consistently shown that THR operations are a reliable and effective means to 
manage the pain and disability of end-stage arthritis patients (Fitzpatrick et al 1998, 
Ethgen et al 2004). Typically, a considerable decrease in pain and improvement in ability 
to function occurs post-operatively, as well as recovery of health-related quality of life to 
the level of control populations (Wiklund and Romanus 1991, O’Boyle et al 1992, 
Fitzpatrick et al 1998, Lucht 2000, Söderman et al 2001, Ethgen et al 2004, Malchau et al 
2005,  Rolfson  et  al  2011).  The  majority  of  patients  are  satisfied  with  their  outcome and  
return to their previous work (Nunley et al 2011). Thus, it is not surprising that THR is 
also among the most cost-efficient surgical interventions of modern medicine, despite the 
operation’s relatively high cost (Quintana et al 2006, Räsänen et al 2007). 
 
5.1.5. Revision THR operations 
Although THR is accepted as a reliable and very cost-effective means to treat end-
stage arthritis, and its functional outcomes are good, the operation is not without 
complications. Although there exists considerable variation between THR-survival rates, 
in 10 to 20 years after the primary operation, typically between 5 and 20% of the inserted 
THRs require a revision (Kavanagh et al 1994, Furnes et al 2001, Puolakka 2001, Berry et 
al 2002, Older 2002, Malchau et al 2005, Mäkelä et al 2008a, 2008b, Corbett et al 2010, 
Hailer et al 2010,). Especially in younger, more active patients, long-term survival of hip 
replacements is limited, and risk for long-term implant loosening considerable (Callaghan 
et al 1998, Lucht 2000, Older 2002, Corbett et al 2010). These revision THR operations 
are often technically demanding and expensive, and show clinical outcomes poorer than 
for the primary THRs.  
Despite new and more durable hip replacement materials and advancements in 
surgical technique, the demand for revision THR operations has shown a steady increase 
during the last two deacades (Dixon et al 2004, Pedersen et al 2005, Marshall et al 2008, 
National agency for Medicines 2009). For example, in the US between 1990 and 2002, the 
incidence of revision THRs increased from 9.5 to 15.2/100 000. Likewise in England 
between 1991 and 2001, revision THR numbers doubled (Dixon et al 2004, Kurtz et al 
2005). Finland currently has about 1000 THR revision operations annually, and although 
the revision numbers have remained about the same for the last decade, they are, based on 
similar trends in other western countries, expected to double in the next 10 to 20 years 
(National agency for Medicines 2009). This increase in revision THR operation numbers 
likely reflects the increasing numbers of primary operations performed and also the fact 
that the primary operations have been increasingly performed on younger and more active 
patients. 
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Most revision operations are performed because of aseptic (40-60%) or septic (10%) 
loosening of hip replacement components, although recurrent dislocation of the hip 
replacement (15%) is also one of the main reasons for revision operations (Lucht 2000, 
Puolakka 2001, Ulrich et al 2007, Bozic et al 2009, National agency for Medicines 2009). 
 
5.2. Septic loosening of THRs 
 
5.2.1. Definition, epidemiology, diagnosis 
Septic loosening of THR refers to osteolysis and loosening primarily caused by 
bacterial infection of hip replacement components (Zimmerli et al 2004). Implant-related 
infection is a severe complication of THR surgery, which often necessitates removal of an 
infected implant and long-term antibiotic treatment before a new implant can be inserted, 
resulting in considerable expense and morbidity (Zimmerli et al 2004). Accordingly, 
extensive measures are undertaken to prevent this devastating complication. Currently, the 
risk for developing infection after THR is less than 1% (Phillips et al 2006, Pulido et al 
2008, Huotari et al 2010, Jämsen et al 2010).  
Recognized risk factors for implant-related infections include both surgery-related 
factors like duration of the operation and patient-related factors like smoking, diabetes 
with high blood glucose, and obesity (Jämsen et al 2010). About half the infections are 
caused by coagulase-negative staphylococci such as Staphylococcus epidermidis, and by 
Staphylococcus aureus. Other less commonly encountered pathogens include 
streptococcus and, in a minority of cases, gram-negative bacteria such as enterococci, 
Escherichia coli, Pseudomonas aeruginosa, or even more rarely anaerobic bacteria 
(Bernard at al 2004, Sia et al 2005, Phillips et al 2006, Esposito and Leone 2008, Pulido et 
al 2008). Based on the clinical picture and time of apparent onset, post-operative joint 
replacement infections are classically divided into three groups: early (occurring <3 
months post-operatively), delayed (3-24 months after surgery), and late (>24 months 
afterwards) (Coventry 1975, Zimmerli et al 2004). 
Early implant infections are caused by virulent bacteria like Staphylococcus aureus 
that gain access to the implant during, or immediately after, the primary surgery. Bacteria 
of high virulence can reach the joint replacement via hematogenous spread from body 
surfaces even years after the primary surgery and cause acute joint-replacement infection 
(late, acute infections). In both instances, the patient typically presents with both local and 
systemic signs and symptoms of an acute infection including fever, hip pain, and apparent 
surgical site infection with local cellulitis, and occasionally even formation of a sinus 
track with a purulent discharge (Zimmerli et al 2004, Sia et al 2005, Trampuz and Widmer 
2006).  
Diagnosis of this type of acute, early or late, joint replacement infection rarely offers 
particular difficulties, whereas diagnosis of delayed, low-grade implant infections may 
present considerable challenges. Such infections are typically caused by slow-growing 
bacteria of relatively low virulence but having the ability to effectively form implant-
related biofilms (for example coagulase-negative staphylococci) (Zimmerli et al 2004, Sia 
et al 2005, Trampuz and Widmer 2006). The clinical presentation of these infections is 
typically mild, with obvious symptoms and signs of infection often absent. The patient 
typically presents with chronic hip pain and possibly with loosening of THR components, 
as evident in radiography.  
As the clinical presentation of low-grade joint replacement infection is not self-
evident and also overlaps with aseptic osteolysis, several attempts have been made to 
develop reliable diagnostic methods for such infections. Routine laboratory blood tests 
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including white blood cell count, C-reactive protein, and erythrocyte sedimentation rate, 
although often elevated during acute joint replacement infection, are rarely useful in the 
diagnosis of low-grade infection due to their low sensitivity (Bernard et al 2004, Zimmerli 
et al 2004, Sia et al 2005, Esposito and Leone 2008, Berbari et al 2010). Similarly, plain 
radiographs have low sensitivity and specificity in these cases. 
Preoperative joint fluid aspirates, sometimes taken repeatedly, are a commonly used 
method in evaluation of suspected low-grade joint-replacement infection. Gram’s staining 
and bacterial culture of aspirated synovial fluid have high specificity but low sensitivity 
(Bernard et al 2004, Zimmerli et al 2004, Sia et al 2005, Esposito and Leone 2008). In 
contrast, increased synovial fluid leukocyte count and an increased proportion of 
neutrophils in the differential count have high sensitivity and specificity for implant-
related infection and have thus shown great promise as a practical diagnostic tool for low-
grade hip- and knee-replacement infection (Spangehl et al 1999, Trampuz et al 2004, 
Ghanem et al 2008, Schinsky et al 2008, Cipriano et al 2012). 
The gold standard for diagnosis of implant-related infection, peri-implant-tissue 
bacterial culture, is subject to false-positive results due to skin contaminants. The risk for 
these false-positives is reduced and an almost 100% specificity achieved if the same 
bacteria can be cultured from more than two peri-implant tissue samples (Zimmerli et al 
2004, Sia et al 2005, Bauer et al 2006, Esposito and Leone 2008). The major weakness of 
peri-implant bacterial cultures is, however, that the method is also subject to false-
negative results; bacteria causing low-grade implant infections typically grow slowly and 
poorly, at least in culture, and they also attach firmly to the implant surface, so that at any 
time point only small number of bacteria are released into tissues. Accordingly, peri-
implant bacterial cultures have relatively low sensitivities ranging from 60 to 94% for 
diagnosis of implant-related infection (Zimmerli et al 2004, Sia et al 2005, Bauer et al 
2006, Esposito and Leone 2008). Sensitivity of these intra-operative bacterial cultures is, 
furthermore, strongly affected by prior antibiotic treatment. 
In addition to intra-operative bacterial cultures, histopathological examination of 
peri-implant tissue samples is a common method for diagnosis of joint-replacement 
infection. Observation of acute inflammation in intra-operative frozen sections (defined as 
1-10 neutrophils per high-power field) has a specificity of more than 90% for implant 
infection but a very variable and generally low sensitivity (Lonner et al 1996, Pace et al 
1997, Della Valle et al 1999, Spangehl et al 1999, Banit et al 2002, Francés Borrego et al 
2006, Nuñez et al 2007, Bori G et al 2007, Kanner et al 2008). Histological examination is 
also challenging, because the amounts of inflammatory infiltrates can vary considerably 
between samples and between specific tissue areas examined and are also subject to 
interobserver variability.  
Several scintigraphy techniques using various radiolabeled markers of infection 
have also been developed for diagnosis of joint replacement infection, but at least thus far 
these methods have shown no particular advantage over joint fluid aspirates or peri-
implant bacterial cultures (Zimmerli et al 2004, Sia et al 2005, Bauer et al 2006). 
No currently available method for detection of implant-related infection offers 
completely satisfactory combination of high sensitivity, specificity, and practicality. Thus 
in clinical practice, diagnostic methods are combined to support clinical judgement and to 
confirm or rule out low-grade joint replacement infection. For example, the working group 
of the Musculoskeletal Infection Society has recently proposed that joint replacement 
infection exists when:  
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1) A sinus tract is communicating with the implant; or  
2) A pathogen is isolated by culture from at least two separate tissue or fluid samples from 
the affected prosthetic joint; or  
3) When four of the following six criteria exist:  
a) Elevated serum erythrocyte sedimentation rate and serum C-reactive protein 
concentration;  
b) Elevated synovial leukocyte count;  
c) Elevated synovial neutrophil percentage;  
d) Purulence in the affected joint;  
e) Isolation of a microorganism in one culture of periprosthetic tissue or fluid;  
f) More than five neutrophils per high-power field in five high-power fields in 
histological analysis of periprosthetic tissue at ×400 magnification;  
 
Implant infection may be present even with fewer than four of these criteria (Parvizi et al 
2011). 
 
5.2.2. Bacterial biofilm 
 Diagnostic and therapeutic difficulties typical for implant-related infection result 
mainly from formation of bacterial biofilm on the surface of implanted material (Costerton 
et al 1999, Trampuz et al 2003, Zimmerli et al 2004). Biofilms are complex multicellular 
and self-organizing structures resembling in many instances eukaryote multicellular 
organisms; bacteria in biofilms share metabolic pathways, communicate, and collectively 
regulate a multitude of physiological activities (Dunne 2002, Donlan 2002). Some 
biofilms even have fluid channels resembling primitive circulation and allow fluid and 
nutrition flow through the structure. Biofilm formation is a common property of 
prokaryote life found widely in different ecosystems, and is also typically utilized by 
common human pathogenic bacteria such as coagulase-negative staphylococci and 
Staphylococcus aureus (Donlan and Costerton 2002, Hall-Stoodley et al 2004). Likewise, 
these bacteria are able to attach to a wide variety of surfaces, including all currently used 
implant materials (Zimmerli and Sendi 2011). 
Bacteria in biofilm attach tightly to the underlying material or more specifically to 
its protein coating; they multiply and produce a polymeric extracellular matrix composed 
primarily of anionic polysaccharides that effectively protect them from environmental 
challenges and also the from host immune system including phagocytes, the complement 
system, and antibodies (Costerton et al 1999, Donlan and Costerton 2002, Zimmerli and 
Sendi 2011). This crippling of the host immune response is exemplified by the fact that 
less-virulent bacteria are able to cause considerable implant-related infection and, on the 
other hand, that the minimum number of microbes that can cause infection is dramatically 
reduced (Zimmerli and Sendi 2011).  
In addition to the host immune system, biofilms are resistant to antibiotics in part 
due to reduced penetration of antibiotics into biofilm, extreme microenvironmental 
conditions residing inside the biofilm (e.g. low pH), and also in part due to the presence of 
very slowly growing bacterial populations inside the structure (Donlan and Costerton 
2002, Dunne WM 2002, Hall-Stoodley et al 2004). Thus, although some parts of the 
biofilm may be lost due to the host immune response or antibiotic treatment, others prevail 
and cause repeated outbursts of infection necessitating implant removal to control the 
infection. Likewise, bacteria that grow on the surface of the implant inside the biofilm are 
not necessarily detected by conventional bacterial culture samples taken from the peri-
implant tissues (Trampuz et al 2007). 
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The natural course and prognosis of this kind of low-grade, biofilm-hidden implant 
infection is variable and currently poorly understood (Donlan and Costerton 2002). It has 
been postulated that such an infection may remain quiescent and go mostly undetected by 
the host immune system for years while low levels of bacteria released from the biofilm 
are causing low grade peri-implant inflammation and eventual osteolysis. As the biofilm-
hiden bacteria are easily missed by conventional bacterial culture methods, what has been 
speculated is that a quiescent joint replacement infection may produce a clinical picture 
overlapping or even indistinguishable from aseptic loosening (Nelson et al 2005). 
 
5.3. Aseptic loosening of THRs 
 
5.3.1. Definition  
Aseptic loosening of THRs refers to a sequence of events in which hip replacement 
that has remained stable and osseointegrated for an extended period of time, possibly even 
for a decade or two, becomes loosened, as the bone surrounding one or more of the THR 
components is resorbed. This resorbed bone is replaced with loose connective tissue 
heavily infiltrated with macrophages and foreign-body giant cells. This tissue is known as 
synovial membrane-like tissue or interface tissue.  
A patient suffering from aseptic loosening typically presents with hip pain and, in 
the most advanced cases, with mechanical instability and shortening of the corresponding 
lower extremity. Development of osteolytic lesions might, however, also be asymptomatic 
and does not necessarily lead to joint-replacement loosening. In these cases, osteolytic 
lesions that might be substantial become evident only in follow-up radiographs. This is 
typically the case with well-osseointegrated uncemented joint replacements, which may 
develop considerable osteolytic lesions while retaining their relatively firm fixation to 
remaining bone. 
Hip radiography shows osteolytic radiolucent lesions surrounding THR, and in the 
case of loosening, may reveal migration of the implant components. Treatment of choice 
is a revision operation in which loosened THR components and accompanying interface 
tissue are removed and replaced with new components. Bone defects left by the osteolytic 
lesions can make fixation of new joint replacement components a technical challenge. 
Osteolysis  and  aseptic  loosening  are  the  primary  long-term  complications  of  THR  
and the leading cause of revision operations, accounting for about two-thirds of THR 
revisions (Ulrich et al 2007, Bozic et al 2009, National Agency for Medicines 2009). 
Especially in younger patient groups, long-term THR survival is limited by aseptic 
loosening (Callaghan et al 1998, Older 2002, Corbett et al 2010).  
 
5.3.2. Mechanisms of aseptic loosening 
According to the traditional definition, loosening of the THR is termed aseptic when 
clinical signs or symptoms of an overt infection are absent, and the diagnostic criteria for 
septic loosening are unfulfilled, essentially meaning that no involvement of bacteria can 
be demonstrated in implant loosening or osteolysis (Holt et al 2007, Purdue et al 2007, 
Goodman et al 2009, Gallo et al 2012). Although it is often said that Charnley himself 
speculated that aseptic implant failures might be actually caused by subclinical infection, 
since his era, involvement of bacteria in the process of aseptic loosening has been 
excluded by definition, and other mechanisms of this phenomenon have been vigorously 
sought (Learmonth et al 2007). 
Suggested mechanisms of aseptic loosening include high oscillating joint fluid 
pressure, stress shielding, and micromotion between the implant and surrounding bone 
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(Sundfeldt et al 2006). The best established of these, however, is the “particle disease” 
theory (Willert and Semlitsch 1977, Harris 1995, 2001, Ingham and Fisher 2005, 
Konttinen et al 2005, Purdue et al 2006, 2007,  Holt et al 2007, Goodman et al 2009, Gallo 
et al 2012). Due to unavoidable abrasion between the hip replacement bearing surfaces 
and implant and bone, hip replacement components slowly wear and erode over time, and 
high amounts of foreign-material wear particles are released into the pseudosynovial fluid, 
surrounding tissues, or both. The exact size, shape, and chemical nature of these wear 
particles varies depending on their origin. Most commonly, however, they are UHMWPE 
particles released from the bearing surface as the femoral metal head slowly abrades the 
UHMWPE liner. Conventional, well-functioning UHMWPE cup liners show a mean 
linear wear rate of about 0.1 mm/year, leading to generation of a vast amount of 
UHMWPE particles (Ilchmann et al 1998, Sochart 1999, Dowd et al 2000, Dumbleton et 
al 2002). Metal-on-metal implants display considerably different wear behavior, with 
diminished  volumetric  wear  but  again  with  release  of  vast  amounts  of  nano-sized  metal  
particles and metal into the interface tissue (Doorn et al 1998, Jacobs and Hallab 2006). 
Additional wear-debris sources include fragmentation and delamination of PMMA 
surrounding the implant, as well as metal or ceramic particles released from alternative 
bearing surfaces or from implants surface modifications due to fretting wear (Harris 2001, 
Holt et al 2007, Purdue et al 2007, Goodman et al 2009).   
Particles released into the pseudosynovial fluid are distributed into the surrounding 
tissues by pressure waves generated in the fluid while the artificial joint is being used, and 
typically the interface tissue is highly loaded with biomaterial wear-particles of various 
types (Willert and Semlitsch 1977, Schmalzried et al 1992, Margevicius et al 1994, 
Maloney et al 1995, Hirakawa et al 1996). Retrieval analyses have shown that UHMWPE 
wear particles show considerable size and morphological variability, most commonly, 
however, being spheroids with mean diameter of about 0.5 to 0.7 µm and with the vast 
majority of particles being between 0.1 and 1 µm (Shanbhag et al 1994a, Campbell et al 
1995, Tipper et al 2000, Howling et al 2001, Koseki et al 2005).  
It is generally accepted that this high-wear particle load causes a foreign-body 
reaction, subsequent chronic low-grade inflammation, and ultimately osteolysis (Willert 
and Semlitsch 1977, Harris 1995, 2001, Ingham and Fisher 2005, Konttinen et al 2005, 
Purdue et al 2006, Holt et al 2007, Purdue et al 2007, Goodman et al 2009, Gallo et al 
2012). Massive macrophage infiltrates and formation of foreign-body giant cells as well as 
ostoclasts at the bone-soft tissue interface are hallmarks of the foreign body reaction, 
typically seen also in the interface tissue surrounding the loosening implant (Figure 2). 
The basic notion of the particle disease hypothesis is that the huge amount of wear 
particles generated are, in the forming interface tissue, phagocytosed by macrophages 
which respond to this foreign material by production of inflammatory cytokines, 
chemokines, and growth factors that lead to recruitment of further macrophages into the 
interface tissue via endothelial activation and chemotaxis. Further, macrophage-derived 
inflammatory mediators lead to local imbalance of the receptor activator of the nuclear 
factor-kB ligand (RANKL) and osteoprotegerin (OPG) system. This increased 
RANKL/OPG  ratio,  along  with  the  inflammatory  cytokines  produced,  creates  a  
microenvironment that favors osteoclastogenesis and osteolysis, finally leading to implant 
loosening (Figure 3). Additionally, chronic inflammation and macrophage activation in 
peri-implant tissues may lead to acidification of the interface tissue, to a pH sufficiently 
low to cause bone demineralization directly (Konttinen et al 2001). 
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Figure 2. Osteolytic lesions in aseptic loosening are composed of hypertrophic interface 
tissue typically from the implant side covered by pseudosynovial membrane. The 
underlying well-vascularized loose connective tissue is heavily infiltrated by macrophages 
organized into sheet-like formations. High amounts of metal, UHMWPE, or other wear 
particles are phagocytosed by macrophages.  Some of the macrophages have fused to form 
multinucleated foreign-body giant cells that often surround larger foreign bodies. 
Osteoclast formation and active bone resorption is observed at the soft tissue-bone 
interface 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The “particle disease” theory in brief: Macrophages are activated by wear 
particles to produce various chemokines and inflammatory mediators. Chemokines recruit 
additional monocytes into interface tissue, and inflammatory cytokines lead both directly 
and indirectly to increased ostoclastogenesis, bone resorption, and implant loosening. The 
exact mechanisms by which wear particles are recognized by macrophages and cause 
macrophage activation are poorly understood. TNF? - tumor necrosis factor alpha; IL - 
interleukin; CCL - chemokine (C-C motif) ligand;  RANKL - receptor activator of nuclear 
factor kappa B ligand; OPG - osteoprotegerin. 
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Several lines of evidence support this possible sequence of events. First, risk for 
developing aseptic osteolysis and implant loosening is directly proportional to the annual 
UHMWPE linear wear rates and to the corresponding dose of wear particles released into 
the peri-implant tissues (Sochart 1999, Han et al 1999, Dowd et al 2000, Dumbleton 2002, 
Wilkinson et al 2005, Emms et al 2010).  
Second, interface tissue is characterized by massive macrophage infiltrates and 
foreign body giant cells that typically contain large amounts of phagocytosed particulate 
material (Willert and Semlitsch 1977, Goldring et al 1983, Goodman et al 1989, Santavirta 
et al 1990, Jiranek et al 1993, Kim et al 1993, Boynton et al 1995, Goodman et al 1997, 
Goodman et al 1998). 
Third, numerous studies have characterized the inflammatory nature of interface 
tissue and documented the increased production of a large array of primarily macrophage-
derived pro-inflammatory cytokines, chemokines, and growth factors including tumor 
necrosis factor alpha (TNF?), interleukin (IL)-1?, IL-6, IL-8, macrophage colony-
stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-
CSF), vascular endothelial growth factor (VEGF), chemokine (C-C motif) ligand (CCL) 2, 
CCL3, and prostaglandin E2 (PGE2) in the interface tissue (Kim et al 1993, Sabokbar et al 
1995, Chiba et al 1994, Xu et al 1996, Ishiguro et al 1997,  Xu et al 1997, Goodman et al 
1998, 2010, Takei et al 2000, Lassus et al 2000, Stea et al 2000, Konttinen et al 2002, 
Spanogle et al 2006, Wang et al 2010). Interface tissue is furthermore characterized by 
increased production of several matrix metalloproteinases (MMPs) and cathepsin K that 
possibly participate in local tissue destruction or remodeling (Takagi et al 1994a, 1994b, 
1995, 1998, Konttinen et al 2001). Increased production of RANKL and decreased or 
unaltered production of OPG is also detectable in interface tissue, and this change in 
RANKL/OPR ratio is likely responsible for the formaton of osteoclasts and foreign body 
giant cells (Mandelin et al 2003, Clohisy et al 2003, Horiki et al 2004, Crotti et al 2004, 
Holding et al 2006, Wang et al 2010).  In agreement with these observations, 
pseudosynovial fluid from aseptically loosened implants induces formation of osteoclasts 
in vitro, an effect likely due to soluble RANKL contained in the fluid, because added OPG 
reduces osteoclast formation (Kim et al 2001, Mandelin et al 2005b).   
Fourth, in various animal model systems, various foreign material particles, 
including PMMA, UHMWPE, and titanium, cause osteolysis, accompanied by 
upregulation of inflammatory cytokines and an increased RANKL/OPG ratio (Goodman 
et al 1990, Spector et al 1990, Gelb et al 1994, Merkel et al 1999, Schwarz et al 2000a, 
Wooley et al 2002, Warme et al 2004, Masui et al 2005, Ren et al 2011).  This particle-
induced osteolysis can be reduced by inhibiting TNF? signaling either by use of a TNF?-
neutralizing antibody or by deleting the TNF receptor. These observations highlight the 
role of TNF? as a key mediator in osteolysis (Merkel et al 1999, Childs et al 2001a, 
2001b, Schwarz et al 2000b).  Likewise, in murine model systems, blocking of RANKL 
signaling either by a RANKL antibody or by OPG diminishes particle-induced osteolysis, 
which is also diminished in mice genetically lacking receptor RANK (Childs et al 2002, 
Ulrich-Vinther et al 2002, Yang et al 2002a, Goater et al 2002).  
Finally, in vitro studies have shown that monocyte-macrophages challenged with 
various types of wear particles are activated to produce a wide variety of pro-
inflammatory cytokines (TNF?, IL-1?, IL-6, PGE2), chemokines (IL-8, CCL2, CCL3), 
growth factors (VEGF, M-CSF, GM-CSF), and MMPs (MMP1, MMP2, MMP9) (Herman 
et al 1989, Murray et al 1990, Glant et al 1993, Shanbhag et al 1995, Maloney et al 1996, 
Blaine et al 1996, Nakashima et al 1998, 1999a, 1999b, Matthews et al 2000a, 2000b, 
Hatton et al 2003). They also show that supernatants from these cultures can induce 
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osteolysis in both in vitro and in vivo assays. The magnitude of the inflammatory and 
osteolytic  effect  depends  on  amount  and  volume  of  particles  as  well  as  on  their  shape,  
size, and exact biomaterial composition (Gelb et al 1994, Shanbhag et al 1994b, Haynes et 
al 1998, Green et al 1998, 2000, Yang et al 2002b, Sethi et al 2003, Ingram et al 2004).  
Further in vitro studies using other relevant cell types of interface tissue, namely 
fibroblasts and osteoblasts, have demonstrated that to some extent, wear particles directly 
and especially macrophage-derived pro-inflammatory cytokines up-regulate RANKL 
production from interface tissue fibroblasts and osteoblasts. This effect provides a direct 
link between wear-particle-induced macrophage activation and increased production of 
RANKL and subsequent osteoclastogenesis (Quinn et al 2000, Mandelin et al 2005a, Wei 
et al 2005, Sabokbar et al 2005, Koreny et al 2006).  Wear particles also directly suppress 
osteoblast  formation  and  function  and  to  some  extent  also  directly  up-regulate  RANKL  
production from osteoblasts, thus directly inhibiting bone formation and promoting its 
resorption (Dean et al 1999a, 1999b, Vermes et al 2000, 2001a, 2001b, Fritz et al 2002, 
Wang et al 2002, Pioletti et al 2002, Pioletti and Kottelat 2004). Likewise, wear particles 
are also able to directly activate interface tissue fibroblasts to produce inflammatory and 
chemotactic mediators as well as MMPs (Yao et al 1995, Manlapaz et al 1996, Yaszay et 
al 2001). 
Further insight into the mechanisms of aseptic loosening has come through genetic 
association studies demonstrating that risk for developing aseptic osteolysis is associated 
with certain polymorphisms in cytokines (TNF?, IL-6 transforming growth factor beta, 
TGF?), matrix metalloproteinases (MMP1, MMP2), and OPG, thus further highlighting 
the underlying inflammatory mechanisms of aseptic osteolysis and implant loosening (Del 
Buono et al 2012). 
 
5.3.3. Suspected role bacterial products in aseptic loosening 
 In recent years, the strict distinction between septic and aseptic hip replacement 
loosening has again been questioned, as bacterial structural products or even biofilms can 
be detected in at least some of the seemingly aseptic interface tissues and explanted 
implants, by means of special sampling methods such as the polymerase chain reaction, 
sonication of explanted implants, or prolonged bacterial cultures  (Tunney et al 1998 and 
1999, Nguyen et al 2002, Clarke et al 2004, Nelson et al 2005, Esteban et al 2008, 2012, 
Kobayashi et al 2008, Schäfer et al 2008, Sierra et al 2011,  Portillo et al 2012).  The most 
convincing support for this till-now unrecognized role of subclinical bacterial infection in 
pathogenesis of aseptic loosening comes from observations that occurrence of “aseptic” 
long-term hip-replacement loosening is reduced by use of  intra-operative antibiotic 
prophylaxis and antibiotic-loaded bone cement (Espehaug et al 1997, Engesaeter et al 
2003). 
Subsequent in vitro and in vivo studies have shown that the various wear particles 
are, in fact, relatively inert and cause only limited macrophage activation and osteolysis 
and that their inflammatory and osteolytic properties largely depend on bacterial structural 
components adhering to their surfaces (Ragab et al 1999, Daniels et al 2000, Bi et al 
2001a, 2001b, 2002, Brooks et al 2002, Cho et al 2002). Due to its easy-to-use and 
sensitive detection method (Limulus assay), bacterial LPS has, in most of these studies, 
served as a model for any bacterial-derived molecule that might adhere to and concentrate 
on wear-particle surfaces (Greenfield et al 2005). In an in vivo setting, in addition to 
subclinical biofilms, such bacterial structural components might find their way into the 
interface tissue via hematogenous spread, being originally released into circulation from 
minor infections in body surfaces such as periodontal tissue, skin, and urinary- and 
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gastrointestinal tracts. In interface tissue these bacterial products then adhere to, and 
concentrate on the hydrophobic surfaces of wear particles (Greenfield et al 2005). This 
hypothesis is supported by observations that LPS is periodically found in the circulation of 
healthy individuals and that at least in a mouse model of particle induced-osteolysis, LPS 
accumulates on the wear particles of the interface tissue (Xing et al 2006, Tatro et al 
2007).  Additionally, orthopedic implants may already be contaminated with variable 
amounts of LPS during the manufacturing process, a contamination difficult to remove by 
standard sterilization procedures (Ragab et al 1999, Bonsignore et al 2012). In agreement 
with these observations, LPS is detectable in at least some seemingly aseptic interface 
tissues (Nalepka et al 2006). There thus seems to be a clear overlap between low-grade hip 
replacement infection and aseptic loosening. 
 
5.4. Monocyte-macrophages 
 
5.4.1. General features 
 Macrophages were identified in the second half of the 19th century by Russian 
scientist Elie Metchnikoff, who, in addition to identifying and naming these cells, 
characterized their key function, phagocytosis, and described its role in both normal tissue 
homeostasis and in immunity (Gordon 2008, Kaufmann 2008). Metchnikoff received the 
1908 Nobel Prize in medicine for these discoveries, thus setting in motion vigorous 
research on innate immunity. Since then, it has become clear that macrophages are very 
versatile, multipurpose, and dynamic cells that play a key role in embryonic development, 
in normal tissue homeostasis, in orchestration of inflammation reaction, in activation of 
adaptive immunity, and in initiation as well as orchestration of tissue healing (Gordon 
2007). Likewise, aberrant macrophage function has been implicated in the pathogenesis of 
several major non-infectious but inflammatory disease groups including atherosclerosis, 
arthritis, and malignancies as well as several major infectious diseases (Kinne et al 2007, 
Solinas et al 2009, Murray and Wynn 2011b, Shalhoub et al 2011). In the context of 
foreign-body reactions to implanted biomaterials, macrophages are considered the main 
mediators of biomaterial and implant rejection (Ingham and Fisher 2005, Anderson et al 
2008). Discovery of pattern-recognition receptors (PRRs) during the past two decades has 
further highlighted the key role that macrophages play in both health and disease (Gordon 
2007). 
 Macrophages are professional phagocyte cells of the innate immune system. They 
are produced in red bone marrow and released into the circulation as precursors called 
monocytes, which home to various tissues under steady-state conditions and differentiate 
into mature macrophages under the guidance of various signals in the local micro-
environment (Geissmann 2010b, Galli et al 2011). Most tissues contain these highly 
specialized macrophage populations, termed resident macrophages, or M0 macrophages, 
that participate in normal tissue homeostasis, housekeeping, immunosurveillance, 
recognition of pathogen invasion, and sensing of sterile tissue damage (Murray and Wynn 
2011b). Collectively, this widespread network of tissue-resident macrophages is known as 
the mononuclear phagocyte system (Ross and Pawlina 2011a). 
 During acute tissue inflammation following neutrophil invasion, monocytes 
adhering to and transmigrating through activated endothelium form the second wave of 
the innate immune response. Once in the inflamed tissues, monocytes mature into 
macrophages which then, due to host- and pathogen derived micro-environmental signals, 
become activated and subsequently vigorously engage their effector functions which 
include phagocytosis of cell debris and pathogens as well as secretion of inflammatory 
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mediators: such macrophages are known as inflammatory, classically activated, or M1 
macrophages (Mosser and Edwards  2008). Once a tissue insult is cleared by the conjoint 
effort of neutrophils and macrophages, M1 macrophages switch their mode of function to 
support healing and regeneration: macrophages effective in these functions are known as 
regulatory, alternatively activated, or M2 macrophages (Mosser and Edwards 2008). If 
tissue insults cannot be cleared by the innate immunity, the inflammation persists, and the 
adaptive immunity is subsequently activated. 
Central features of macrophage function include phagocytosis of cell debris and 
invading pathogens as well as subsequent killing of phagocytosed pathogens by effective 
production of an array of microbicidal mediators (Gordon 2007, Mosser and Edwards 
2008, Murray and Wynn 2011b). Additionally, macrophages are effective secretory cells 
that participate in regulation of the inflammation reaction by carefully orchestrated 
secretion of both pro- and anti-inflammatory cytokines and chemokines. Subsequent tissue 
healing is, at least in part, attributable to various growth factors secreted by macrophages.  
Additional macrophage characteristics are considerable functional plasticity and 
phenotypical adaptability to various signals derived from the local micro-environment 
(Gordon 2007, Mosser and Edwards 2008, Galli et al 2011, Murray and Wynn 2011b). 
Rapid migration to the local lymph nodes and effective antigen presentation to the T 
lymphocytes in the context of sufficient expression of co-stimulatory molecules, and the 
subsequent activation of the adaptive immune response, are attributes that currently most 
clearly distinguish dendritic cells from macrophages (Geissmann et al 2010b). 
Nevertheless, macrophages also express major histocompatibility complex (MHC) I and II 
molecules and are able to present antigens to activated and immunocompetent T 
lymphocytes that reciprocally coordinate macrophage function by secreting interferon 
gamma (IFN?) or IL-4 (Geissmann et al 2010a). Macrophages are thus important effector 
cells in the cell-mediated arm of adaptive immunity. Equally, high expression of Fc-
receptors allows macrophages to effectively recognize antibody-opsonized pathogens and 
toxins; thus they function as effector cells also for the humoral arm of the adaptive 
immune system.  
 
5.4.2. Myeloid development and blood monocytes 
 Cells of monocyte-macrophage lineage originate from a self-renewing pool of 
multipotent hematopoietic stem cells residing in the red bone marrow (Geissmann 2010b). 
Hematopoietic stem cells give rise to common lymphoid and myeloid progenitors which 
then differentiate into mature lymphoid and myeloid lineage cells via successive 
commitment steps with increasingly restricted differentiation potential. Intermediates in 
this monocyte-macrophage hematopoietic development lineage include common myeloid 
progenitors, granulocyte-macrophage progenitors, monoblasts, promonocytes, and finally 
monocytes that are released into the circulation (Auffray et al 2009). This process of 
monocytopoiesis takes about 2 days and is dependent, at least in mice, on expression of 
the colony-stimulating factor 1 receptor, ligands of which are M-CSF and IL-32, while the 
role of other cytokines like GM-CSF is considered to be primarily modulatory (Auffray et 
al 2009). Several transcription factors have been identified in monocytopoiesis, the most 
important of which is PU.1 (Lawrence and Natoli 2011). Continuous high expression of 
PU.1 is required throughout monocytopoiesis, and it apparently defines monocyte-
macrophage cell identity (or the macrophage-specific global genomic landscape) by 
regulating available enhancer-binding sites on deoxyribonucleic acid (DNA). All other 
transcription factors regulating subsequent monocyte-macrophage differentiation and 
activation steps function in the general context defined by the PU.1. 
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 Monocytes account for 1 to 10% of circulating leukocytes (Auffray et al 2009). 
They remain in circulation for various periods, typically about 3 days (Ross and Pawlina 
2011a). In blood-smear preparations, monocytes are readily distinguishable from other 
mononuclear leukocytes by their relatively large size, lack of apparent granules, kidney-
shaped or indented nuclei, and their large cytoplasm-to-nucleus ratio (Ross and Pawlina 
2011a). For three decades, what has, however, been recognized is that monocytes are a 
heterogenous and functionally diverse population of cells (Gordon and Taylor 2005, 
Auffray et al 2009, Geissmann 2010b). About 5% of circulating monocytes represent 
tissue dendritic cell precursors, and the remaining 95% are “actual” monocytes that can be 
further divided into two broad categories based on morphological and functional features 
and specific cell-surface markers. The larger fraction, comprising about 90% of actual 
monocytes, is made up of large, “classical”, CD14+CD16- monocytes showing high 
phagocytic activity, a suppressed ability to produce pro-inflammatory cytokines, and a 
correspondingly higher tendency to produce anti-inflammatory cytokines in response to 
PRR stimulation.  The remaining monocyte fraction is formed by small “non-classical” 
CD14+CD16+ monocytes with a high inherent capacity to produce inflammatory cytokines 
and an enhanced ability for antigen presentation (Ziegler-Heitbrock 2007).  
 Despite the fact that the existence of these monocyte populations has been known 
for some time, they are still relatively poorly characterized, in particular, with their roles 
in health and disease poorly understood. According to an established model, CD14+CD16- 
monocytes home to tissues under steady state conditions and preferably differentiate into 
M0 or M2 macrophages, thus representing the precursors of resident macrophages, 
whereas CD14+CD16+ monocytes  home  primary  to  inflamed  tissues,  where  they  
differentiate preferably into M1 macrophages and inflammatory dendritic cells (Gordon 
and Taylor  2005, Auffray 2009, Geissmann 2010b). This model, although likely 
oversimplified, is supported by clinical observations that the circulating numbers of 
CD14+CD16+ monocytes increase during infectious and inflammatory disorders, and also 
by mouse studies in which corresponding murine inflammatory monocyte populations 
(often designated as Ly6+/Grl+ monocytes) are recruited to tissue in early stages of 
inflammation (Mizuno et al 2005, Arnold et al 2007, Auffray et al 2007, Nahrendorf et al 
2007, Ziegler-Heitbrock 2007). As inflammation evolves towards healing, Ly6-/Grl- 
monocytes, resembling human CD14+CD16- monocytes and with a more M2-like 
phenotype, are recruited into regenerating tissue; once there, they promote tissue healing 
and regeneration (Arnold et al 2007, Auffray et al 2007, Nahrendorf et al 2007).  
Tissue-resident macrophage populations may originate primary from blood 
CD14+CD16- monocytes.  This matter is, however, complicated by discoveries that at least 
some (Langerhans cells of the epidermis and microglia) tissue-resident macrophage or 
dendritic cell populations are self-renewing; under steady state conditions they repopulate 
themselves from the circulating monocyte pool, but only slowly, if at all (Merad et al 
2002, Ajami et al 2007). Thus, the complex dynamics of the monocyte-macrophage 
system, especially the origins and maintenance of tissue-resident macrophage populations, 
is still poorly understood. What is, however, generally agreed upon is that considerable 
infiltration of blood monocytes into peripheral tissues occurs during tissue inflammation 
(Gordon and Taylor 2005, Auffray et al 2009, Geissmann 2010b). 
 
5.4.3. Tissue-resident macrophages 
Macrophages are present in most tissues under steady state conditions as highly 
specialized and tissue-specific subpopulations, as exemplified by liver Kupffler cells, 
microglia of the central nervous system, histiocytes of the connective tissue, pulmonary 
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alveolar macrophages, and type B lining cells of the synovial tissue (Gordon and Taylor 
2005, Murray and Wynn 2011b). Resident macrophage populations can comprise as much 
as 10 to 20% of the total number of tissue cells. These tissue-specific resident macrophage 
populations participate both in general tissue housekeeping and in regulation and 
maintenance of the local tissue specific-micro-environment (Pollard 2009, Galli et al 
2011, Murray and Wynn 2011b).  
One of the most important functions of resident macrophages is clearance of the 
impressive number of apoptotic cell bodies (estimated to be more than >109 cells per day) 
created daily throughout the system (Elliott and Ravichandran 2010). This rapid migration 
to and recognition of apoptotic bodies, and the subsequent phagocytosis and digestion 
along the endolysosomic pathway is mediated by release of chemotactic mediators  from 
apoptotic cells and a specific set of cell-surface receptors, e.g. Bai1, Tim-4 and Stabilin-2 
expressed on macrophages (Elliott and Ravichandran 2010). Signaling via these receptors 
leads  to  production  of  anti-inflammatory  cytokines  like  IL-10  and  TGF?. This rapid 
clearance of apoptotic cells without inflammation is imperative for maintenance of 
immunological tolerance, as highlighted by the fact that inefficient removal of apoptotic 
bodies and subsequent secondary necrosis of these bodies has been linked to several 
different autoimmune diseases (Elliott and Ravichandran 2010). Likewise, tissue-resident 
macrophages participate in ECM turnover by secreting proteianases and in regulation of 
local cell growth and differentiation by secreting growth factors (Pollard 2009, Murray 
and Wynn 2011b, Galli et al 2011).  
Tissue-resident macrophages also continuously survey their environment for foreign 
bodies, pathogens, and other danger signals by means of various sets of cell-membrane, 
endosomal, and cytoplasmic receptors, including at least three sets of PRRs (including, 
importantly, TLRs) and a group of scavenger receptors, Fc-receptors, and complement 
receptors. These macrophage populations thus also form the first line of defense against 
invading pathogens and are important in initiating an inflammation reaction if activated in 
sufficient amounts by danger-signal molecules in a process known as macrophage 
activation (Murray and Wynn 2011b). 
 
5.4.4. Macrophage activation 
 Macrophage activation, also called innate macrophage activation to make it distinct 
from the full M1 macrophage phenotype, refers to a complex set of macrophage responses 
elicited by their recognition of invading microbes or other danger signals (Gordon 2003, 
Martinez et al 2008, Mosser and Edwards 2008). Currently, macrophage activation is best 
understood in the context of TLR signaling. In brief, TLRs recognize various microbial 
and also host-derived danger-signal molecules. Subsequent signaling through various 
TLRs leads to activation of inflammatory transcription factors including interferon 
regulatory factor (IRF) 5, mitogen-activated protein kinases (MAPK), activator protein 1 
(AP-1), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-?B), and 
possibly IRF3 (only TLR3 and TLR4) which are collectively responsible for the 
macrophage activation phenotype.   
Using genome-wide microarray transcription profiling and human macrophage 
cultures challenged by various types of bacteria (gram-positive, gram-negative, and 
mycobacterium) it has been possible comprehensively to characterize   the shared 
transcriptome changes induced by these three types of bacteria (Boldrick et al 2002, Nau 
et al 2002, Jenner and Young 2005). These transcriptome changes, now collectively 
known as the macrophage activation program, consist of about 200 genes induced or 
suppressed in response to these bacterial challenges. Induced genes of the activation 
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program include pro-inflammatory cytokines and chemokines, membrane receptors, 
adhesion molecules, intracellular signaling components of PRRs, MMPs, and also 
reciprocal activation of anti-inflammatory factors that limit macrophage activation in the 
manner of negative feed-back loop (Boldrick et al 2002, Nau et al 2002, Jenner and Young 
2005). 
Importantly, the vast majority of transcriptional changes in a macrophage activation 
program induced in response to whole bacteria can be induced also by isolated bacterial 
structural components (LTA, LPS, lipoarabinomannan) which are ligands for different 
TLRs, thus indicating that the macrophage activation program actually is primarily formed 
by TLR-responsive elements, whereas the role of various other macrophage receptors 
seems, in comparison, rudimentary (Nau et al 2002).  
 
5.4.5. Macrophage polarization 
 In addition to innate activation induced by TLR signaling, macrophages can assume 
distinct activation phenotypes as a response to the local cytokine microenvironment. 
Reflecting the concept and following the nomenclature of CD4+ T helper lymphocyte 
polarization into Th1 and Th2 cells, a corresponding concept has been established of 
functional macrophage polarization into M1 and M2 macrophages, or “classically” and 
“alternatively” activated macrophages (Gordon 2003, Ma et al 2003, Mantovani et al 
2004, Mosser and Edwards 2008, Galli et al 2011, Lawrence and Natoli 2011). According 
to this paradigm, M1 macrophages are related to and meditate Th1 polarized effector 
functions and M2 macrophages correspondingly to Th2 effector functions. Despite the 
apparent clarity of this definition, the nomenclature in the field is somewhat complicated 
and not well defined. 
 Classical macrophage activation referred originally to the macrophage phenotype 
that is induced by macrophage exposure to IFN? and TNF? (Mosser and Edwards 2008). 
As the myeloid differentiation factor 88 (MyD88)-dependent TLR signaling pathway 
leads to auto- and paracrine production of TNF?, this original definition of M1-inducing 
signals has since been modified  to include priming with IFN? followed by activation to 
the full classical macrophage phenotype by TLR signaling (Mosser and Edwards 2008). 
The concept of the M1 macrophage has, however, continued to widen and is in the current 
literature used to describe macrophages primed with IFN? (without TLR signaling) and 
also sometimes macrophages that have been differentiated with GM-CSF (Verreck et al 
2004, 2006, Fleetwood et al 2007, Mosser and Edwards 2008, Lawrence and Natoli 2011). 
Furthermore, signaling via TLR3 and TLR4 induces production of type 1 interferons that 
have effects on macrophages somewhat similar as to those of IFN?;  thus,  certain  TLR  
ligands can induce the M1-like phenotype without any external source of INF? (Mosser 
and Edwards 2008).  
The original description of alternative macrophage activation referred to a 
macrophage phenotype   induced by macrophage exposure to IL-4 (Stein et al 1992). This 
description of M2 macrophages was soon expanded to encompass macrophage exposure 
to  closely  related  IL-13,  and  has  since  then  been  widened  still  more  to  include  
macrophages exposed to M-CSF that show  some similarity to IL-4 exposed macrophages 
(Verreck et al 2004, 2006, Fleetwood et al 2007, Hamilton 2008, Lawrence and Natoli 
2011).  
It is generally agreed that M1 macrophages are proficient effector cells of Th1-
related cell-mediated immunity and that they are effective producers of inflammatory 
mediators. M1 macrophages are also especially effective in killing phagocytosed 
pathogens that might otherwise be resistant to endolysosomal conditions and are effective 
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in antigen presentation (Martinez et al 2008). The role in immunity of M2 macrophages is 
less well defined and more multidimensional, ranging from parasite immunity to wound 
healing (Martinez et al 2009, Mosser and Edwards 2008). This functional and 
phenotypical definition of the M1 and M2 macrophage is, however, also problematic, 
because the phenotypes of human and mouse M1 and M2 macrophages have some major 
discrepancies (Martinez et al 2009, Murray and Wynn 2011a). For example, high nitric 
oxide production is typical for cultured mouse M1 macrophages, but not for cultured 
human M1 macrophages. Likewise, the enzyme arginase 1 is up-regulated in mouse M2 
macrophages but apparently not in human macrophages. 
 
5.4.6. Classical macrophage activation (M1 macrophages) 
 Despite the prevailing confusion over macrophage nomenclature, M1 macrophages 
refer to an inflammatory macrophage phenotype that is especially related to Th1 -response 
and immunity against intracellular pathogens. Priming with the Th1-derived pro-
inflammatory cytokine INF? is also fundamentally related to M1 phenotype. 
INF? is a pro-inflammatory cytokine secreted primary by innate or adaptive immune 
lymphocytes (Schroder et al 2004). During initial recognition of pathogens or danger 
signals via TLRs, antigen-presenting cells are induced to produce various pro-
inflammatory cytokines such as IL-12 that recruit and activate natural killer lymphocytes. 
It is thought that these natural killer lymphocytes are responsible for initial production of 
INF? and initial macrophage activation; additionally signaling through TLR3 and TLR4 
leads to production of type 1 interferons, which then, acting in an auto and paracrine 
manner, can partially substitute for INF? in inducing the M1 phenotype (van Boxel-
Dezaire et al 2006, Mosser and Edwards 2008, Trinchieri 2010). Subsequently, IL-12 
production polarizes the T helper-cell response towards the Th1-type, which then migrates 
to the tissue and produces large quantities of INF?. This thus further guides macrophage 
activation (Schroder et al 2004, Mosser and Edwards 2008).   
IFN? binds to an IFN? receptor, which then signals via the Janus-kinase signal 
transducer and activator of transcription (JAK-STAT) pathway, leading to activation of 
the transcription factors STAT1 and IRF5 (Schroder et al 2004, Lawrence and Natoli 
2011). STAT1 is crucial for induction of the M1 phenotype and leads directly to 
transcription of the majority of M1-related genes, as does IRF5, the role of which is more 
modulatory.  
Activation of these pathways has profound effects on the macrophage phenotype 
and leads to up-regulation of genes and macrophage functions important for cell-mediated 
immunity (Mosser and Edwards 2008). First, the microbicidal effector functions of the 
macrophage are enhanced by increased production of reactive oxygen and nitrogen species 
by inducing various components of NADPH oxidase and nitric oxide synthase pathways, 
as well as up-regulation of lysosomal enzymes and production of antimicrobial pepetides 
and complement components (Schroder et al 2004). As a result, macrophages are able to 
effectively kill phagocytosed pathogens that might otherwise be resistant to 
endolysosomal conditions. Second, IFN? sensitizes macrophages to pathogen recognition 
by up-regulationg TLRs, inflammasome components, Fc-receptors, and some of their 
signaling machineries (Zarember et al 2002, Schroder et al et al 2006, O'Mahony et al 
2008). Third, antigen presentation is enhanced in classically activated macrophages by up-
regulation  of  MHC-  and  co-stimulatory  molecules  as  well  as  by  effective  antigen  
processing (Schroder et al 2004). Fourth, what further characterizes the M1 macrophage 
activation is production of high levels of IL-12 that support a developing Th1 response; 
production of other pro-inflammatory cytokines (TNF?, IL-1?, IL-6, IL-23); inhibition of 
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anti-inflammatory cytokine production; and production inflammatory chemokines (CCL2, 
CCL3, CCL4, IL-8, CXCL9, CXCL10, CXCL11) (Mantovani et al 2004).  
 
5.4.7. Alternative macrophage activation (M2 macrophages) 
In addition to classical macrophage activation, macrophages can assume various 
other functional phenotypes, collectively known as alternative macrophage activation. 
These alternatively activated macrophages are a heterogeneous and poorly-defined group 
of cells that participate in a wide range of physiological and pathological processes such 
as Th2-polarized responses, allergy, parasite immunity, tissue healing, homeostasis, and 
fibrosis (Mosser and Edwards 2008). The phenotype of these alternatively activated 
macrophages is perhaps best characterized in relation to classically activated 
macrophages; the former generally antagonize M1 functions and produce IL-10 instead of 
IL-12 (Mosser and Edwards 2008). Despite the prevailing confusion in the macrophage 
nomenclature, the designation “M2 macrophage” is largely reserved for macrophages 
exposed to IL-4 (Stein et al 1992, Gordon 2003). 
IL-4 is produced by various innate immune cells such as eosinophils, mast cells, and 
basophils and also by activated Th2-lymphocytes. The signals leading to IL-4 production 
and a subsequent Th2-type of adaptive immune response are complex and only partially 
understood, but are generally related to detection of parasites and also to tissue injury 
(Martinez et al 2009, Paul and Zhu 2010). 
IL-4 binds to an IL-4 receptor which signals through the JAK-STAT6 pathway, and 
many of the M2 genes are upregulated directly by STAT6 (Martinez et al 2009, Lawrence 
and Natoli 2011). The IL-4 receptor also utilizes other less well-characterized signaling 
pathways that lead to activation of the peroxisome proliferator-activated receptor-? 
(PPAR?) and phosphoinositide 3-kinase (PI3K),  having a direct effect on the transcription 
of M2-related genes (Lawrence and Natoli 2011). Importantly, PPAR? also exerts a direct 
suppressive effect on production of inflammatory cytokines mediated by inhibiting the 
actions of STAT1, AP-1, and NF-?B (Ricote et al 1998, Pascual et al 2005, Bouhlel et al 
2007). 
 In comparison to classically activated macrophages, M2 polarization is characterized 
by suppression of pro-inflammatory cytokine production, a suppressed ability to kill 
intracellular pathogens via diminished production of microbiocidal effector molecules, 
and suppressed antigen presentation ability, and also by production of high or moderate 
levels of IL-10 instead of IL-12 (Gordon S 2003, Martinez et al 2009). Membrane 
receptors with a scavenger function are upregulated, as are a variety of molecules involved 
in tissue regeneration, wound healing, granuloma formation, and immunity against larger 
parasites (Martinez et al 2009). For instance, at least in mouse M2 macrophages, the 
metabolisim of arginine shifts from production of nitric oxide to production of L-ornithine 
(utilized to produce polyamines) and L-proline (used for cell growth and collagen 
synthesis) via strong upregulation of the enzyme arginase; this may serve to contain larger 
parasites but also may be useful during tissue regeneration. Accordingly, in mouse model 
systems, Th2 response and M2 macrophage activation are crucial in resistance against and 
the expulsion of parasite infection (Martinez et al 2009). In addition, M2 macrophages 
secrete a distinct profile of chemokines (CCL13, CCL14, CCL17, CCL18, CCL22, 
CCL24) specifically recruiting Th2 cells, basophils, and eosinophils (Mantovani et al 
2004).   
 Since the original definition of M2 polarization, several other macrophage 
phenotypes differing from the M1 or M2 macrophage phenotypes have been described, 
including macrophages exposed to IL-10, glucocorticoids, TGF?, and immune complexes 
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in combination with TLR stimulus. It has been suggested that these macrophages, 
collectively characterized by high IL-10 production, should be characterized as 
deactivated or as regulatory macrophages (Mosser and Edwards 2008). In addition to 
production of IL-10, these macrophage subgroups produce variable amounts of pro-
inflammatory cytokines but do not produce ECM components, their characteristic that 
most clearly distinguishes them from M2 macrophages (Mosser and Edwards 2008). 
Moreover,  macrophages  are  readily  able  to  switch  their  functional  status,  for  
example from pro-inflammatory (high IL-12 phenotype) to anti-inflammatory (high IL-10 
phenotype) according to the signals derived from their local microenvironment (Stout et al 
2005, Murray and Wynn 2011a). Thus, these macrophage polarization states likely reflect 
a continuum of functional states rather than fixed phenotypes (Mosser and Edwards 2008). 
 
5.4.8. Role of colony-stimulating factors 
 Mature human macrophages can be maintained and differentiated in vitro by use of 
either M-CSF or GM-CSF. Although most likely an over-simplification, one suggestion is 
that macrophages differentiated with M-CSF represent non-activated tissue-resident 
macrophages while also displaying a clear resemblance to M2 macrophages, and that GM-
CSF induces an M1-like phenotype (Verreck et al 2004, 2006, Fleetwood et al 2007, 
Hamilton 2008). In vivo, M-CSF is secreted under steady state conditions by several cell 
types, and detectable levels of M-CSF are found in the circulation. In contrast, the 
production of GM-CSF is local and induced, primarily during inflammation. One 
suggestion is that systemic levels of M-CSF maintain the general monocyte-macrophage 
population in the quiescent M0- or M2-like phenotype during the steady state, but GM-
CSF, produced by macrophages themselves or by local mesenchymal cells as a response 
to TLR stimulus, induces the M1-like phenotype during early stages of inflammation 
(Hamilton 2008). 
 
5.4.9. Osteoclasts and bone resorption 
A  further  example  of  the  diversity  of  the  monocyte  macrophage  system  is  the  
osteoclast, a multinucleated giant cell formed by fusion of precursor cells of the 
monocyte-macrophage lineage and responsible for resorption of bone tissue during the 
normal physiological process of bone remodeling and also during pathological bone loss 
that occurs for example in osteoporosis, rheumatoid arthritis, or indeed, during aseptic 
loosening (Novack and Teitelbaum 2008).  
Bone is a specialized connective tissue composed of a mineralized ECM responsible 
for mechanical and structural properties of bone, and the group of cells that produce and 
maintain this matrix (Ross and Pawlina 2011b). In addition to bone-resorbing osteoclasts, 
bone tissue contains mesenchymal stem cells which differentiate into osteoblasts as 
instructed by signals from the local microenvironment, for instance bone morphogenetic 
proteins. Osteoblasts produce and secrete the protein constituents of the bone ECM and 
also facilitate its mineralization process. When completely surrounded by bone matrix, 
osteoblasts are termed osteocytes, and they participate in the maintenance of local bone 
matrix. Ostocytes maintain contact with each other and with bone-lining cells by means of 
elongated processes that pierce the bone matrix in discrete canaliculi. Bone-lining cells 
represent both osteoprogenitor cells and osteocytes.  
The ECM of bone tissue is composed primarily of type I and type V collagens and to 
a lesser extent of non-collagenous proteins including proteoglycan macromolecules and 
associated glycosaminoglycans, multiadhesive glycoproteins (osteonectin, osteopontin), 
osteocalcin, and various growth factors and cytokines including bone morphogenetic 
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proteins (Ross and  Pawlina  2011b). This complex protein matrix is covered with calcium 
phosphate in the form of hydroxyapatite crystals.   
Adult bone tissue, both compact and spongy bone, is organized into cylindrical 
osteons comprising concentric lamellae surrounding Volkmann’s canal, containing the 
blood vessels that nourish the cells of the osteon (Ross and Pawlina 2011b).  A lamellar 
structure is created and maintained by a continuous process of bone remodeling in which 
old bone is first removed by an advancing front of osteoclasts (cutting cone), and the 
resulting bone defect is filled in by the following front of osteoblasts actively producing 
and secreting bone-matrix proteins (closing cone) so that the amount of bone removed and 
produced remains about the same (Raggatt and Partridge 2010, Crockett et al 2011). This 
process of bone remodeling allows bone tissue to adjust to external stresses and to repair 
developing fatigue fractures, and is thus imperative for maintaining bone tissues 
mechanical stability.  
For  a  long  time  what  has  been  recognized  is  that  bone  remodeling  and  osteoclast  
function is under tight control by a multitude of regulatory factors including systemic 
hormones (parathyroid hormone, glucocorticoids, calcitonin, testosterone, estrogen) and 
locally produced cytokines that either enhance or suppress osteoclast differentiation and 
function. The exact molecular mechanisms that control osteoclast formation and function 
have, however, been elucidated only during the last 15 years. 
 Osteoclast formation and function is primarily controlled by RANKL and its 
corresponding receptor, receptor activator of nuclear factor kappa B (RANK), expressed 
on the circulating osteoclast  precursors (Boyle et  al  2003, Lacey et  al  2012).  RANKL, a 
member of the TNF superfamily, is a cell membrane-bound protein that under some 
conditions  can  also  be  solubilized.  RANKL  is  produced  by  osteoblasts,  bone-marrow  
stromal cells, and by activated lymphocytes (Anderson et al 1997, Wong et al 1997, Fuller 
et al 1998, Lacey et al 1998, Yasuda et al 1998). The RANKL-RANK system is further 
regulated by osteoprotegerin (OPG), a soluble decoy receptor for RANKL that inhibits its 
signaling. OPG is produced in the steady state by osteoblasts and bone marrow stromal 
cells (Simonet et al 1997). In addition to RANKL, a low level of M-CSF is required for 
osteoclastogenesis (Tanaka et al 1993). 
RANK signaling activates several intracellular signaling cascades including NF-?B, 
MAP kinases, and AP-1, all of which support osteoclastogenesis and are also induced by 
TNF? signaling via its type 1 receptor. The most important, and apparently unique 
property of intracellular RANK signaling is, however, the recruitment of high amounts of 
TRAF6 adaptor and subsequent downstream activation of transcription factors nuclear 
factor of activated T cells (NFAT) 1 and NFAT2 (Novack and Teitelbaum  2008). 
Together with M-CSF-induced signaling through the CSF-1 receptor activating PI3K 
pathway, which supports osteoclast precursor survival, this complex combination of 
transcription factors leads to fusion of osteoclast precursors and development of functional 
osteoclasts (Novack and Teitelbaum 2008). 
Bone resorption by osteoclasts is a complex process involving several steps, 
collectively known as the resorption cycle (Väänänen et al 2000, Teitelbaum 2007, 
Novack and Teitelbaum 2008). After migration to a resorption site, an osteoclast adheres 
to bone by a specialized membrane domain known as the sealing zone that 
circumferentially attaches the osteoclast by its margins to bone matrix. An isolated space 
known as Howship's Lacuna is thus formed between the osteoclast and underlying bone.  
Integrin ?v?3 is critical for both osteoclast attachment to the bone and for the subsequent 
cell membrane polarization steps. After attachment, a highly specialized membrane 
domain called ruffled border is created by the fusion of lysosomal vesicles with the 
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osteoclast cell membrane facing Howship's Lacuna (Väänänen et al 2000, Teitelbaum 
2007, Novack and Teitelbaum 2008). Cytoplasmic carbonic anhydrase II creates carbonic 
acid and subsequently proton ions that are actively pumped into Howship’s lacuna by 
proton pumps located on the ruffled border. In the   low pH of the lacuna, hydroxyapatite 
crystals are dissolved and the protein matrix of the bone digested by lysosomal proteinases 
released into the lacuna. The most important of these proteinases is cathepsin K, although 
MMPs also participate in matrix digestion.  The resultant bone-digestion products are 
removed from the lacuna by transcytosis (Salo et al 1997). After resorption, the osteoclast 
assumes another cycle of bone resorption or undergoes apoptosis. 
In the presence of M-CSF, RANKL is both necessary and sufficient in inducing 
osteoclast differentiation, whereas OPG inhibits this. Thus the RANK-RANKL-OPG 
system is the final common pathway that regulates osteoclast formation and function, and 
further, the local RANKL/OPG ratio is the most important factor regulating bone 
resorption (Boyle et al 2003, Novack and Teitelbaum 2008, Lacey et al 2012,). The list of 
additional factors that regulate osteoclast formation, function, and survival is quite 
extensive, but most of these factors act through modulation of the local RANKL-OPG 
balance.  Once the osteoclast  is  first  formed via the action of M-CSF and RANKL, some 
factors also have direct effects that support or inhibit osteoclast function. 
Importantly, several inflammatory cytokines and chemokines like TNF?, IL-1?, IL-
6, IL-7, and CCL2-4 support osteoclast function either directly or indirectly via induction 
of RANKL and M-CSF expression and suppression of OPG production (Walsh et al 2006, 
Takayanagi 2009, Koide et al 2010). TNF? appears to play a special role in the regulation 
of osteoclast formation, as it partially activates signaling cascades similar to those of 
RANKL, and it is evident that TNF? can induce osteoclastogenesis in the presence of low 
levels of M-CSF and RANKL (Novack and Teitelbaum 2008). It is of note that the 
macrophage-polarizing factors IFN? and IL-4, as well as IL-10, inhibit osteoclastogenesis 
(Walsh et al 2006, Takayanagi 2009, Koide et al 2011). These inflammation-related 
mechanisms are probably important in the pathogenesis of inflammatory bone loss 
associated for example with rheumatoid arthritis and, indeed, also with the development of 
aseptic loosening. 
 
5.5. Toll-like receptors and other pattern-recognition receptors 
 
5.5.1. Receptor Toll  
 Receptor  Toll  was  initially  discovered  as  a  receptor  controlling  dorso-ventral  axis  
formation in embryos of Drosophila melanogaster (Anderson et al 1985, 1985b). Later 
researchers recognized that receptor Toll also plays a critical role in the antifungal and 
antibacterial defense of adult Drosophila,  because  a loss-of-function mutation in the 
receptors rendered Drosophila highly vulnerable to these infections (Lemaitre et al 1996). 
This observation was in part explained by sequence homology searches which revealed 
that the cytoplasmic domain of receptor Toll displayed similarities to the cytoplasmic 
domain of the mammalian IL-1 receptor (Gay and Keith 1991). This suggested that similar 
signaling pathways leading to production of antimicrobial products were activated by both 
Drosophila Toll and mammalian IL-1-receptor signaling pathways (Gay and Keith 1991). 
Subsequently, in mice and humans further sequence homology searches revealed a group 
of transmembrane receptors that had the previously known IL-1 receptor family 
intracellular signaling domain but a unique Toll-like extracellular domain (Medzhitov et al 
1997, Rock et al 1998).  Thereafter, one of these Toll-like receptors (TLRs) was proven to 
be the long-sought specific receptor for the gram-negative bacterial cell membrane 
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structural component lipopolysaccharide (LPS) that mediates LPS-induced septic shock 
(Poltorak et al 1998). Together, these findings reveal a novel and critical system by which 
innate immunity specifically recognizes pathogens and other danger signals. The novelty 
and importance of this discovery was highlighted by the Nobel Prize in medicine awarded 
to Bruce Beutler and Jules Hoffmann in 2011 for their pioneering work in the 
characterization of the TLR system. 
 
5.5.2. TLR structure and function 
 Currently  TLRs  have  been  established  as  an  evolutionary  ancient  system  of  PRRs  
which allow innate immunity to specifically recognize and react to endo- and exogenous 
danger-signal molecules derived from various infective agents and likely also from sterile 
tissue damage (Medzhitov and Janeway 1997, Hoffmann et al 1999, Akira et al 2001, 
Janeway and Medzhitov 2002, Medzhitov 2007). Stimulation of TLRs with the 
appropriate ligand leads to production of pro-inflammatory and antimicrobial mediators, 
to production of inflammasome components, and to up-regulation of co-stimulatory 
molecules in antigen-presenting cells, thus linking the activation of innate and adaptive 
immunity seamlessly together. 
 Since the initial discovery of LPS-recognizing TLR4, several other members of this 
family have been recognized in humans and mice. Currently, the human TLR family 
contains 10 members, called TLR1-10, and the mouse TLR family 12 members, called 
TLR1-13. (Akira and Takeda 2004, Akira et al 2006, Beutler 2009, Kawai and Akira 
2010). TLR11 to 13 are absent from humans, and TLR10 is non- functional in mice. In 
humans, TLR1 to 9 are relatively well characterized, but the ligands for and the signaling 
of TLR10 is currently poorly understood (Table 1). Structurally, TLRs are 
transmembrane-receptor proteins that consist of three domains, an ectodomain containing 
leucine-rich repeats that mediate recognition of repeat molecular patterns, a 
transmembrane membrane-anchoring domain, and an intracellular Toll-interleukin 1 
receptor (TIR) domain that initiates and conveys downstream intracellular signaling 
cascades (Jin and Lee 2008).  
 TLRs are expressed on a wide variety of innate and adaptive immune cells such as 
neutrophils, monocyte-macrophages, mast cells, and lymphocytes but also on cells of 
mesenchymal origin (Akira et al 2006).  Based on their cellular location and the type of 
ligands recognized, TLRs are divided into two broad categories (Akira and Takeda 2004, 
Akira et al 2006, Beutler 2009, Kawai and Akira 2010). TLR1, TLR2, TLR4, TLR5, 
TLR6, and TLR10 are localized to the cell membrane and recognize mainly bacterial, 
fungal, and protozoan structural elements located on external surfaces of these pathogens; 
these  are exposed to TLRs usually by direct cell-to-cell contact or by binding of soluble 
ligands released from the outer surface of these pathogens into the extracellular space.  In 
contrast, TLR3, TLR7, TLR8, and TLR9 are localized to inner surfaces of intracellular 
membrane compartments such as endo(lyso)somes and phagosomes, where they recognize 
bacterial- and viral-derived nucleic acids normally contained within pathogens; these are 
exposed to TLRs only after lysis of the pathogen by endolysosomal enzymes (Akira and 
Takeda 2004, Akira et al 2006, Beutler 2009, Kawai and Akira 2010).  
35 
 
Table 1. Human TLRs, their cellular localization, intracellular signaling pathways and 
activated transcription factors. (*) Pathway exists specifically in plasmacytoid dendritic 
cells. Data from Kumar et al (2009) and Kawai and Akira (2010). TLR - toll-like receptor; 
MyD88 - myeloid differentiation factor 88; TRIF - TIR domain–containing adaptor 
inducing interferon-?; NF-?B - nuclear factor kappa-light-chain-enhancer of activated B 
cells; MAPK - mitogen-activated protein kinases; IRF - interferon regulatory factor. 
 
Receptor Localization Pathway Transcription factors Mediators produced 
TLR1 Cell membrane MyD88 NF-?B, IRF5, MAPKs  Inflammatory cytokines 
TLR2 Cell membrane MyD88 NF-?B, IRF5, MAPKs Inflammatory cytokines 
TLR3 Endosome TRIF NF-?B, IRF5, MAPKs 
IRF3 
Inflammatory cytokines 
Type 1 interferons 
TLR4 Cell membrane MyD88 
TRIF 
NF-?B, IRF5, MAPKs 
IRF3 
Inflammatory cytokines 
Type 1 interferons 
TLR5 Cell membrane MyD88 NF-?B, IRF5, MAPKs Inflammatory cytokines 
TLR6 Cell membrane MyD88 NF-?B, IRF5, MAPKs Inflammatory cytokines 
TLR7 Endosome MyD88 NF-?B, IRF5, MAPKs 
IRF7* 
Inflammatory cytokines 
Type 1 interferons* 
TLR8 Endosome MyD88 NF-?B, IRF5, MAPKs Inflammatory cytokines 
TLR9 Endosome MyD88 NF-?B, IRF5, MAPKs 
IRF7* 
Inflammatory cytokines 
Type 1 interferons* 
TLR10 Cell membrane MyD88 NF-?B, IRF5, MAPKs Inflammatory cytokines 
 
 
5.5.3. PAMPs, alarmins, and DAMPs 
 Exogenous, or foreign, ligands for TLRs include a wide range of bacterial-, viral-, 
fungal- and protozoa-derived biomolecules such as lipids, lipoproteins, carbohydrates, 
peptides, and nucleic acids collectively designated as pathogen-associated molecular 
patterns (PAMPs, Table 2) (Janeway 1989, Janeway and Medzhitov 2002). Reflecting the 
system’s old phylogenetic age, PAMPs are typically well-conserved and fundamental 
structural components of pathogens, and, as their name implies, typically have a polymeric 
and repeating molecular structure (Medzhitov and Janeway 1997, Hoffmann et al 1999, 
Akira  et  al  2006).  These  typical  PAMP  characteristics  are  exemplified  by  four  TLR  
ligands: LPS and LTA, fundamental cell-membrane structural liposaccharides of gram-
negative and gram-positive bacteria recognized by TLR4 and TLR2 respectively, double-
stranded RNA typically originating from viruses and recognized by TLR3, and bacterial 
CpG DNA recognized by TLR9 (Poltorak et al 1998, Yoshimura et al 1999, Alexopoulou 
et al 2001, Hemmi et al 2000).  
In addition to these exogenous TLR ligands signaling tissue infection by foreign 
pathogens, endogenous TLR ligands have also been identified (Table 2) (Akira and 
Takeda 2004, Rifkin et al 2005, Wagner 2006, Miyake 2007, Kono and Rock 2008, Kawai 
and Akira 2010). These endogenous TLR ligands, collectively known as “alarmins” in 
reference to their ability to alarm the innate immune system of sterile-tissue damage, are 
host molecules that are normally securely contained in healthy tissues; they are exposed to 
TLR recognition only after release from their restricted physiological compartments by 
cell- and tissue damage (Bianchi 2007, Kono and Rock 2008). Once released, alamins can 
bind to their corresponding TLRs and other PRRs of the innate immunity and thus initiate 
an inflammation reaction and subsequent activation of the adaptive immune system. 
Typical sources of molecules that can function as alarmins include necrotic cells and 
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damaged ECM (Bianchi 2007, Kono and Rock 2008). During physiological processes like 
cell apoptosis and subsequent rapid clearance of apoptotic bodies by tissue-resident 
macrophages, or during normal ECM turnover, no alarmin molecules are released, and 
thus the innate immune system can effectively sense sterile tissue damage and further 
distinguish it from normal apoptotic clearance of senescent or pre-malignant cells (Kono 
and Rock 2008, Kawai and Akira 2010). 
Several molecules normally contained in the intracellular compartment and released 
during cell necrosis can function as alarmins (Bianchi 2007, Kono and Rock 2008, Kawai 
and Akira 2010). For example, uric acid, a physiological end-product of purine base 
metabolism, is physiologically present in relatively high concentrations in cell cytoplasm. 
Once released during cell necrosis, uric acid tends to form crystals due to the high sodium 
concentration of extracellular space. These monosodium urate microcrystals are ligands 
for TLR2 and NALP3 inflammasome, and their formation and recognition by innate 
immune cells are also the underlying mechanisms of gout arthritis (Shi et al 2003, Liu-
Bryan et al 2005, Martinon et al 2006).  In addition to uric acid, several other intracellular 
components such as heat-shock proteins (HSPs) can function as alarmins via recognition 
by TLR2 or TLR4 (Kono and Rock 2008). Some of the intracellular alarmins  such as the 
high-mobility group box 1 (HMGB1) can also be released from activated innate immune 
cells, allowing these alarmins to function in a cytokine-like manner, further adding to the 
complexity of alarmin signaling (Scaffidi et al 2003). 
During sterile tissue damage, ECM can be damaged and degraded either directly due 
to the underlying tissue insult or indirectly via the action of various proteases released 
from either necrotic cells or invading and activated innate immune cells (Kono and Rock 
2008, Kawai and Akira 2010). Several components of the fragmented ECM such as 
biglycan, hyaluronic acid, versican, and fibronectin extradomain A can function as 
alarmins by ligation of TLR2 or TLR4 (Okamura et al 2001, Jiang et al 2005, Schaefer et 
al 2005, Kim et al 2009).  
Since the description of the first endogenous TLR ligands, a vigorous debate has 
arisen over their actual nature and their significance for the immune system. Some authors 
have  demonstrated  that  the  inflammatory  and  TLR2-  or  TLR4-stimulating  properties  of  
some alarming molecules are actually due to minute bits of LPS contamination. Thus an 
alternative to the endogenous TLR ligand hypothesis is that during infection and 
inflammation, alarmin molecules serve as PAMP-binding and -presenting molecules that 
improve the sensitivity of PAMP detection during tissue infection, rather than being actual 
endogenous TLR ligands themselves (Tsan and Gao 2004, Erridge 2010). Some alarmin 
molecules, however, clearly possess TLR-stimulating activity independent of PAMP 
contamination, and because it undeniably makes sense that the immune system is also able 
to sense sterile tissue damage, the generally accepted view is that actual endogenous TLR 
ligands do exist (Seong and Matzinger 2004, Matzinger 2007, Kono and Rock 2008, 
Kawai and Akira 2010). Collectively, exogenous PAMPs and endogenous alarmins are 
referred to as danger-associated molecular patterns (DAMPs), called this to refer to a 
larger shift in immunological paradigm. According to this postulated “danger model,”  the 
immune system in general is more interested in detecting and clearing what is potentially 
dangerous than in discriminating between self and non-self  (Matzinger 1994, 2002). 
Danger signals can be derived both from exogenous (e.g. bacteria) or endogenous sources 
(e.g. necrotic cells), and both of these share common properties absent under physiological 
conditions,  for  example,   exposed  hydrophobicity  or  extracellular  RNA  and  DNA  
(Matzinger 2002, 2007, Seong and Matzinger 2004). 
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Table 2. Examples of endo- and exogenous TLR ligands.  Data from Akira and Takeda 
(2004), Akira et al (2006), Kono and Rock (2008), Kumar et al (2009), and Erridge 
(2010). HSP - heat-shock protein; ECM - extracellular matrix;  HMGB1 - high-mobility 
group box 1; ssRNA - single stranded RNA; dsRNA - double stranded RNA. 
 
 
TLR PAMP Source Alarmin Source 
TLR1/2 Triacyl lipopeptides Bacteria 
Mycobacteria 
  
TLR2 Peptidoglycan 
Lipoteichoic acid 
Porins 
Lipoarabinomannan 
Zymosan 
Phospholipomannan 
Gram+ bacteria 
Gram+ bacteria 
Neisseria 
Mycobacteria 
Fungi 
Candica albicans 
HSPs 
HMGB1 
Uric acid 
Biglycan 
Hyaluronan 
Versican 
Necrotic cells 
Necrotic cells 
 
ECM 
ECM 
ECM 
TLR3 ssRNA, dsRNA Viruses RNA Necrotic cells 
TLR4 Lipopolysaccharide 
Mannan 
Envelope proteins 
Gram- bacteria 
Candida 
Viruses 
HSPs 
HMGB1 
Uric acid 
Biglycan 
Hyaluronan 
Heparan sulfate 
Tenascin-C 
Fibrinogen 
Fibronecting 
Surfactant protein A 
?-defensin 
Necrotic cells 
Necrotic cells 
Necrotic cells 
ECM 
ECM 
ECM 
ECM 
ECM 
ECM 
ECM 
Macrophages 
TLR5 Flagellin Flagellated 
bacteria 
  
TLR6/2 Diacyl lipopeptides 
Lipoteichoic acid 
Zymosan 
Mycoplasma 
Gram+ bacteria 
Fungi 
  
TLR7 ssRNA Viruses RNA Necrotic cells 
TLR8 ssRNA Viruses RNA Necrotic cells 
TLR9 dsDNA,  
CpG-DNA 
Viruses  
Bacteria 
DNA Necrotic cells 
                
 
 
     
5.5.4. TLR signaling 
After binding of their corresponding ligands, TLRs form receptor dimers which 
initiate intracellular signal transduction cascades by conformational changes and 
subsequent recruitment of several adaptor molecules to their intracellular TIR domain 
(Akira and Takeda 2004, Akira et al 2006, Kumar et al 2009, Kawai and Akira 2010). 
Most TLRs function as homodimers, but TLR2 typically forms receptor heterodimers with 
TLR1, TLR6, and TLR10, thus expanding the possible ligand specificities of these 
particular receptors. For instance, due to subtle differences in the molecular structure of 
TLR1 and TLR6 ectodomains, the TLR2-TLR1 heterodimer recognizes triacylated 
lipopeptides, while the TLR2-TLR6 dimer recognizes diacylated lipopeptides (Jim and 
Lee 2008). TLRs also utilize co-receptors. The best known example is LPS recognition by 
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TLR4, where soluble LPS is first bound to LPS-binding protein present in the circulation. 
Next the LPS-binding protein complex is bound to cell-surface CD14, which then delivers 
the LPS complex to TLR4 that functions in a complex with additional co-receptor, 
myeloid differentiation protein 2 (Kawai and Akira 2010). 
 TLR-ligand interaction and subsequent receptor dimerisation initiate intracellular 
signaling by recruitment of various adaptor molecules to the receptor’s TIR domain. 
Currently, four different TIR domain-containing adaptor proteins have been recognized: 
myeloid differentiation factor 88 (MyD88), a MyD88 adaptor-like (Mal), a TIR domain-
containing adaptor inducing IFN-? (TRIF), and a TRIF-related adaptor molecule (TRAM). 
MyD88 is recruited by all TLRs except TLR3, and most TLRs recruit MyD88 directly to 
their TIR domain; TLR2 and TLR4, however, use MAL as an additional adaptor between 
the TIR domain and MyD88. TLR3 recruits TRIF directly, whereas TLR4 uses TRAM as 
an additional adaptor between the TIR domain and TRIF. The signals derived from these 
various adaptor molecules thus converge into two primary intracellular signaling 
pathways: MyD88-dependent and TRIF-dependent pathways (Akira and Takeda 2004, 
Akira et al 2006, Kumar et al 2009, Kawai and Akira 2010). The major difference between 
these two signaling pathways, in addition to different mediators of the intracellular-
signaling intermediate steps, is whether the pathway leads to production of type I 
interferons.  
 Except for TLR3, all TLRs use, either directly or via adaptor MAL, the MyD88-
dependent signaling pathway which leads, via several intermediate steps, to activation of 
inflammatory transcription factors IRF5, MAP kinases, AP-1, and NF-?B, resulting in an 
inflammatory reaction mediated by production of various inflammatory chemokines, 
cytokines, growth factors, inflammasome components, and costimulatory molecules 
(Akira and Takeda 2004, Akira et al 2006, Kumar et al 2009, Kawai and Akira 2010). 
 The TRIF-dependent signaling pathway is utilized exclusively by TLR3 and partly, 
via adaptor TRAM, by TLR4, which uses also the MyD88-dependent signaling pathway. 
The TRIF-dependent pathway leads, via intermediate steps, to activation of MAPKs and 
NF-?B but also to activation of transcription factor IRF3, leading to production both of 
inflammatory cytokines and of type I interferons—in macrophages, these typically being 
IFN? (Akira and Takeda 2004, Akira et al 2006, Kumar et al 2009, Kawai and Akira 
2010).  
 There also exist cell-type-specific differences in TLR signaling allowing further 
elaboration of DAMP-induced cellular responses. The best characterized example of this 
cell-type-specific TLR signaling is plasmacytoid dendritic cells, which apparently exist to 
proficiently sense and repel viral infections. In plasmacytoid dendritic cells, TLR7 and 
TLR9 use a non-conventional MyD88-dependent signaling pathway, activation of which 
leads,  in  addition  to  traditional  activation  of  MAPKs  and  NF-?B,  to  the  activation  of  
transcription factor IRF7 and subsequent production of type I interferons, typically both 
IFN? and IFN? (Akira and Takeda 2004, Akira et al 2006, Kumar et al 2009, Kawai and 
Akira 2010). 
 
5.5.5. Regulation of TLR signaling 
Unlimited and overt inflammatory responses are potentially detrimental and even 
lethal to the host, as exemplified by various autoimmunity disorders and septic shock. As 
the TLR system, along with other PRRs, is largely responsible for the initial sensing of 
danger and initial activation of both the innate and adaptive arms of the immune system, it 
is not surprising that multiple levels of TLR signaling regulation exist (Liew 2005, Lang 
and Mansell 2007, Kawai and Akira 2010). These regulatory mechanisms both restrict 
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initial  TLR  activation  and,  after  successful  TLR  signaling,  shut  down  the  signal  so  that  
collateral damage to host tissues is limited, and tissue repair and regeneration processes 
can commence. 
The several potential mechanisms of TLR signaling regulation  recognized  include 
production of soluble decoy receptors (thus far recognized for TLR2 and TLR4), splice 
variants of TLR intracellular signaling adaptors, TLR degradation via ubiquitination, and 
overt TLR signaling-induced apoptosis (Liew 2005, Lang and Mansell 2007, Kawai and 
Akira 2010). Additionally, intracellular TLR-signaling pathways include several proteins 
that bind to and inhibit different levels of TLR-signaling cascades (Liew 2005). Some of 
these (PI3K, TOLLIP, TRAILR) are constitutively expressed in monocyte-macrophages 
and limit TLR signaling in a continuous manner, thus creating in-built resistance, or a 
threshold  to  be  overcome  by  TLR  signaling,  while  the  expression  of  others  (TANK,  
IRAKM, SOCS, A20) is regulated to accommodate to prevailing conditions. 
Activation of TLR signaling with a appropriate ligand typically leads, in addition to 
the pro-inflammatory response, also to production of anti-inflammaotry mediators and 
reciprocal up-regulation of inhibitory signaling mediators and suppression TLR signaling 
(Liew 2005, Lang and Mansell 2007, Kawai and Akira 2010). The best-known example of 
these negative feedback-loop mechanisms typical for TLR signaling is endotoxin 
tolerance; LPS-treated macrophages become ractory to subsequent LPS treatments and in 
response to a repeated LPS stimulus produce quantities of IL-10 instead of pro-
inflammatory cytokines (Biswas and Lopez-Collazo 2009). The underlying mechanisms 
of this phenomenon are complex and include suppression of TLR4 signaling on multiple 
levels (Biswas and Lopez-Collazo 2009).  
In addition to signaling-induced negative feed-back inhibition, TLR signaling is 
regulated by several factors including the local cytokine microenvironment and systemic 
hormones that typically have broad effects on many levels of TLR signaling and can 
influence  TLR  expression  and  degradation  levels  directly,  regulate  the  amounts  of  their  
intracellular signaling inhibitors or directly activate/repress TLR-induced transcription 
factors (Liew 2005, Lang and Mansell 2007, Kawai and Akira 2010). Indeed, a concept of 
a tissue-specific or tissue-regulated immune reaction has been recently introduced 
(Matzinger 2007, Matzinger and Kamala 2011). One premise of this model is that signals 
derived from the local microenvironment determine the tissue-specific threshold for TLR 
signaling. For example, due to the physiologically prevailing strong anti-inflammatory 
milieu, the innate immune cells residing in the wall of the gut do not react to the normal 
flora despite the abundance of potential PAMPs. 
In general, pro-inflammatory cytokines up-regulate TLR expression and promote 
TLR signaling, whereas anti-inflammatory cytokines, especially IL-10, effectively down-
regulate TLR expression and suppress their signaling by elevating the amounts of their 
intracellular signaling inhibitors (Liew 2005, Lang and Mansell 2007, Kawai and Akira 
2010). Among systemic hormones, the effects of glucocorticoids on TLR signaling are 
those most widely studied (Chinenov and Rogatsky 2007). Not surprisingly, 
glucocorticoids suppress several layers of TLR signaling by raising the amounts of their 
intracellular signaling inhibitors and directly interacting with TLR-activated transcription 
factors.  
 
5.5.6. TLRs and macrophage polarization 
Macrophage polarization has profound effects on TLR expression and signaling. 
IFN? priming enhances TLR expression and signaling, and, accordingly,  IFN? treatment 
effectively sensitizes M1 macrophages to TLR ligands; the expression of some TLR-
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regulated genes requires this IFN? priming, while the dose-response curve of other genes 
is shifted by the IFN? treatment so that lower concentrations of TLR ligand are sufficient 
to cause gene reading (Schroder el al 2006, Hu et al 2008). The negative feedback loops 
typical of TLR signaling are also suppressed and, for example, IFN? treatment eliminates 
endotoxin tolerance (Adib-Conquy et al 2002, Bosisio et al 2002, Chen et al 2010). This 
enhancement of TLR signaling on M1 macrophages is the result of the complex cross-talk 
between IFN? and TLR signaling pathways (Schroder el al 2006, Hu et al 2008). For 
example, the levels of TLRs, their co-receptors, and various intracellular signaling 
components are directly up-regulated, and inhibitory signaling mediators down-regulated 
by IFN? and the accompanying activation of STAT1 (Muzio et al 2000 and  2001, Bosisio 
et al 2002, Zarember et al 2002, Tamai 2003, Radstake et al 2004, O'Mahony et al 2008). 
Additionally, IFN?-induced STAT1 and TLR signaling-activated transcription factors, like 
NF-?B, synergize by binding to promoter-regions of the same target genes (Schroder el al 
2006). Furthermore, TLR signaling pathways reciprocally enhance IFN? signaling by 
partially activating STAT1 via MAP kinase pathways (Schroder el al 2006). Finally, IFN? 
suppresses TLR-signaling-induced production of IL-10 (Hu et al 2006, 2008). 
Regulation of TLR signaling in M2 macrophages is less well understood, but it 
appears that in M2 macrophages, TLR signaling is generally inhibited, possibly by  
general inhibition of inflammatory signaling pathways partly mediated by PPAR?, by 
direct down-regulation of TLR expression, or by increased production of IL-10 (Staege et 
al 2000, Lawrence and Natoli 2011). A possibly analogous phenomenon of TLR-signaling 
up-regulation via Th1-related cytokines and down-regulation by Th2-related cytokines 
also occurs in various other cell types (Faure et al 2001, Wolfs et al 2002, Mueller et al 
2006, Romieu-Mourez et al 2009). Enhancement of TLR signaling in M1 macrophages 
and suppression of TLR signaling in M2 macrophages likely reflect the natural course of 
an inflammation-resolution-healing sequence and a corresponding switch in macrophage 
phenotype from inflammatory M1 to M2 macrophages that promote tissue regeneration 
and healing. 
 
5.5.7. Other PRRs, inflammasome, and IL-1? 
 Since the discovery of TLRs, at least three additional PRR families have been 
identified (Medzhitov 2007, Kawai and Akira 2010). C-type lectin-like receptors (such as 
the mannose receptor) are localized to cell membrane and participate in microbial 
recognition and a subsequent inflammatory reaction via NF-?B activation. NLR receptors 
(divided into NOD-like receptors and NALPs) and RIG-I-like receptors are large families 
of cytoplasmic PRRs. Although the detailed mechanisms of DAMP recognition and 
subsequent signaling by these various receptors are still under investigation, these 
cytosolic PRRs may participate in recognition of various danger signals located in the 
cytoplasmic compartment, including viral and bacterial nucleic acids and toxins. Signaling 
through these receptors leads to NF-?B activation but also to production if type I 
interferons (Medzhitov 2007, Kawai and Akira 2010).  
Importantly, NALP activation is required for the assembly of an inflammasome, a 
large cytoplasmic multiprotein complex responsible for activation of caspase-1, which is 
required for secretion of the strong inflammatory mediators IL-1? and IL-18 (Davis et al 
2011, Strowig et al 2012).  Inflammasome assembly is initiated by a large repertoire of 
DAMPs. In contrast to TLRs, NALPs may sense more general cellular stress such as 
generation of reactive oxygene species, rather than recognizing specific DAMPs. In the 
context of wear-debris recognition and induced responses, it is noteworthy that several 
phagocytosed crystalline structures (uric acid, cholesterol, hydroxyapatite crystals) as well 
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as inhaled foreign bodies (asbestos fibers, silica) can activate NALP3 inflammasome via 
endosomal damage and release of endo(lyso)somal constituents into the macrophage 
cytoplasm (Davis  et al 2011, Strowig et al 2012). 
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6. Aims of the study 
 
 
Wear-particle-induced macrophage activation to the inflammatory phenotype is 
considered a fundamental event in the pathogenesis of aseptic loosening, and the sequence 
of events leading from macrophage activation to osteolysis is well characterized.The exact 
mechanisms by which biomaterial particles are recognized by macrophages and how their 
phagocytosis leads to macrophage activation have, however, remained elusive. Recent 
observations are that wear particles of various natures are relatively inert, cause only 
limited macrophage activation and osteolysis, and have their inflammatory properties 
largely dependent on bacterial structural components adhering to their surfaces. This led to 
the hypothesis that recognition of bacterial product-coated wear particles and subsequent 
activation of interface tissue macrophages may be mediated by TLRs. In addition, as 
immunological research indicates that the expression of TLRs and macrophages’ ability to 
produce inflammatory mediators is largely dependent on macrophage polarization, we 
further hypothesized that macrophage polarization may be an important determinant of the 
way that macrophages react to wear particles. 
 
Accordingly, the specific aims of this study were  
 
1. To characterize the possible presence of TLR1-9 in the aseptic interface tissue. 
 
2. To compare the inflammatory cell profile and localization of TLR4 and TLR9 between 
septic and aseptic interface tissues. 
 
3. To discover whether wear particles directly regulate TLR levels in a mouse model of 
wear-particle-induced inflammation and in a macrophage culture system. 
 
4. To discover whether macrophage polarization affects macrophage wear-particle 
responses.   
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7. Materials and methods  
 
7.1. Patients and samples (I, II, IV) 
 
7.1.1. Ethical considerations 
The ethics committees of Helsinki University Central Hospital (I, II, IV) and of the 
Rizzoli Orthopaedic Institute (II) approved the use of patient samples in studies of this 
thesis.  
 
7.1.2. Controls (I, II) 
Samples  of hip joint synovial tissue were came from primary total joint replacement 
operations performed for clinically and radiologically diagnosed primary osteoarthritis of 
the hip joint. Patients with secondary osteoarthritis and rheumatoid arthritis were excluded 
on the basis of patient history, clinical symptoms, radiological examination, and 
laboratory data. Five patients (one man, four women, mean age 73.6) undergoing primary 
hip arthroplasty were included in Study I, and five patients (one man, four women, mean 
age 74.4) in Study II. Additionally, ten patients (four men, six women, mean age 67.2) 
were included in the TLR-expression profiling study (Pajarinen J, Jämsen E, Konttinen 
YT, unpublished results) 
 
7.1.3. Patients with aseptic THR loosening (I-II) 
Tissue samples of synovial membrane-like interface tissue were obtained from total 
hip joint revision operations performed for aseptic loosening of the THR components. 
Initial diagnosis of aseptic loosening was by clinical and radiological evaluation and was 
later confirmed by negative intraoperative bacterial cultures and also by typical histology. 
Four  patients  with  aseptic  THR  loosening  (two  men,  two  women,  mean  age  70.5)  were  
included in Study I, and five (two men, three women, mean age 71.2) in Study II.  
Additionally, twelve patients (three men, nine women, mean age 67.9) were included in 
the TLR-expression profiling study (Pajarinen J, Jämsen E, Konttinen YT, unpublished 
results)  
 
7.1.4. Patients with septic THR loosening (II) 
Tissue samples of peri-implant tissue came from total hip joint revision operations 
performed for septic THR loosening. Initial diagnosis of septic THR loosening was by 
clinical, laboratory, and radiological evaluation later confirmed by positive intraoperative 
bacterial cultures. Ten patients (two men, eight women, mean age 61.2) with THR 
infection were included in Study II. In five cases, the implant was infected by 
Staphylococcus epidermidis, in four cases by Propionibacterium acnes, and in one case by 
alpha-hemolytic Streptococcus. 
 
7.1.5. Tissue processing (I, II) 
Immediately after collection, all tissue samples intended for immunohistochemistry 
were fixed in 30% formaldehyde for 24 to 48 h, dehydrated in ethanol, cleared in xylene, 
and embedded in paraffin. Tissue sections 5 to 8 µm thick were then cut with a 
microtome, deparafinized in xylene, and rehydrated in a decreasing ethanol series. For 
examination of general tissue architecture, tissue sections were stained with standard 
hematoxylin-eosin and then further analyzed with immunohistochemistry. 
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For the unpublished TLR-expression profiling study, tissue samples were 
immediately after collection snap-frozen in isopentane, precooled in dry ice, and stored at 
-75 ºC until use. About 0.1-mg tissue pieces were cut, with the tissue continuously frozen 
by dry ice, and total RNA was isolated from these tissue pieces with Trizol reagent 
(Invitrogen, Carlsbad, CA, USA) and a Ultra-Turrax tissue homogenizer  (Janke & 
Kunkel, IKA-Laborthecnik), followed by RNA purification using RNeasy Mini Kit 
(Qiagen, Düsseldorf, Germany). Total RNA was stored at -75ºC until use.  
 
7.1.6. Cell samples (III, IV) 
For the particle stimulations of Study III, the mouse monocyte/macrophage cell line 
RAW 264.7 was bought from ATCC (Manassas, Virginia, USA). For human peripheral 
blood monocyte isolation (PBMC) and monocyte-macrophage differentiation and particle 
stimulation studies in Study IV, buffy coats of four healthy blood donors were obtained 
from the Finnish Red Cross Blood Service. 
 
7.2. Titanium particle preparation (III, IV) 
 
Titanium particles, mean diameter 3.7 +/- 1.8 ?m as determined by scanning 
electron microscopy, were bought from Alfa Aesar (Ward Hill, MA, USA). To minimize 
any possible LPS contamination, the particles were washed with alternating cycles of 20-
hour incubation in 25% nitric acid and 0.1 N NaOH in 95% ethanol (Ragab et al 1999).  
Between these treatments, particles were washed twice in cell-culture-grade PBS. After 
five  cycles  of  washes,  particles  were  resuspended  in  PBS and  stored  at  +4  °C until  use.   
After washes, particle LPS levels were determined by Limulus amebocyte lysate 
chromogenic endpoint assay kit. Study III used  a kit with a minimum LPS detection limit 
of  0.125  EU/ml  (BioWhittaker,  Walkersville,  MD,  USA)  and  Study  IV  a  kit  with  a    
minimum LPS detection limit of 0.01 EU/ml (Hycult Biotech, Uden, the Netherlands). In 
both instances, particle LPS levels were below these assays’ detection limits. For in vitro 
macrophage stimulation experiments, particles were diluted in cell culture medium to 
obtain the indicated concentrations and for the in vivo particle-induced inflammation 
model, particles were diluted in carrier solution consisting of 8.5 mg/ml sodium 
hyaluronate in PBS. 
 
7.3. In vivo model of particle-induced inflammation (III) 
 
 A mouse model of particle-induced inflammation was produced at Stanford 
University (Orthopedic Research Laboratory, Stanford, CA, USA). Briefly, 14 adult (12- 
to 14-week-old) male C57BL/6 WT mice were obtained from the Stanford University in-
house breeding colony. Institutional guidelines for the care and use of laboratory animals 
were strictly followed. Animals were anesthetized with an intraperitoneal injection of a 
1:1 ketamine/xylazine, after which the distal femur was accessed through a medial 
parapatellar arthrotomy. A 27-gauge needle was used to penetrate the intercondylar notch 
to gain access to the medullary cavity of the femur. A 25-gauge needle was then drilled 
into the femur, after which 1.39x108 titanium particles in 100 µl of carrier solution were 
injected into the intramedullary canal in the right femur, but the carrier solution without 
particles was injected into the intramedullary canal of the left femur. Kirschner wires of 
25-gauge stainless steel (McMaster-Carr, Chicago, IL, USA), cut into 10-mm rods, 
cleaned, and steam autoclaved, were then inserted bilaterally into both femoral canals.  
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Seven animals each were killed at 2 or 10 weeks postoperatively. Distal femurs were 
cut, fixed in 10% neutral buffered formalin (Sigma-Aldrich, St. Louis, MO, USA) for 24 h 
at 48ºC, and decalcified in 23% formic acid for 48 h at room temperature. The stainless-
steel rod was carefully extracted before the samples were embedded in paraffin. Beginning 
at 5 mm from the knee joint, 5-µm transverse sections were cut from the distal femur, 
deparafinized in xylene, and rehydrated in decreasing ethanol series. For the examination 
of general tissue architecture, tissue sections underwent routine hematoxylin-eosin 
staining, andTLRs were analyzed at both time points with immunohistochemistry. 
 
7.4. Immunohistochemistry (I, II, III) 
 
 Immunohistochemical evaluation of aseptic and septic interface tissues and control 
synovial tissues as well as of mice femurs was done either manually (for TLRs, in Studies 
I, III) or by an automated immunohistochemial staining robot (for cell type markers, Study 
II). For both the manual and automated protocols, antigen retrieval was first performed on 
deparaffinized and rehydrated tissue sections at 98ºC in 10 mM citrate buffer, pH 6.0, for 
24 min in Milestone Mega T/ T microwave oven (Milestone s.R.L., Sorisole, Italy) and by 
a specific antigen retrieval program, followed by cooling down at room temperature for 20 
min and washing with phosphate-buffered saline (PBS, pH 7.4). Neutrophil elastase 
staining required no antigen retrieval (Study II). 
 For manual staining of TLRs, tissue sections were then treated serially with 1)  3% 
H2O2-methanol for 20 min; 2) 10% normal goat serum (Vector Laboratories, Burlingame, 
CA, USA) diluted in 0.1% bovine serum albumin (BSA) in PBS for 1 h; 3) One of the 
polyclonal, affinity-purified rabbit anti-human IgG antibodies specific for givenTLR and 
displaying cross-reactivity to corresponding mouse TLRs (Table 3), diluted in 0.1% BSA-
PBS,  overnight at 4 ºC; ) Biotinylated goat anti-rabbit IgG (Vector Laboratories) diluted 
in 0.1% BSA-PBS for 1 h; 5) Avidin-Biotin-peroxidase complex (Vector)for 1 h, and 
finally, 6) H2O2-3,3-diaminobenzidine tetrahydrochloride (DAKO A/S, Glostrup, 
Denmark) for 5 min, followed by washing in distilled water. Between steps 1 and 2 and 3, 
4, and 5, the sections were washed for 3x5 min in PBS. The specificity of the staining was 
confirmed by including negative controls stained with normal rabbit IgG (Jackson 
Immunoresearch, West Grove, PA, USA) at the same concentration as the highest specific 
primary rabbit antibody (2.7 µg/mL).All the incubations were done at room temperature 
and  in humidified chambers unless otherwise stated. 
 Immunohistochemical staining of cell type-specific markers was done by  the MSIP 
protocol of the DAKO TechMate Horizon Immunostainer robot (DAKO A/S) and the 
ChemMate LSAB staining kit (DAKO A/S), by manufacturer-provided protocols.  
Sections were serially treated with 1) primary antibodies specific for given cell type 
marker (Table 4) diluted in manufacturer-provided antibody diluent buffer (DAKO) for 25 
min; 2) biotinylated anti-rabbit or anti-mouse secondary antibodies in diluent buffer for 25 
min; 3) peroxidase blocking solution (DAKO) for 3x3 min; 4) peroxidase-conjugated 
streptavidin for 25 min, and finally with 5) H2O2-3,3-diaminobenzidine tetrahydrochloride 
(DAKO A/S) for 5 min. Between the steps, sections were washed withChemMate washing 
buffer for 3x5 min and dried with absorbent pads. All incubations were done at room 
temperature. Specificity of the staining was confirmed by including negative controls 
stained with irrelevant IgGs of the same subclass and used in similar concentration, as the 
specific cell-marker antibodies (mouse control antibodies from DAKO, normal rabbit IgG 
from Jackson Immunoresearch). 
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 After both the manual and automated immunohistochemical staining, sections were 
counterstained in hematoxylin for 5 s, washed with running tap water for 5 min, 
dehydrated in increasing ethanol series, cleared in xylene, and mounted in mounting 
medium. 
 Stained tissue sections were examined under, and photographed with a Leitz Diaplan 
microscope (Wild Leitz, Wetzlar, Germany) coupled to a 5MP digital DFC420 camera 
and Application Suite 3.0 image analysis system (both from Leica Microsystems, Wetzlar, 
Germany). The number of TLR-positive cells was calculated in a representative high 
power field (I) or the number of TLR and specific cell marker-positive cells was evaluated 
on a semi-quantitative scale (II, III): no positive staining (-); occasional positive cells (±); 
some positive cells (+); moderate numbers of positive cells (++); and large numbers of 
positive cells (+++), by two observers. 
 
Table 3. Dilutions of anti-TLR primary antibodies in the studies. All Polyclonal rabbit IgG 
and from Santa Cruz Biotechnology (Santa Cruz, CA, USA). (*)Dilution used in Study III. 
TLR - toll-like receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Details of primary antibodies to identify differing cell populations in aseptic, 
septic, and control synovial, and peri-implant tissues (Study II). (1) Novocastra, 
Newcastle, UK, (2) Stressgen, Victoria, Canada, (3) Original concentration of the CD163 
antibody was lacking with only the working antibody dilution provided. CD - cluster of 
differentiation; NE - neutrophil elastase; HSP - heat-shock protein; Ig - immunoglobulin. 
 
 
Antibody Cell type From Type Dilution 
CD3 T lymphocytes DAKO Polyclonal  rabbit IgG 5 µg/ml 
CD20 B lymphocytes DAKO Monoclonal mouse IgG2a? 0.7 µg/ml 
CD68 Macrophages DAKO Monoclonal mouse IgG?? 0.85 µg/ml 
CD138 Plasma cells Novocastra1 Monoclonal mouse IgG?? 1.25 µg/ml 
CD163 Macrophages Novocastra Monoclonal mouse IgG?? 1/503 
NE Neutrophils DAKO Monoclonal mouse IgG?? 0.65 µg/ml 
HSP47 Fibroblasts Sressgen2 Monoclonal mouse IgG2b 1.0 µg/ml 
 
Antibody Dilution Study 
TLR1 0.8/0.5* µg/ml, I, III  
TLR2 2.7/1.3* µg/ml I, III 
TLR3 2.0 µg/ml I 
TLR4 1.3/1.3* µg/ml I, II, III 
TLR5 0.8/1.3* µg/ml I, III 
TLR6 1.0 µg/ml I 
TLR7 0.8 µg/ml I 
TLR8 2.7/1.3* µg/ml I, III 
TLR9 0.5/0.5 µg/ml I, II, III 
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7.5. Cell cultures (III, IV) 
 
7.5.1. Mouse macrophage particle stimulation (III) 
Mouse monocyte/macrophage cell line RAW 264.7 was cultured in high glucose 
DMEM (Life Technologies, Grand Island, NY, USA) with 10% FCS and 1% antibiotics in 
humidified 5% CO2-in-air in a +37°C incubator. Cells were refreshed twice a week, split 
1:10 with scraping once a week, counted with aZ1 Coulter Particle Counter (Beckman 
Coulter, Indianapolis, IN, USA) and used in the experiments at passages 8 to 10. For 
particle stimulations, cells were transferred to 6-well plates (BD, Franklin Lakes, NJ, 
USA), 2x105 cells per well, in 2 ml of medium. Cells were allowed to adhere for 1 to 2 h, 
after which the medium of the particle-stimulated cell group was changed to 2 ml of 
medium supplemented with approximately 1x107 particles, equaling about 100 particles 
per cell. Corresponding control cells received only culture medium. After 0, 2, 6, 10, and 
24 hours of particle stimulation, the medium was removed and total RNA extracted with 
Trizoll reagent (Invitrogen), and stored at -75 °C until used for quantitative real time-PCR 
analysis (qRT-PCR) of TLR mRNA expression. 
 
7.5.2. Human monocyte isolation and differentiation (IV) 
PBMC were isolated from buffy coats of healthy blood donors by the Ficoll-Paque 
PLUS (GE Healthcare, Piscataway, NJ, USA) density gradient method. To exclude 
lymphocytes from the cell culture model, monocytes were further purified from other 
PBMC populations by CD14+ positive selection using the MACS system (Miltenyi 
Biotech, Bergisch Gladbach, Germany). The number of the CD14+ cells obtained was 
counted with a Z1 Particle Counter (Beckman Coulter), after which cells were divided into 
tissue-culture-treated 24-well plates (BD), 3x105 cells /well in 0.5 ml of Gibco RPMI-1640 
GlutaMAX-1 medium (Life Technologies) supplemented with 10% fetal bovine serum 
(FBS) and penicillin-streptomycin antibiotic cocktail (complete medium). Cells were 
allowed to adhere for 1 hour in an incubator, after which non-adherent cells were removed 
by  a  gentle  rinse  with  PBS.  The  remaining  adherent  monocytes  were  differentiated  into  
mature M0 macrophages by culturing them for 7 days in complete medium supplemented 
with 100 ng/ml of macrophage-colony-stimulating factor (M-CSF, R&D systems, 
Minneapolis, MN, USA). Cells were maintained in a humidified, 5% CO2-in-air, +37 °C 
incubator and refreshed once during the 7-day differentiation. 
 
7.5.3. Induction of macrophage polarization (IV) 
Following macrophage differentiation, macrophages were polarized by 1-day culture 
in a complete medium supplemented with 100 ng/ml of M-CSF (M0 polarization), 20 
ng/ml IFN? (M1 polarization), or 20 ng/ml IL-4 (M2 polarization) (all from R&D 
systems).  
 
7.5.4. Particle stimulation of polarized macrophages (IV) 
After 1-day macrophage polarization, complete medium containing the polarizing 
cytokines was removed, and M0, M1, and M2 macrophages were subjected to titanium 
particles suspended in complete medium at a concentration of 6x106 particles/ml equaling 
about 10 particles / macrophage. Corresponding control macrophages received the 
particle-free complete medium. After 4 or 24 hours of particle stimulation, cell-culture 
supernatants were collected, centrifuged, and stored at -75 °C until used. Immediately 
after supernatant removal, cells were rinsed with PBS and total RNA was extracted with 
the RNeasy Mini Kit (Qiagen). Total RNA was stored at -75 °C until used; 4-hour total 
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RNA samples were used for microarray and quantitative RT-PCR analyses and 24-hour 
cell-culture supernatants for protein suspension array. 
 
7.5.5. Live-cell and time-lapse imaging (IV) 
 Macrophage cultures maintained in 24-well plates as described were examined 
under and photographed with an Eclipse Ti-E inverted microscope (Nikon Instruments, 
Melville, NY, USA) in phase-contrast mode, with an environmental chamber capable of 
maintaining standard cell culture conditions (5% CO2-in-air at +37°C), Prior ProScan III 
motorized XY stage and DS-QiMc camera with an NIS-Elements advanced research 
software version 3.1. ensemble (all components and software from Nikon). Monocyte-to-
macrophage differentiation and subsequent macrophage polarization was documented by 
images taken once a day. 
 Macrophage-particle co-cultures were observed with time-lapse microscopy starting 
from 15 min after addition of the particles. Images of the co-cultures were taken at 15-min 
intervals; from pre-fixed, representative locations, for 6 hours,  and several additional 
images were taken  24 hours  after addition of the particles from representative locations. 
 Phagocytotic activity of the different macrophage types was assessed by quantifying 
the  particles  remaining  outside  the  cell  at  a  given  time  point  in  a  total  of  six  randomly  
chosen view fields per cell type.  To this end, an automated image analysis algorithm was 
developed to measure the particles left in the background (=outside the cells) of each 
image. Briefly, the background was first segmented from cells and particles based on its 
color (most frequent color ± 5 grayshades in a 8-bit image) in Matlab (The MathWorks, 
Natick, MA, USA). Particles were segmented from cells based on their size (1-50 pix) and 
circularity (>0.85) by ImageJ. 
 Motility of the different macrophage types was assessed from 6-hour follow-up 
images by use of a manual tracking plug-in for ImageJ (v. 1.43u National Institute of 
Health,  Bethesda,  MD,  USA).  Briefly,  the  velocity  of  120  randomly  chosen  cells,  in  six  
view fields per cell type, was determined by manually tracking the approximated focal 
point of the cell.  
 
7.6. Microarray (IV) 
 
 Genome-wide expression profiling and subsequent data-analysis of titanium 
particle-induced trascriptome changes in different macrophage types was performed in the 
Biomedicum Functional Genomics Unit (Helsinki, Finland). Four-hour particle-stimulated 
and corresponding control macrophages of one representative donor were included in the 
analysis. This experiment was performed following protocols provided by the microchip 
manufacturer (Illumina, San Diego, CA, USA). The quality of the extracted total RNA 
was evaluated by NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, 
DE, USA) and Agilent Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, 
USA). Total RNA was then used for complementary RNA (cRNA) in vitro transcription 
and labeling by the TotalPrep RNA Amplification Kit (Illumina).  A normalized amount 
of labeled cRNA was hybridized with the probes on HumanHT-12 v4 Expression 
BeadChip in anhybridization oven, followed by washing and staining with Cy3-
streptavidin (all from Illumina). The BeadChip was scanned with iScan with iScan Control 
Software, and the data were analyzed with GenomeStudio (2010.2) with the Gene 
Expression Module (1.7.0, all from Illumina). 
 Genes with a fold difference in expression ?1.5 between particle-stimulated and 
unstimulated macrophages were considered significant and included in additional analysis. 
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Gene ontology enrichment analysis was by Fisher's Exact Test, and involved comparing 
the frequency of each present GO term to its  frequency in a reference gene set.  Multiple 
hypotheses-corrected P-values of less than 0.05 were considered significant. Signaling 
pathway impact analysis (SPIA) performed as described by Tarca et al (2009). 
 
7.7. cDNA synthesis and qRT-PCR (III, IV) 
 
The amount and quality of the total RNA extracted from 4-hour particle-stimulated- 
and unstimulated human M0, M1, and M2 macrophages (Study IV);  0-, 2-, 6-, 10-, and 
24-h particle-stimulated and unstimulated mouse RAW 264.7 macrophages (Study III); 
and frozen synovial and interface tissues (in the TLR-expression profiling study), was 
measured with a NanoDrop 1000 spectrophotometer (Thermo scientific). Complementary 
DNA (cDNA) was then synthesized, using an equal amount of total RNA from each 
sample  and  either  a  VILO  Superscript  cDNA  synthesis  kit  (Invitrogen,  Carlsbad,  CA,  
USA) in Study III or  iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) in Study 
IV and in the TLR-expression profiling study.  
For  quantitative  real-time  PCR,we  prepared  a  reaction  mix  comprising   sample  
cDNA, a pair of purpose-designed human or mouse forward and reverse primers (Tables 5 
and  6),  and  iQ  SYBR  Green  Supermix  (Bio-Rad).  qRT-PCR  was  then  done  with  iQ5  
Real-Time PCR Detection System (Bio-Rad). In Study III, results were normalized to ?-
actin (ACTB), whereas three housekeeping genes: ACTB, porphobilinogen deaminase 
(PBGD), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served for 
normalization of the results in Study IV. In the TLR expression profiling study, two 
housekeeping genes, PBGD and large ribosomal protein P0 (RPLP0), served for results 
normalization. 
In Study III, TLR quantification was done by comparing the fluorescence of sample 
PCR  products  with  the  fluorescence  of  a  dilution  series  of  an  external  standard  of  each  
TLR in question. In Study IV, and in the TLR expression profiling study, results were 
obtained by use of the comparative Ct method (Schmittgen and Livak 2008). 
Primer  pairs  were  designed  with  Beacon  designer  software  (v7.5  Premier  Biosoft  
international, Palo Alto, CA, USA) and the National Center for Biotechnology 
Information BLAST online program. For Study III primers were manufactured by Proligo 
(Paris, France) and for Study IV and for TLR expression profiling study by Oligomer 
(Helsinki, Finland). 
 
Table 5. Human primer sequences used in Study IV and in the TLR expression profiling 
study.  bp  –  Base  pairs;  OSM  -  oncostatin  M;  IL  -  interleukin;  CCL  -  chemokine  (C-C  
motif) ligand; CXCL - chemokine (C-X-C motif) ligand; TNFSF - tumor necrosis factor 
super family; RANKL - receptor activator of nuclear factor kappa B ligand; OPG - 
osteoprotegerin; TRAP - tartrate-resistant acidic phosphatase; CTSK - cathepsin k; TLR - 
toll-like receptor; ACTB - ?-actin; GAPDH - glyceraldehyde 3-phosphate dehydrogenase; 
PBGD - porphobilinogen deaminase; RPLP0 - large ribosomal protein P0. 
 
Gene Primer sequence Product (bp) 
OSM Forward (5’) GGGAGGCGCTGCTCTAAGTCG 
Reverse (3’)  GGACGCTGCTCAGTCTGGTCCTTG 
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IL-6 Forward (5’) AGGAGACTTGCCTGGTGAAA 
Reverse (3’)  GAGGTGCCCATGCTACATTT 
329 
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IL-8 Forward (5’) ACTTCTCCACAACCCTCTGG 
Reverse (3’)  TCTGCAGCTCTGTGTGAAGG 
229 
CCL2 Forward (5’) ATTCCCCAAGGGCTCGCTCA 
Reverse (3’)  GGTTTGCTTGTCCAGGTGGTCC 
231 
CCL3 Forward (5’) GGCTTCGCTTGGTTAGGAAGATGA 
Reverse (3’)  CAGAAGGACACGGGCAGCAGAC 
294 
CCL4 Forward (5’) GAGCAGCTCAGTTCAGTTCCAGGTC 
Reverse (3’)  AGTAGCTGCCTTCTGCTCTCCAGCG 
248 
CCL20 Forward (5’) ACTCCACCTCTGCGGCGAAT 
Reverse (3’)  CTGCCGTGTGAAGCCCACAA 
106 
CXCL2 Forward (5’) TAAGGGCAGGGCCTCCTTCAGG 
Reverse (3’)  TGGGCAGAAAGCTTGTCTCAACCCC 
141 
TNFSF9 Forward (5’) CAGCAGAACATTTTGGGCCACCA 
Reverse (3’)  AGCTTTCGCCCGACGATCCC 
83 
TNFSF14 Forward (5’) TGCTGGGTTGACCTCGTGAGAC 
Reverse (3’)  CGGGTGGGTCTGGGTCTCTTGC 
177 
RANKL Forward (5’) GAGCGCAGATGGATCCTAAT 
Reverse (3’)  GCTTCAAGCTTGCTCCTCTT 
274 
OPG Forward (5’) TGTGAGGAGGCATTCTTCAG 
Reverse (3’)  GGTTAGCATGTCCAATGTGC 
265 
TRAP Forward (5’) CTGTCCTGGCTCAAGAAACA 
Reverse (3’)  CCATAGTGGAAGCGCAGATA 
299 
CTSK Forward (5’) ACCCAACAGGCAAGGCAGCTAA 
Reverse (3’)  GCAATGCCACAGGCGTTGTTCT 
325 
TLR1 Forward (5’) CGGAGGCAATGCTGCTGTTCAG 
Reverse (3’)  TGTAGGGGTGCCCAATATGCCT 
130 
TLR2 Forward (5’) GCTGCTCGGCGTTCTCTCAGG 
Reverse (3’)  TGTCCAGTGCTTCAACCCACAACT 
190 
TLR3 Forward (5’) TGCCGTCTATTTGCCACACACTTC 
Reverse (3’)  GTGCACTTGGTGGTGGAGGATGC 
175 
TLR4 Forward (5’) CCTGCGTGGAGGTGGTTCCTA 
Reverse (3’)  CCAGAAAAGGCTCCCAGGGCTA 
289 
TLR5 Forward (5’) TGTTGGCGCTGTCCGAACCT 
Reverse (3’)  AGGTGGTCTCCCATGATCCTCG 
211 
TLR6 Forward (5’) AAGAGATCTTGAATTTGGACTCATATC 
Reverse (3’)  TGAAGCTCAGCGATGTAGTTC 
278 
TLR7 Forward (5’) TCTTGGCACCTCTCATGCTCTGC 
Reverse (3’)  GTGAGGTTCGTGGTGTTCGTGGG 
281 
TLR8 Forward (5’)  CTGCGCTGCTGCAAGTTACGGA 
Reverse (3’)  TTGCCCACCGTTTGGGGAACTTC 
234 
TLR9 Forward (5’) CCCAGCATGGGTTTCTGC 
Reverse (3’)   ACTTCAGGAACAGCCAGTTG 
160 
ACTB Forward (5’) CAGCGGAACCGCTCATTGCCAATGG 
Reverse (3’)  TCACCCACACTGTGCCCATCTACGA 
295 
GAPDH Forward (5’) AAGGTCATCCCTGAGCTG 
Reverse (3’)  TGCTGTAGCCAAATTCGTTG 
310 
PBGD Forward (5’) AGATGCGGGAACTTTCTCTG 
Reverse (3’)  ACATGCCCTGGAGAAGAATG 
237 
RPLP0 Forward (5’) GGCGACCTGGAAGTCCAACT 
Reverse (3’)  CCATCAGCACCACAGCCTTC 
149 
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Table 6. Mouse primer sequences used in Study III.  bp – Base pairs; TLR - toll-like 
receptor; ACTB - ?-actin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.8. Protein suspension array (IV) 
 
Levels of 39 chemokines, cytokines, and growth factors in 24-hour particle-
stimulated and corresponding control M0, M1, and M2 macrophage culture supernatants 
were measured with the Milliplex MAP Human Cytokine/Chemokine premixed 39 Plex 
kit  (Millipore,  Billerica,  MA,  USA)  and  Bio-Plex  Suspension  Array  System  (Bio-Rad  
Laboratories). A pooled cell culture supernatant sample was prepared by combining equal 
volumes of culture supernatant derived from four independent particle stimulation 
experiments. This pooled sample was analyzed in two technical replicates. A 20% 
increase or decrease in cytokine-, chemokine-, or growth-factor concentration compared to 
that in control cells was considered significant. Cytokines included in the analysis were 
CCL2, CCL3, CCL4, CCL7, CCL11, CCL22, chemokine (C-X3-C motif) ligand 
(CX3CL) 3, CXCL1, CXCL10, granulocyte colony-stimulating factor (G-CSF), GM-CSF, 
VEGF, epidermal growth factor (EGF), TGF-?, fibroblast growth factor (FGF)-2, fms-like 
tyrosine kinase 3 ligand (FLT-3 ligand), IFN-?2, IFN-?, IL-1?, IL-1?, IL-1ra, IL-2, sIL-
2r?, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, 
IL-17, sCD40L, TNF?, and TNF?. 
 
7.9. Statistical analyses (I, III, IV) 
 
Statistical analyses used R (version 2.9.0, Studies I, III) or Graphpad Prism version 
4.0 (GraphPad Software, La Jolla, CA, USA, Study IV and the TLR-expression profiling 
study). Results are expressed as mean ± standard error of mean and two-sided P values 
less than 0.05 were considered significant. A nonparametric Mann-Whitney test served for 
pair-wise comparison of variables in Studies I, III, and in the TLR-expression profiling 
study. A nonparametric Friedman test with Dunn’s post-hoc test for matched groups 
allowed comparison of differences between groups in Study IV. 
Gene Primer sequence Product (bp) 
TLR1 Forward (5’) GCTGGCCTGACTCTTACAGG 
Reverse (3’)  TCTGGATGAAGTGGGGAGAC 
465 
TLR2 Forward (5’) GACTCACAGCAGCCATGAAA 
Reverse (3’)   TCGCGGATCGACTTTAGACT 
451 
TLR4 Forward (5’)  GCTTTCACCTCTGCCTTCAC 
Reverse (3’)  AGGCCCCAGAGTTTTGTTCT 
432 
TLR5 Forward (5’) ATTCCTCGTCATCACCCTTG 
Reverse (3’)  TGCTTTTGCAGAAACCCTCT 
480 
TLR8 Forward (5’)  CTTTCCAGCACTTCCCTCAG 
Reverse (3’)  GAAGACGATTTCGCCAAGAG 
460 
TLR9 Forward (5’)  TGTCCTTCCTACCCAACCTG 
Reverse (3’)  AAGAGTGAAAGGCCAAAGCA 
454 
ACTB Forward (5’) CTTCTTTGCAGCTCCTTCGT 
Reverse (3’)   GTGCCAGATCTTCTCCATGT 
310 
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8. Results 
 
8.1. Histopathology of aseptic and septic THR loosening (I, II) 
 
8.1.1. Tissue architecture and cell populations 
In control synovial samples, well-vascularized and, in some areas, slightly edemic 
loose connective tissue stroma was visible under a typical synovial lining layer. The tissue 
stroma  was  relatively  acellular,  and  the  most  common  cell  type  was  HSP47+ fibroblast, 
whereas inflammatory cell populations were scarce. Some scattered CD68+ and CD163+ 
macrophages were, however, evident and represented the second most common cell 
population encountered. Macrophages observed were small and did not form larger 
clusters. Minimal infiltrations by scattered CD3+T cells and by small groups of CD20+ B 
cells also occurred, whereas no CD138+ plasma cells were visible. Neutrophils dectected 
were intravascular. 
In aseptic synovial membrane-like interface tissues, two primary types of tissue 
architecture appeared: in some samples, large areas of relatively acellular and collagen-
rich fibrotic tissue   were visible, whereas in other samples an intensive and cell-rich 
foreign  body  reaction  was  observable.   In  fibrotic  areas,  the  HSP47+ fibroblast was the 
most commonly encountered cell, and in the areas of foreign-body reaction, loose 
connective tissue stroma was heavily infiltrated by large CD68+ and CD163+ macrophages 
forming sheet-like infiltrates, foreign body giant cells and some granulomas. By polarized 
light microscopy, phagocytosed UHMWPE particles were detectable in most samples and, 
in samples with apparent metallosis, phagocytosed metal particles were also visible. Some 
scattered CD3+ T cells and HSP47+ fibroblasts were located between the large macrophage 
infiltrates. No apparent neutrophil, CD20+ B cell, or CD138+ plasma cell infiltration into 
tissue was detectable. 
In septic synovial membrane-like interface tissues, some samples or sections showed 
large areas of necrosis and fibrosis, whereas other samples or sections consisted of loose 
connective tissue heavily infiltrated by heterogeneous inflammatory cell populations 
interspersed among HSP47+ fibroblasts.  Large CD68+ and CD163+ macrophage infiltrates 
consisting of large macrophages organized in sheet-like infiltrates and foreign body giant 
cells were visible. Some phagocytosed wear particles were detectable. Neutrophils formed 
considerable infiltrates in some, but not all, areas. High numbers of scattered and nodular 
CD3-positive T lymphocytes and also nodular CD20+ B cell infiltrates were present. Some 
of the B cells had been activated to the CD138+ plasma cell. 
 Summary of the cell populations present in control, aseptic, and septic interface 
tissues is in Figures 4 and 6. 
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Figure 4. Cell populations in osteoarthritic control synovial membrane, aseptic, and septic 
interface tissues were evaluated by immunohistochemistry with cell-type-specific 
antibodies (Study II). The number of positive cells in each tissue was evaluated on a 
semiquantitative scale (vertical axis), with no positive staining (-); occasional positive 
cells (±); some positive cells (+); moderate numbers of positive cells (++); and large 
numbers of positive cells (+++).  
8.1.2. TLR expression and cell localization 
In  control  synovial  samples,  all  TLRs  were  present,  and  the  mean  number  of  
TLR+cells was 26.9 ± 8.3 per high-power field (Table 7). In control samples, TLR 
immunoreactivity occurred mainly in the vascular endothelium and in some synovial 
lining cells. Occasional macrophages and fibroblasts in tissue stroma were also positive 
for the TLRs. No clear difference in staining pattern or cell populations of different TLRs 
was detectable, although the number of cells positive for TLR9 appeared to be markedly 
low. In qRT-PCR analysis, all of the TLRs were expressed in the control synovial tissues 
(Table 8, Pajarinen J, Jämsen E, Konttinen YT, unpublished results). 
In aseptic synovial membrane-like interface tissues, all TLRs were present, with the 
mean number of TLR-positive cells being 56.9 ± 14.7 per high-power field (Table 7). In 
addition to vascular endothelium, fibroblasts, and occasional synovial lining cells, sheet-
like macrophage infiltrates, and foreign body giant cells were heavily positive for all of 
the TLRs. No clear difference occurred in the staining pattern among TLRs, because the 
infiltrating macrophages seemed to be positive for all of the TLRs. In qRT-PCR analysis, 
all  of  the  TLRs  were  expressed  in  the  aseptic  interface  tissue,  and  the  expression  of  all  
TLRs except TLR3 and TLR7 was significantly higher than in control tissues. Similarly, 
in comparison to control tissues, the expression of the macrophage-derived chemokines 
IL-8, CCL2, CCL3, and CCL4, as well as osteoclast markers TRAP and cathepsin K were 
significantly upregulated and OPG downregulated, while RANKL was unaffected (Table 
8). 
 In septic synovial membrane-like interface tissues, TLR immunoreactivity appeared 
especially in macrophages but also in infiltrating neutrophils and in vascular endothelium. 
Infiltrating lymphocytes were TLR positive, but the exact identity of these cells could not 
be confirmed. No clear difference in staining pattern among TLRs was detectable because 
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the infiltrating inflammatory cell populations, mainly macrophages and neutrophils, 
seemed to be positive for both of the TLRs. 
 Summary of the TLR localization in control, aseptic, and septic interface tissues 
appears in Figures 5 and 6. 
 
8.1.3. Control stainings 
All control immunohistochemical stainings done with irrelevant IgGs used at the same 
concentration but instead of the primary antibodies were negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  5.  TLR4  and  TLR9  localization  in  various  cell  types  in  osteoarthritic  control  
synovial membrane, aseptic, and septic interface tissues as evaluated by 
immunohistochemistry (Study II). Vertical axis as in Figure 4. 
 
 
 
55 
 
Table 7. Mean number of TLR immunoreactive cells in controlosteoarthritic synovial 
membrane and in aseptic interface tissues as determined by immunohistochemical staining 
(Study I). TLR - toll-like receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Expression of selected chemokines (A), osteoclast markers (B), and TLRs (C) in 
control osteoarthritic synovial tissues and in aseptic interface tissue as determined by 
qRT-PCR (Pajarinen J, Jämsen E, Konttinen YT, unpublished results). Fc - fold change; 
other abbreviations as in Table 5. 
 
 
 Gene Relative 
expression 
control 
Relative 
expression 
aseptic 
Fc P value 
A IL-8 81 ± 32 1008 ± 319 12.4 0.001 
 CCL2 1161 ± 250 4494 ± 930 3.9 0.015 
 CCL3 5 ± 2 146 ± 62 29.7 <0.001 
 CCL4 155 ± 50 696 ± 322 4.5 0.034 
B RANKL 6 ± 2 5 ± 2 - ns 
 OPG 245 ± 70 38 ± 15 -6.7 0.005 
 TRAP 20 ± 5 1912 ± 313 95.6 <0.001 
 CTSK 3213 ±  725 14777 ± 1806 4.6 <0.001 
C TLR1 59 ± 5 165 ± 20 2.9 <0.001 
 TLR2 108 ± 24 196 ± 25 1.8 0.023 
 TLR6 31 ± 6 63 ± 10 2 0.005 
 TLR4 194 ± 42 279 ± 34 1.4 0.022 
 TLR5 91 ± 15 166 ± 27 1.8 0.038 
 TLR3 279 ± 56 190 ± 27 - ns 
 TLR7 399 ± 64 541 ± 103 - ns 
 TLR8 166 ± 21 438 ± 63 2.6 0.001 
 TLR9 2.5 ± 0.5 4.7 ± 0.7 1.9 0.030 
 
 
Receptor Control Aseptic 
TLR1 22 ± 4.1 49 ±14.2 
TRL2 27.8 ± 2.7 61 ± 22.3 
TLR3 36.8 ± 10.1 75.3 ± 19.5 
TLR4 22.3 ± 5.4 71.8 ± 26.2 
TLR5 24.5 ± 4.6 45.8 ± 18.9 
TLR6 14.8 ± 1.4 54 ±  15 
TLR7 26.8 ± 8.6 56.5 ± 14.5 
TLR8 40.5 ± 7.3 69 ± 17.1 
TLR9 3.8 ± 2.8 40.5 ± 9.0 
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Figure 6. Immunohistochemical staining results of Studies I and II. In osteoarthritic 
synovial membrane, occasional small CD68+ macrophages are visible, scattered among 
fibroblasts (a). In contrast, interface tissue from aseptic loosening is characterized by 
massive infiltration of CD68+ macrophages and formation of foreign body giant cells (b). 
These large macrophages and foreign body giant cells express all of the TLRs 
investigated, including TLR1 (c), TLR2 (d), TLR4 (e) and TLR6 (f). In osteoarthritic 
synovial membrane (g) and in aseptic interface tissue (h) only occasional CD3+ T 
lymphocytes are visible, scattered among the fibroblasts and macrophage infiltrates, but 
no B lymphocytes or plasma cells were detectable. In contrast, in septic loosening, diffuse 
infiltrates of CD3+ T lymphocytes (j) and nodular infiltrates of CD20+ B lymphocytes (j) 
and CD138+ plasma cells (k) were observable.  In septic interface tissue samples NE+ 
neutrophil infiltrates were also detectable in some areas (l).  Scale bars 50 µm. CD - 
cluster of differentiation; TLR - toll-like receptor; NE - neutrophil elastase. 
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8.2. Effect of wear particles on TLR expression (III) 
 
8.2.1. Mouse model of particle-induced inflammation 
 In femur samples collected two weeks after the implantation, active bone 
remodeling and callus formation occurred in both study groups (stainless-steel rod with or 
without titanium particles). Inflammatory cells were visible in bone marrow. After ten 
weeks of implantation, inflammation and active bone remodeling had ceased, and callus 
had consolidated into compact bone. The rod channel was surrounded by circumferential 
woven bone that often formed struts radiating toward the cortical bone. In the particle 
group, titanium particles occurred in the intramedullary space and within the fibrous 
interface tissues. Some of the particles had been phagocytosed by bone marrow 
macrophage-like cells. TLR immunoreactive cells were visible among the bone-marrow, 
bone,  endosteal,  and  periosteal  cells.  The  number  of  TLR  immunoreactive  cells  was  
generally higher in two-week samples than in ten-week samples, and additionally, the 
number of TLR-immunoreactive cells seemed to be reduced in the particle group at both 
time-points  as  compared  to  the  non-particle  group.  A  summary  of  the  
immunohistochemical staining results is in Figures 7 and 8. 
 
8.2.2. In vitro mouse macrophage culture 
Mouse monocyte/macrophage cell line RAW 264.7 expressed the investigated TLRs 
at the mRNA level, as indicated by qRT-PCR. Although TLR expression levels tended to 
be lower in the particle-stimulated cells than in non-stimulated control cells, no clear 
differences in TLR expression levels were detectable at any of the time-points during 24-
hour particle stimulation. 
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Figure 7. Number of TLR immunoreactive cells in endosteum, bone, and periosteum in a 
mouse intramedullary model of particle-induced inflammation (Study III). A stainless 
steel  wire  with  (particles)  or  without  (control)  titanium particles  was  inserted  bilaterally  
into the mouse femoral canal; the number of peri-implant TLR immunoreactive cells was 
evaluated two and ten weeks post-operatively. Vertical axis as in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Number of TLR immunoreactive cells in bone marrow in a mouse 
intramedullary model of particle-induced inflammation (Study III). A stainless steel wire 
with  (particles)  or  without  (control)  particles  was  inserted  bilaterally  into  the  mouse  
femoral canal, and the number of peri-implant TLR immunoreactive cells was evaluated 
two and ten weeks post-operatively. Vertical axis as in Figure 4. 
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8.3. Effect of macrophage polarization on wear-particle responses (IV) 
 
8.3.1. Cell morphology, motility, and particle phagocytosis 
 Monocyte-to-macrophage differentiation and subsequent macrophage polarization 
had an impact on the cell morphology, motility, and phagocytotic activity of macrophage 
subtypes. During monocyte-to-macrophage differentiation, initially small and rounded 
monocytes adhered, spread to the culture surface, and actively proliferated, already by  
day one forming large colonies and spreading over the culture dish. After full macrophage 
differentiation and polarization, M0 macrophages were mostly elongated and spindle-
shaped, M1 macrophages clearly rounded, and M2 macrophages mostly cone-shaped, 
likely reflecting their high mobility rate. After titanium-particle addition, rapid 
phagocytosis of particles was observable; only 15 min after particle addition, considerable 
numbers of particles appeared in the intracellular compartment of all three macrophage 
subtypes. 
In time-lapse microscopy, M0 and M2 macrophages actively moved around the 
culture dish, at the same time phagocytosing foreign particles on a relatively large surface 
area, while M1 macrophages were practically stationary and phagocytosed titanium 
particles only from their immediate surroundings, leaving large quantities of titanium 
particles between their cell bodies. During a 6-hour follow-up, the average speed of M0 
macrophages was 5.0 nm/s ± 1.4, of M1 macrophages 2.6nm/s ± 0.65, and of M2 
macrophages 6.3 nm/s ± 1.5. After 24 hours of particle addition and phagocytosis, the 
percentage of background area covered by particles, and thus not phagocytosed by 
macrophages, was 0.43% ± 0.01 for M0 macrophages, 0.86 ± 0.09 for M1 macrophages, 
and 0.43% ± 0.02 for M2 macrophages.  
 
8.3.2. Microarray and qRT-PCR 
A summary of 4-hour titanium particle stimulation-induced transcriptome changes 
in M0, M1, and M2 macrophages is  in Table 9 and a selected list of these particle-induced 
genes in various  macrophage types with fold change ? 2 in Table 10 (with a more detailed 
listing of the genes involved provided in the original publication).  The most prominent 
wear particle responses occurred in M1 macrophages and the least in M2 macrophages. 
The wear particle-induced transcriptome changes were highly unique in each macrophage 
subtype,  with  only  one  gene  in  common  for  the  wear  particle  response  of  all  three  cell  
types, RND3, up-regulated in all three macrophage subtypes. Eight genes were up-
regulated both in M0 and M1 macrophages (IL-8, CCL20, JUN, IRAK2, DUSP5, GEM, 
HES4, ZC3H12C), whereas only one gene was in common in the wear-particle response 
of M0 and M2 macrophages (MARCKSL1). Three genes were up-regulated in both M1 
and M2 cells (ATF4, IER3, HEG1), whereas one gene was up-regulated in M1 
macrophages but down-regulated in M2 macrophages (CXCL1).  
GO and SPIA analyses were subsequently performed to identify possible functional 
groups of genes or signaling pathways that might be activated by wear-particle stimulation 
in  the  three  macrophage  subtypes.  A  summary  of  these  analyses  is  in  Table  11  (with  a  
more detailed listing of the GO terms involved provided in the original publication).  
To verify results of the microarray experiment, qRT-PCR was performed for 
selected genes in a larger sample size (Table 12). 
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Table 9. Summary of the effect of macrophage polarization on wear-particle-induced 
transcriptome changes (Study IV). M0, M1, and M2 macrophages were subjected to 
titanium particles for four hours, and the subsequent transcriptome changes in each 
macrophage subtype analyzed by genome-wide microarray analysis. Number of genes 
involved and up- or down -regulated in each macrophage subtype is included . “Unique”   
signifies the percentage of genes up- or down-regulated only in the corresponding 
macrophage subtype. 
 
 
 
 
Table 10. Selected particle-induced or suppressed genes among  macrophage types (Study 
IV). M0, M1, and M2 macrophages were subjected to titanium particles for four hours, 
and the subsequent transctiptome changes in each macrophage subtype analyzed by 
genome-wide microarray analysis. Only genes with fold change of ? 2 are presented. In 
M0 macrophages, no genes with fold change of ? 2 were detectable. 
 
M0 
Gene Description Fold change 
- - - 
M1 
Gene Description Fold change 
CCL3L1 chemokine (C-C motif) ligand 3-like 1  4.6 
CCL3 chemokine (C-C motif) ligand 3  4.2 
CCL20 chemokine (C-C motif) ligand 20 4.1 
CCL4L2 chemokine (C-C motif) ligand 4-like 2 3.2 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9  3.2 
OSM oncostatin M 2.6 
IL-?? interleukin 1, beta 2.4 
CXCL2 chemokine (C-X-C motif) ligand 2 2.3 
IL-8 interleukin 8  2.2 
PTGS2 prostaglandin-endoperoxide synthase 2 2.2 
M2 
Gene Description Fold change 
PLXND1 plexin D1 0.5 
MARCKSL1 MARCKS-like 1 0.5 
FMNL1 formin-like 1 0.5 
THBS1 thrombospondin 1 0.5 
CABP5 calcium- binding protein 5 0.5 
 
Cell type Tota no. of genes 
altered 
Up-regulated 
genes 
Down-regulated 
genes 
Unique 
M0 63 32 31 84% 
M1 192 145 47 94% 
M2 59 33 26 92% 
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Table 11. Results of the gene ontology (GO) and signaling pathway impact analyses 
(SPIA) of the microarray data (Study IV). M0, M1, and M2 macrophages were subjected 
to titanium particles for four hours, and the subsequent transcriptome changes in each 
macrophage subtype analyzed by genome-wide microarray analysis (Study IV). To 
identify possible functional groups or signaling pathways activated, GO (A) and SPIA (B) 
analyses of microarray expression data were necessary. (A) In M0 macrophages, one GO 
term was significantly enriched, in M1 macrophages, 115 different GO terms were 
significantly enriched, but none in M2 cells. The ten statistically most enriched GO 
biological process terms in M1 macrophages are shown. (B) According to the SPIA, two 
signaling pathways were activated in M0 macrophages, four in M1 macrophages, and 
none that could be recognized in M2 macrophages. 
 
A Cell type GO term Number of Genes P value 
 M0 Chemokine activity 4 0.029 
 M1 Inflammatory response 26 <0.001 
  Immune response 35 <0.001 
  Response to external stimulus 32 <0.001 
  Chemotaxis 16 <0.001 
  Negative regulation of cellular process 55 <0.001 
  Regulation of phosphorylation 26 <0.001 
  Negative regulation of kinase activity 12 <0.001 
  Signal transduction 61 <0.001 
  Cell communication 51 <0.001 
  Apoptosis 36 <0.001 
 M2 - - - 
B Cell type SPIA pathway Number of genes P value 
 M0 Chemokine signaling 6 0.0054 
  Toll-like receptor signaling 5 0.0132 
 M1 Cytokine-receptor interaction 19 <0.001 
  Chemokine signaling 13 <0.001 
  NOD-like receptor signaling 9 <0.001 
  Toll-like receptor signaling 7 <0.001 
 M2 . - - 
 
 
Table 12. Results of the qRT-PCR (Study IV). M0, M1, and M2 macropages were 
subjected to titanium particles for four hours, and the expression levels of selected genes 
were analyzed by qRT-PCR. Data represented as fold change between particle-stimulated 
and unstimulated samples. * = P<0.05 between M1 and M2. Abbreviations as in Table 5. 
 
Gene M0 M1 M2 
OSM 3.4 ± 1.0 9.6 ± 2.1* 2.0 ± 0.4 
IL-8 2.6 ± 0.3 4.7 ± 0.5 2.5 ± 0.4 
CCL3 2.1 ± 0.2 4.7 ± 0.9* 1.4 ± 0.2 
CCL20 3.9 ± 0.6 8.6 ± 4.0 2.3 ± 1.0 
CXCL2 3.5 ± 1.0 5.9 ± 1.0 2.9 ± 1.2 
TNFSF9 2.8 ± 1.0 6.7 ± 1.1* 1.1 ± 0.1 
TNFSF14 1.9 ± 0.4 2.5 ± 0.3 1.2 ± 0.1 
IL-6 1.7 ± 0.3 8.0 ± 4.2 1.1 ± 0.1 
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8.3.3. Protein suspension array 
An overview of 24-hour titanium-particle stimulation-induced qualitative proteome 
changes in M0, M1, and M2 macrophages is in Table 13 (with more detailed listing of 
mediators similarly or differentially regulated provided in the original publication). 
Qualitatively, M0 and M1 macrophage wear-particle-response profiles resembled each 
other, while the M2 response profile was more distinct from the other two macrophage 
types. However, quantitative analysis of wear particle responses revealed that the wear-
particle  responses  of  M0  and  M1  macrophages  were,  in  fact,  also  dissimilar  and,  in  
comparison to M0 macrophages, the wear-particle responses in M1 macrophages were 
generally enhanced, as detailed in Table 14. In M2 macrophages, chemotactic and pro-
inflammatory particle responses typical for M0 and M1 cells were effectively suppressed, 
although an increase in IL-8, CCL7, and IL-1? and a decrease in IL-10 production 
occurred (Table 14).  Interestingly, wear-particle stimulation had no effect on production 
of IFN-?2, IFN-?, or IL-4 in any macrophage subtype. 
In addition to wear-particle responses, some observations about the nature of 
different macrophage subtypes were possible. Unstimulated M0 and M1 macrophages 
produced high basal levels of CXCL10, while M2 macrophages displayed high basal 
secretion of CCL22, IL-10, IL-1ra, and TGF?. In addition, M1 macrophages produced 
high amounts of IFN-?, and M2 macrophages of IL-4, likely reflecting positive auto- and 
paracrine feedback loops. 
Basal secretion levels of CCL2 were very high and beyond the suspension-array 
detection range in all of these macrophage subtypes. Likewise, the production of IL-8 and 
CXCL10  was  over  the  arrays’  detection  range  in  particle-stimulated  M0  and  M1  
macrophages. and of CCL22 in both stimulated and unstimulated M2 macrophages. No 
IL-2, IL-3, IL-5, IL-9, IL-13, IL-17, or TNF-? was produced by any of the macrophage 
types, neither at basal level nor after particle stimulation. 
 
 
 
Table 13. Summary of the effect of macrophage polarization on wear-particle-induced 
proteome changes (Study IV). M0, M1, and M2 macropages were subjected to titanium 
particles for 24 hours, and subsequently the concentration of 39 cytokines, chemokines, 
and  growth-factors  in  the  cell  culture  media  was  evaluated  by  protein  suspension  array.   
The total number of mediators, as well as the number of mediators, increased or decreased 
by wear- particle stimulus in macrophage subtypes is presented.  “Unique” indicates the 
number of mediators exclusively up-regulated/down-regulated in the corresponding 
macrophage subtype. 
 
 
 
 
 
 
 
 
Cell type Total Increased Decreased Unique 
M0 20 17 3 2/1 
M1 22 22 0 5/0 
M2 10 3 7 1/6 
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Table 14. Cytokine levels (pg/µl) in particle-stimulated (+) and unstimulated (-) 
macrophage subpopulations as determined by protein suspension array. M0, M1, and M2 
macrophages were subjected to titanium particles for 24 hours, and subsequently the 
concentration  of  39  cytokines,  chemokines,  and  growth-factors  in  the  cell  culture  media  
was evaluated by protein suspension array. In comparison to M0 macrophages, the wear-
particle responses in M1 macrophages were generally enhanced, and especially the 
production of mediators listed under A was higher in M1 than in other macrophage types. 
Mediators in section B were produced in similar magnitudes by both particle-stimulated 
M0 and M1 macrophages. Particle responses in M2 macrophages were generally 
suppressed, although an increase in IL-8, CCL7, and IL-1? and a decrease in IL-10 
production occurred (B, C, D). Type I interferon INF-?2 remained unaffected by particle 
stimulation. In addition to having an impact on macrophage wear-particle responses, basal 
secretion of several mediators was affected by macrophage polarization (D). (#) over 
assay’s detection range. For abbreviations see section 7.8. 
 
  M0 M1 M2 
  - + - + - + 
A TNF? 9.5 54.5 54.5 323.8 18.5 18.5 
IL-1? 1.2 4.2 1.9 7.2 1.4 1.0 
CCL3 54.6 266.8 83.7 1282.9 74.1 67.6 
IL-7 8.1 10.6 10.6 23.1 9.4 8.8 
IL-12p40 5.0 4.6 5.3 11.0 7.9 5.7 
IL-12p70 1.8 2.1 2.7 3.9 1.6 1.4 
GM-CSF 5.2 11.1 7.5 23.6 7.8 7.9 
G-CSF 1.2 2.9 2.1 8.3 7.5 5.4 
EGF 12.5 11.1 6.3 13.5 11.5 10.9 
sIL-2RA 3.5 3.6 4.9 9.4 5.0 4.7 
sCD40L 16.6 11.9 13.7 18.9 7.1 7.1 
FLT3lig. 11.3 13.5 10.0 19.9 13.0 11.9 
B IL-6 6.8 9.4 7.0 9.4 8.0 5.2 
 CCL4 411.7 1084.1 333.0 1253.1 748.7 693.1 
 CCL7 408.3 620.3 568.9 768.2 186.8 232.2 
 CCL11 20.3 25.5 20.2 32.2 15.6 16.8 
 CXCL1 1119.3 1576.6 888.5 1235.0 300.8 281.3 
 FGF2 19.6 28.2 21.1 32.8 20.6 19.8 
 VEGF 80.9 141.4 96.3 184.8 67.9 74.9 
C IL-8 7124.0 #8946 7583.0 #9131 1372.0 2963,8 
 IL-?? 24.1 21.6 27.8 27.6 2.8 6.3 
 IFN-?2 29.3 31.0 31.2 35.9 22.4 22.4 
D CXCL10 #29121 #26495 #28671 #30053 1651.1 711.5 
 CCL22 6467.0 4858.0 3223.0 4385 #41463 #29986 
 IL-10 5.9 8.2 1.02 2.3 28.0 17.9 
 IL-1ra 65.3 81.9 86.7 159.4 218.2 207.3 
 TGF? <1 <1 <1 <1 20.3 21.7 
 IFN? 22.9 24.5 639.1 613.7 6.0 4.5 
 IL-4 194.9 177.4 193.4 208.6 3051.2 2927.2 
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9. Discussion 
 
9.1. Histopathology of aseptic and septic THR loosening (I,II) 
 
9.1.1. Cell populations of aseptic and septic interface tissue 
We analyzed cell populations present in the aseptic and septic interface tissues and 
in control synovial tissue, using antibodies raised against cell-type-specific markers. We 
evaluated the presence and relative amount of tissue fibroblasts (HSP47), macrophages 
(CD68 and CD163), neutrophils (neutrophil elastase), T cells (CD3), B cells (CD20), and 
plasma cells (CD163). 
In comparison to control synovial tissue that contained mostly fibroblasts and 
occasional macrophages, likely representing tissue-resident macrophages, the aseptic 
interface tissue was characterized by massive macrophage infiltrates composed of large 
CD68+ and CD163+ macrophages organized into sheet-like formations or chain-like 
structures. Foreign-body giant cell formation was also consistently observable. Some 
scattered T cells were apparent between macrophage infiltrates, but neutrophils, B cells, 
and plasma cells were absent. These findings are in agreement with various reports 
consistently describing the macrophages and foreign body giant cells as the hallmarks of 
the foreign body reaction in the aseptic interface tissues (Willert and Semlitsch 1977, 
Goldring et al 1983, Goodman et al 1989, Santavirta et al 1990, Jiranek et al 1993, Kim et 
al 1993, Boynton et al 1995, Goodman et al 1997, 1998). Likewise, the presence of some 
scattered T lymphocytes and the rarity or absence of neutrophils, B cells, and plasma cells 
is in line with previous findings (Jiranek et al 1993, Boynton et al 1995, Goodman et al 
1997, Goodman et al 1998, Baldwin et al 2002, Arora et al 2003). 
In septic synovial interface tissues, in addition to occasional areas of sheet-like 
macrophage  infiltrates  closely  resembling  those  of  the  aseptic  interface  tissues  and  thus  
possibly reflecting underlying and developing foreign body reaction, all of the 
investigated inflammatory cell populations were detectable.  In some areas, hundreds of 
neutrophils formed considerable infiltrates, thus fitting well into earlier descriptions 
defining the septic interface as containing 1 to 10 neutrophils in a high-power field. T and 
B lymphocytes as well as plasma cells also formed considerable infiltrates in some areas, 
with T cells displaying a more scattered distribution, and B cells and activated plasma 
cells forming clearly nodular structures. 
Some uncertainty regarding these results stems from the somewhat untypical 
microbiological status of our sample set, namely the high proportion of Propionibacterium 
acnes-culturepositive tissue samples. Propionibacterium acnes is a common skin-derived 
contaminant in these cultures, and traditionally, Propionibacterium is thought to cause 
actual hip-replacement infections only rarely. This view is, however, somewhat 
challenged by recent reports describing Propionibacterium as a important  and previously 
under-diagnosed agent causing hip replacement infections (Zeller et al 2007, Butler-Wu et 
al 2011, Perry et al 2011). The nature of Propionibacterium acnes-culture- positive 
findings in our sample set thus remains uncertain, but regardless of the evident possibility 
of false-positive results for bacterial cultures, no clear difference was detectable in the 
histological picture between infective agents. 
The  number  of  neutrophils  in  the  interface  tissue  has  served  as  a  relatively  useful  
histopathological marker of low-grade implant-related infection (Lonner et al 1996, Pace 
et al 1997, Della Valle et al 1999, Banit et al 2002, Francés Borrego et al 2006, Bori et al 
2007, Nuñez et al 2007, Kanner et al 2008). Likewise, an increased number and 
65 
 
proportion of neutrophils in joint fluid aspirates has successfully served as a preoperative 
marker of implant-related infection (Spangehl et al 1999, Trampuz et al 2004, Ghanem et 
al 2008, Schinsky et al 2008, Cipriano et al 2012). The sensitivity and specificity of these 
methods have been extensively evaluated, whereas the usefulness of lymphocyte infiltrates 
in the histopathological diagnosis of implant-related infection has undergone only limited 
evaluation (Athanasou et al 1995, Pandey et al 1999). Similarly, reports evaluating the 
proportion of lymphocyte subpopulations in preoperative joint-fluid aspirates of suspected 
joint replacement infections are scarce (Niki et al 2006). This is a relevant lack of 
knowledge, as in theory, lymphocytes—especially B cells and plasma cells—would seem 
like ideal marker cells for implant-related infection; B cells and plasma cells are only 
rarely seen in aseptic interface tissues, likely do not participate in development of foreign-
body reaction, and are classical, long-lived, markers of chronic inflammation. Thus, for 
detecting low-grade, implant-related infection that releases bacteria only periodically, such 
lymphocyte subpopulations might be better suited than are the neutrophils classically 
associated with acute, ongoing inflammation. 
Aseptic loosening has traditionally been considered as primarily driven by innate 
immunity and by macrophages in particular. Conversely, the role of lymphocytes, and of 
the adaptive immunity response in general, in the pathogenesis of aseptic loosening is 
somewhat controversial and not well established. Activation of adaptive immunity 
requires that a specific antigen, processed and bound to MHC II, is presented to T cells in 
a local lymph node by matured dendritic cells that express sufficient numbers of co-
stimulatory molecules. As it seems very unlikely that foreign-body particles could 
function as antigens that can stimulate T-cell activation, some other foreign-body reaction-
related antigen should be mediating this process, assuming that T cell activation is 
assumed or observed. One possibility is that danger-signal molecules suspected to be 
concentrated on particle surfaces could function as such antigens. PAMPs would more 
likely be involved than alarmins, because self-molecules should generally not evoke any 
T-cell response. The route from the particles’ surface-bound PAMP to MHC II still seems 
somewhat complex. Furthermore,  if  PAMPs were to effectively function as antigens and 
elicit a T-cell response, B cell activation would also be assumed. Based on this purely 
theoretical consideration, therefore, participation of the T cell in the foreign-body reaction 
seems unlikely. 
Indeed, studies investigating the role of T cells in aseptic loosening generally have 
not found strong support for their role in its pathogenesis (Goodman 2007). For example, 
lymphocyte-derived marker cytokines, IL-2, IFN?, or IL-4, are not uniformly found in the 
interface tissue; wear particles do not evoke T cell activation in co-cultures; and in mice 
models, the extent of osteolysis or observed foreign body reaction is independent of the 
existence of lymphocytes (Santavirta et al 1991, Goodman et al 1994, Jiranek et al 1995, 
Li et al 2001, Taki et al 2005, Rodriguez et al 2009).  On the other hand, most studies 
investigating the cellular constituents of aseptic interface tissue have reported scattered T 
lymphocyte infiltrates, similar to ones observed in the current study, in the majority of 
cases.  One estimate is that T cells can account for as much as 10% of the cellular 
constituents of the interface tissue (Baldwin et al 2002, Arora et al 2003). Another claim is 
that the majority of these are activated Th1 cells and that they support macrophage 
activation. These results are inconclusive, however, as other studies contradict them; the 
ultimate relevance of these T-cell infiltrates remains still to be determined (Goodman 
2007). However, in the case of metal particles and ions released primarily from metal-on-
metal implants, activated T cell infiltrates are more constantly seen and also are suspected 
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to play a larger role by participating in a cell-mediated hypersensitivity reaction against 
metal particles (Hallab et al 2001). 
In contrast to T cells, B cells and plasma cells are detectable in only a minority of 
cases of aseptic loosening, and the role of plasma cells and antibodies in the pathogenesis 
of aseptic loosening is generally not considered significant (Goodman et al 1989, 
Santavirta et al 1990, Jiranek et al 1993, Kim et al 1993, Goodman et al 1998, Pandey et al 
1999).  Indeed, B cell maturation into plasma cells is a complex and multistep process that 
requires not only specific antigen recognition by the B cell receptor, but also a subsequent 
second  activating  signal  from  dendritic  cell-activated  T-helper  cells.  Thus  the  role  of  B  
cells  in  the  pathogenesis  of  aseptic  loosening  seems  even  more  unlikely  than  that  of  T  
cells. 
As indicated by our results, however, B cells and plasma cells are clearly present in 
septic interface tissues, likely because living bacteria contain an abundance of potential 
lymphocyte-activating antigens. Once phagocytosed and disintegrated by antigen-
presenting cells, these are sufficient to cause full-blown activation of the adaptive immune 
system, including activation of T cells and maturation of B cells into antibody-producing 
plasma cells.  In this regard, it is tempting to speculate that the presence of CD20+ B cells 
and mature plasma cells reported in some of the aseptic interface tissues might, in fact, 
indicate a subclinical biofilm-hidden infection that is mostly quiescent but occasionally 
releases bacteria. These bacteria cause intermittent activation of innate and adaptive 
immune systems which then clear the invading pathogen but also release osteolytic 
cytokines leading to implant loosening. Once an outburst of infection is controlled, short-
lived neutrophils go into apoptosis and are removed by macrophages, whereas local B 
cells and plasma cells, with potentially longer life-spans, remain. 
Although this hypothesis arising from current observations is tempting, it is largely 
not supported by the existing literature. The few studies that have investigated the 
feasibility of lymphocyte infiltrates in histopathological detection of implant-related 
infection have reported sensitivities lower than those achieved with detection of neutrophil 
infiltrates (Athanasou et al 1995, Pandey et al 1999). Likewise, analysis of lymphocyte 
subpopulations in the preoperative joint fluid aspirates is not useful in detecting knee 
replacement-related infection (Niki et al 2006). Data in this field is, however, limited, and 
further studies are warranted to explore the possibility that analysis of lymphocyte 
subpopulations in either histological samples or aspirated preoperative joint fluid might be 
useful in diagnosis of low-grade implant-related infection. 
 
9.1.2. TLR expression and cell localization in aseptic interface tissue 
We analyzed the presence and cell distribution of different TLRs in control synovial 
membranes and in aseptic and septic interface tissues, by use of  antibodies specific for 
these different TLRs. Additionally, we evaluated TLR expression in control synovial 
membranes and in aseptic interface tissues with qRT-PCR. In control synovial tissues, 
TLR immunoreactivity was concentrated on some of the synovial lining cells, likely 
representing type A macrophage-like lining cells, vascular endothelium, and on occasional 
resident macrophages and fibroblasts in tissue stroma. Osteoarthritic synovial tissue is 
thus well equipped to recognize and react to possible foreign pathogens. Furthermore, 
TLR presence, especially RNA- and DNA-recognizing TLR3, TLR7, and TLR8 in 
synovial membrane, might also be relevant to the pathogenesis of autoimmune arthritis. In 
septic synovial tissues, macrophages and neutrophils accounted for most of the TLR 
immunoreactivity observed. 
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In comparison to control synovial tissues, the number of TLR immunoreactive cells 
was roughly doubled in aseptic interface tissues. The most apparent reason for this was the 
considerable macrophage infiltrates that accounted for most of the TLR immunoreactivity 
in the aseptic interface tissues. Despite the obviously increased number of TLR 
immunoreactive cells in the aseptic interface, the difference in number of TLR+ cells did 
not reach statistical significance, likely due to the small number of samples investigated. 
However, in qRT-PCR analysis, utilizing a larger sample set, all TLRs, excluding TLR3 
and TLR7, were significantly up-regulated in aseptic interface tissues when compared to 
their corresponding expression levels in control synovial membrane. 
The sample set for the qRT-PCR analysis was validated by quantifying the 
expression levels of several chemokines previously linked to the pathogenesis of aseptic 
loosening (Goodman 2010). Increased production of the chemokines IL-8, CCL2, CCL3, 
and to a lesser extent, CCL4 in aseptic interface tissue has been reported in several earlier 
studies and is further confirmed by ours. These chemokines are also typically observed 
products of macrophages stimulated by various types of particles in vitro.  Somewhat 
surprisingly, RANKL expression levels in the aseptic interface were low and did not differ 
from control synovial membrane levels, whereas OPG was significantly down-regulated in 
aseptic interface tissues. Although these findings contradict some previous findings of 
elevated RANKL levels and unchanged OPG levels, the resulting RANKL/OPG ratio still 
would seem to favor osteoclastogenesis. Similar results have also been reported 
(Koulouvaris et al 2008) Accordingly, the expression of osteoclast markers tartrate-
resistant acidic phosphatase (TRAP) and catepsin K (CTSK) was strongly elevated in 
aseptic interface tissues, indicating active osteoclast formation in aseptic interface tissue. 
 Increased expression of TLRs in the interface tissue and their localization to 
infiltrating macrophages does not by any means convincingly show that TLRs mediate 
wear-particle-induced macrophage activation. This, however, at least indicates that 
infiltrating macrophages are expressing and even actively producing most of the TLRs; it 
suggests that these macrophages are well capable of recognizing danger signals in the 
interface tissue. Considering that some of the wear particles’ inflammatory properties have 
been attributed to the bacterial structural components adhering to particle surfaces, and 
that TLRs generally mediate the recognition of such bacterial products, it seems likely that 
TLRs are involved in the recognition of PAMP-opsonized wear particles and in 
subsequent macrophage activation. 
In this regard, especially noteworthy is the increased expression of TLR1, TLR2, 
TLR4, TLR6, and TLR9 in the interface tissues.  These receptors recognize PAMPs that 
may most likely occur in the interface tissue including LPS (TLR4), gram-positive 
bacterial biofilms (TLR2/1, TLR2/6, TLR2, TLR9), and other gram-positive bacterial 
products possibly finding a route into interface tissue via the circulation.  Endogenous 
TLR2 and TLR4 ligands have been identified, and thus one possibility is that these 
alamins as well—released by local cell necrosis and extracellular matrix fragmentation—
may adhere to wear-particle surfaces, mediating particle recognition and a subsequent 
macrophage activation. 
The significance of increased production of TLR5 and TLR8 in interface tissue 
remains undetermined, but might, like the active upregulation of other TLRs, indicate a 
shift in macrophage polarization towards the M1 phenotype. Interestingly, the two TLRs 
not up-regulated in aseptic interface tissue, TLR3 and TLR7, recognize viral-derived 
ssRNA structures and thus probably do not participate in recognition of wear particles. 
The apparent discrepancy between the immunohistochemical staining and qRT-PCR 
results in the expression of these two TLRs might result from the fact that macrophages 
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express some basal level of these two TLRs, as indicated by immunohistochemistry, but 
they are not induced to produce them further, as indicated by the qRT-PCR. 
Direct, functional evidence that TLRs are involved in wear-particle recognition is 
emerging. Maitra et al (2008) showed that modified alkane polymers, released from 
UHMWPE and oxidized by interface tissue cells, can directly and specifically bind to 
TLR2 and TLR2/1 dimers and activate pro-inflammatory signaling as indicated by 
activation of NF-?B. Schmidt et al (2010) demonstrated that nickel ions are directly 
recognized by TLR4. Similarly, a 2012 report by Tyson-Capper et al shows that clinically 
relevant concentrations of cobalt ions, commonly released from metal-on-metal implants, 
can directly bind to and activate TLR4 signaling. Together these studies demonstrate that 
inorganic materials can, in some instances, be directly recognized by TLRs. 
 Pearl et al (2011) showed that knockout mice lacking the TLR adaptor protein 
MyD88 were highly resistant to PMMA particle-induced osteolysis and experienced no 
bone loss, whereas wild-type mice exhibited  a roughly 15% decrease in local bone 
volume during a 10-day follow-up. Likewise, in macrophages isolated from the bone 
marrow of these mice lacking MyD88, PMMA particle-induced TNF? production was 
half the TNF? production of PMMA-particle-stimulated macrophages isolated from wild-
type mice. Similarly, reduced TNF? production in particle-stimulated RAW 264.7 cells 
occurred if an MyD88-specific inhibitor was added to the culture system. Furthermore, at 
least during the 12-hour culture system, TNF? production was not dependent on the 
existence of TLR-adaptor TRIF; macrophages from TRIF knockout mice responded to 
particle stimulus with actually increased TNF? production, possibly due to compensatory 
up-regulation of TLRs and their intracellular signaling molecules in these knockouts.  
The results of Pearl et al suggest that the MyD88-dependent pathway and associated 
TLRs are directly involved in the pro-inflammatory responses elicited by PMMA 
particles,  and  that  at  least  in  this  relatively  short-duration  culture  system,  the  TRIF-
dependent pathway does not seem to play a role.  The in vitro results were unaffected by 
PMMA-particle  LPS contamination,  because  similar  results  occurred  with  Polymyxin  B,  
an effective LPS-binding agent. However, the in vitro culture system apparently contained 
proteins (10% FBS); and naturally in the mouse model of particle-induced osteolysis used, 
a plentitude of potential DAMPs, both endo- and exogenous, are present and available to 
bind to particle surfaces and mediate their recognition. What thus cannot be concluded is 
that TLRs bind to and recognize PMMA particles directly without any DAMP 
involvement. Moreover, although TNF? production in particle-stimulated MyD88-
deficient macrophages was reduced to half, these macrophages still produced considerable 
amounts of TNF?, indicating that some other mechanisms are still able to mediate particle 
recognition. Furthermore, we must note that disrupting MyD88 not only affects the TLR 
signaling but also impairs the IL-1 signaling pathway (O’Neill 2008). This adds some 
uncertainty to the results of the Pearl study, as IL-1? is an essential pro-inflammatory 
mediator of particle-induced inflammation; for example in caspase-1 knock-out mice, 
genetically unable to produce IL-1?, osteolysis is reduced in a mouse calvarian model of 
particle-induced inflammation (Burton et al 2012). On the other hand, these results by the 
Burton group also must  be interpreted cautiously, because caspase 1 is required for the 
activation  of  MAL and is  thus  required  for  the  activation  of  pro-inflammatory  signaling  
via TLR2 and TLR4 (Miggin et al 2007).  
Greenfield et al (2010) studied the role of TLR2 and TLR4 in the recognition and 
osteolysis caused by bacterial product-contaminated titanium particles. Using a mouse  
calvarial  model  of  particle-induced  osteolysis  similar  to  that  of  Pearl  et  al,  and  TLR2-/-, 
TLR4-/-, and TLR2-/-/TLR4-/- knockouts, as well as wild-type control mice, the Greenfield 
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group showed that the magnitude of osteolysis caused by titanium particles was about 5% 
greater at day 7 if particles are contaminated with PAMPs (either with LTA or LPS) and 
that this effect is dependent on the existence of their corresponding receptors TLR2 or 
TLR4. Concurrent results came from their in vitro experiments in which bone marrow 
macrophages isolated from these mouse strains and challenged with titanium particles up-
regulated TNF? mRNA expression if LTA- or LPS-contaminated particles and the 
corresponding receptors TLR2 and TLR4 were also present on the macrophages. In 
contrast to results by Pearl et al, LTA- or LPS-free particles caused no detectable TNF? 
mRNA production. Interestingly, however, the amount of osteolysis caused by titanium 
particles that were not contaminated with LTA or LPS was similar in both wild-type mice 
and TLR knockouts, demonstrating that the recognition of, and osteolysis caused by, 
titanium particles without bacterial contamination is not mediated by TLR2 or TLR4. This 
somewhat contradicts the findings of the Pearl group. Furthermore, although bacterial-
product contamination raised osteolysis by about 5 percentage points, titanium particles 
without contamination also caused a clear osteolytic reaction.  
Although fascinating, the study by Greenfield et al reflects the shortcomings of the 
PAMP hypothesis of wear-particle recognition. The majority of the studies supporting the 
role of bacterial products in wear-particle recognition have followed the logic that wear 
particles with bacterial products cause more osteolysis in vivo, or more release of 
inflammatory mediators from macrophages in vitro, than do wear particles without 
bacterial contaminants (Ragab et al 1999, Daniels et al 2000, Bi et al 2001a, 2001b, 2002, 
Cho et al 2002, Brooks et al 2002). However, as LPS and also LTA are some of the most 
potent activators of the macrophages yet known, it seems somewhat obvious that particles 
contaminated with these products induce stronger reactions than do particles without 
them. Furhermore, wear particles of various natures clearly have inflammatory and 
osteolytic properties that are independent of PAMP, and perhaps also alarmin binding. 
The fundamental question is thus to what extent are these PAMPs present in the aseptic 
interface tissue? As PAMPs seem to be present in the interface tissues in at least some 
instances, it seems likely that at least in such cases, TLR-mediated wear-particle 
recognition and macrophage activation seems likely. 
The discrepancy between the studies of Pearl et al indicating that MyD88 adapter is 
required for full, bacterial-product-free, PMMA particle-induced responses and Greenfield 
et al’s indicating that TLR2 (and thus probably also TLR2/1 and TLR2/6 receptor 
dimmers) or TLR4 are not required for full, bacterial-product-free, titanium-particle-
induced responses is intriguing. This discrepancy could have many explanations starting 
from the different material of the particles. An observation similar in both studies, mainly 
that particle-induced osteolytic responses were reduced but not completely abolished by 
disruption in TLR signaling, is, however, perhaps even more noteworthy. It thus seems 
that wear particles as such have some TLR-signaling-independent inflammatory properties 
which are further enhanced if exo- or endogenous DAMPs bind to the particle surface. 
This is likely the case in all in vivo systems, in which implanted biomaterials are 
immediately covered by a layer of host proteins and may also accumulate foreign bacterial 
products. We thus concluded that it is possible that TLRs are involved in wear-particle 
recognition, either by directly binding to the particles’ polymeric surface, but probably 
more often via recognition of either exo- or endogenous DAMP molecules adhering to the 
particles’ surfaces. The TLRs most clearly implicated in this process are TLR2 and 
TLR2/1, TLR2/6 dimers, and TLR9 as well as TLR4. The expression of all these receptors 
was increased in the interface tissue, and they localized to macrophage infiltrates. 
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9.2. TLR regulation as a response to titanium-particle stimulus (III) 
 
TLR regulation as a response to titanium-particle stimulus we investigated both in 
vivo, with a mouse intramedullary model of particle-induced inflammation, and in vitro, 
with a mouse monocyte/macrophage cell line challenged with titanium particles.  
The results of the in vivo experiment were somewhat surprising and their meaning 
difficult to interpret. On the control side, the number of TLR immunoreactive cells 
declined between the second and tenth week, likely reflecting physiological resolution of 
the surgical trauma-caused inflammatory reaction and possibly even reflecting the 
associated shift in the local macrophage activation state from the pro-inflammatory M1 
phenotype towards the M2 phenotype, and subsequent reduction in TLR numbers. 
Surprisingly, the number of TLR immunoreactive cells was generally reduced on the 
side  that  received  titanium  particles,  a  phenomenon  observed  both  two  and  ten  weeks  
post-operatively. The reason for this TLR down-regulation in the particle group remains 
somewhat elusive. One possibility is that the initial, strong inflammatory reaction caused 
by titanium particles leads to rapid down-regulation of the TLR system in order to limit 
the collateral damage from unrestrained inflammation. Indeed, studies using the same 
model system have reported a clear inflammatory reaction at two weeks after implantation 
on the particle side with increased production of CCL2, IL-6, and M-CSF (Warme et al 
2004). Moreover, a periprosthetic membrane composed of fibroblasts and macrophages 
developed in about half of the cases that received titanium particles.  Development of bone 
erosions also occurred, as well as bone remodeling. It is thus possible that the rapid down-
regulation of the TLR system on the particle side was due to an initially stronger 
inflammation reaction. 
Still, results of the in vivo experiment are somewhat difficult to interpret. As shown 
here, the aseptic interface tissue and foreign body reaction is characterized by an increase 
in the number of TLR-positive cells and evident up-regulation of TLR expression rather 
than by a reduction in the number of TLR-positive cells or TLR down-regulation. One 
possible explanation for this discrepancy between the model system and the patient 
samples stems fom the limitations of the model system.  In contrast to the clinical situation 
where a continuous load of wear particles is released in the interface tissues, the titanium 
particles in the mouse model were delivered in single application. Using cultured human 
macrophages challenged in vitro with a single application of PMMA or titanium particles 
for nine days, Koulouvaris et al (2008) have shown that the expression of one possible M2 
macrophage marker, chitinase 1, was up-regulated during the 9-day follow up, and 
concluded that long-term particle exposure would cause M2 rather than M1 macrophage 
polarization. Although these results are hardly conclusive, one possibility is thus that in 
the current experimental setting, also, one using single-dose and long-term particle 
exposure, particles had been, after a short inflammatory reaction, effectively contained in 
endosomes of macrophages that had assumed an M2-like phenotype and that this was 
reflected in the generally reduced TLR  levels. 
One additional possibity for this discrepancy in TLR regulation between the clinical 
setting and the mouse model system is that the reaction to the pure titanium particles 
might differ considerably from the UHMWPE or PMMA particles that are most prevalent 
in the clinical setting. Indeed, an otherwise similar mouse model system, but one utilizing 
UHMWPE particles instead of titanium particles, found a more clear-cut formation of 
macrophage infiltrates and giant cells as well as bone erosion, possibly resembling more 
closely the situation in human interface tissue (Epstein et al 2005). 
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In our macrophage culture system, the LPS-free titanium particles showed no effect 
on TLR mRNA expression during the 24-hour particle stimulation. Few studies have 
investigated TLR regulation in macrophages challenged with wear particles. Using 
cultured rat bone marrow macrophages, Takagi et al (2007) have shown that TLR4 and 
TLR9 mRNA levels were significantly down-regulated to about one-third their initial 
expression level after 3 hours of titanium-particle stimulation. Testing for possible LPS 
contamination of the particles used in the study by Takagi et al was not reported, so what 
cannot be definitively concluded is whether the TLR down-regulation observed was due to 
the effect of titanium particles alone. Indeed, using a similar rat bone-marrow-derived 
macrophage culture system. Hirayama et al (2011) showed that if titanium particles 
contained LPS, TLR4 and TLR9 mRNA levels were down-regulated more rapidly, 
although pure titanium particles seemed also to cause an eventual decline in the levels of 
these TLRs during 12-hour follow-up. In contrast, TLR2 mRNA levels were up-regulated 
and TLR5 levels unaffected by stimulation with LPS-containing particles. In experiments 
by Pearl et al (2011), PMMA-particle stimulus was associated with relative down-
regulation of all TLRs, and of some of their intracellular signaling mediators in MyD88-/- 
knockout mice- derived macrophages, whereas in TIRF-/- knockout macrophages,  this 
effect was abolished. 
The wider meaning of these in vitro macrophage stimulation results remains to be 
determined. Based on current knowledge, we conclude that at least in the in vitro setting, 
wear-particle stimulus seems to cause only subtle changes in TLR levels and perhaps 
preferably down-regulation rather than up-regulation of TLRs, especially if particles are 
contaminated with bacterial products. This phenomenon is consistent with the negative-
feedback loops typical of TLR signaling and is probably altered by factors inducing the 
full M1 macrophage phenotype. It can thus be further concluded that, at least based on 
results obtained from TLR regulation studies, particles without bacterial-product 
contamination cause only minimal activation of the TLR system, because  the negative 
feedback mechanisms are not engaged by LPS-free particles. What thus seems likely is 
that what is responsible for the up-regulation of TLR in interface tissues is other factors 
and signals derived from the peri-implant microenvironment, rather than any direct effect 
of the wear particles or contaminating PAMPs.  
 
9.3. Effect of macrophage polarization on wear-particle responses (IV) 
 
To assess the effect of macrophage polarization on macrophage wear-particle 
responses, we produced M0, M1, and M2 macrophages and stimulated them with LPS-
free titanium particles. These macrophages’ response to stimulation was evaluated and 
compared by genome-wide microarray analysis, qRT-PCR, and a protein suspension 
array. Gene ontology and signaling pathway analyses allowed further analysis of the 
possible biological significance of the gene- expression changes. Furthermore, 
macrophage-polarization-induced changes in cell morphology, motility, and phagocytotic 
activity we evaluated by means of time-lapse phase contrast microscopy.  
We found that macrophage wear-particle responses were greatly influenced by 
macrophage polarization state, because each of the macrophage types responded to wear-
particle stimulus with a unique profile of transcriptome and proteome changes. In 
comparison to M0 macrophages, the overall inflammatory and chemotactic response to 
wear particles was enhanced in M1 macrophages, as indicated by GO and SPIA as well as 
by detailed examination of the trascriptome and proteome changes.   
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In addition to production of cytokines (TNF?, IL-1?, IL-6), chemokines (IL-8, 
CCL3) and growth factors (GM-CSF) previously recognized as playing a role in the 
pathogenesis of aseptic loosening,  our wide screening methods made it  possible to 
identify several novel, potentially osteolytic cytokine mediators from M1 and to a lesser 
extent M0 wear-particle response. These factors, including OSM, TNFSF9, TNFSF14, 
CXCL2, CCL20, CCL4, CCL7, IL-7, sCD40L, FLT 3 ligand, G-CSF, and FGF-2 support 
osteoclast formation or function in other settings but have not yet been linked to the 
foreign-body response (Lean et al 2001, Abe et al 2002, Palmqvist et al 2002, Shimoaka et 
al 2002, Nakano et al 2004, Yu et al 2004, Hui et al 2005, Lee S et al 2005, Edwards et al 
2006, Lee H et al 2006, Hirbe et al 2007, Lisignoli et al 2007, Yang et  al 2008, Ishida et 
al 2009, Ha et al 2010, Walker et al 2010, Guihard et al 2012) These mediators are thus 
interesting topics for further studies and novel targets for therapeutic interventions. 
In contrast, all these wear-particle responses were effectively suppressed in M2 
macrophages, which seemed to respond to particle stimulus with only sporadic 
trascriptome changes that formed no functional groups. Still, the M2 macrophages actively 
moved around the culture dish and effectively phagocytosed titanium particles; the 
conclusion thus is that M2 macrophages effectively constrained wear particles into 
intracellular compartments without any inflammation reaction. 
A similar phenomenon emerged from  Trindade et al (1999a, 1999b), who showed  
that IFN? pre-treatment enhances the production of TNF? and IL-6 from human 
monocytes stimulated with PMMA particles and that IL-4 pre-treatment suppresses the 
production of TNF?, IL-1?, and GM-CSF from PMMA-particle-stimulated human 
monocytes when compared to non-treated monocytes. Im and Han (2001) showed a 
similar suppressive effect of IL-4 pre-treatment on production of TNF? and IL-6 from 
human monocytes stimulated with titanium-alloy particles. Likewise, a very recent study 
by Rao et al (2012) demonstrated that IL-4 administration even after the particle stimulus 
reduces production of TNF? from isolated mouse bone marrow macrophages stimulated 
with PMMA particles with or without LPS. This phenomenon was more clear-cut in the 
PMMA+LPS  group,  likely  due  to  a  more  prominent  inflammatory  reaction  due  to  LPS  
presence, but reduction in production of TNF? occurred in both groups. Additionally, the 
results of Rao et al demonstrate that sequential modulation of a macrophage phenotype, 
from the LPS-induced M1-like phenotype to the IL-4-induced M2-like phenotype, 
successfully reduces PMMA particle-induced TNF? production. 
In addition to IL-4, also IL-10 and IL-1ra can reduce wear-particle-induced 
inflammatory responses.  Both Pollice et al (1998) and Trindade at al. (2001) 
demonstrated the IL-10s’ ability to diminish TNF? and IL-6 production from PMMA- and 
titanium particle-stimulated cultured human monocytes; Im and Han (2001) demonstrated 
a similar phenomenon by using titanium alloy particles. Yang et al (2004) demonstrated—
in a mouse air-pouch model of particle-induced osteolysis—the ability of both IL-10 and 
IL-1ra gene transfer to effectively mitigate UHMWPE particle-induced inflammation and 
the accompanied osteolysis.  
These studies, consistent with the current results, provide clear evidence of the 
principle that modulation of the macrophage activation state in the interface tissue, either 
with biomaterial solutions or pharmacologically, might serve as a useful means to reduce 
the inflammatory and osteolytic reaction resulting from unavoidably forming wear 
particles.   Similarly,  results  suggest  that,  at  least  in  a  cell-culture  setting,  wear  particles  
cause only limited macrophage activation, and that their pro-inflammatory properties are 
at least partially dependent on prevailing micro-environmental conditions. Here, the 
phenomenon  was  modeled  with  IFN?,  but  the  principle  is  possibly  expandable  to  
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encompass other M1-inducing factors that might be present in the interface tissue such as 
bacterial biofilms or exo- or endogenous danger signal molecules adhering to wear-
particle surfaces. Indeed, LPS typically used as a model of wear-particle-adhering PAMP 
causes, via recognition by TLR4 and the subsequent TIRF-dependent signaling pathway, 
the production of type-1 interferons and thus an M1-like macrophage phenotype via auto- 
and paracrine signaling. Additionally, balance of M-CSF and GM-CSF, which induce M2 
and M1-like macrophage phenotypes, might be a similarly important factor in determining 
macrophages’ wear-particle responses. The extent to which wear particles cause 
inflammation and osteolysis may thus be dependent on the local balance of M1- and M2- 
inducing factors; modulation of this balance might provide a novel target for therapeutic 
interventions. 
An interesting hypothesis raised by the current results is that in addition to local 
micro-environmental factors, systemic factors such as chronic low-grade systemic 
inflammation and the accompanying chronic production of inflammatory cytokines, 
associated with atherosclerosis, metabolic syndrome, and periodontitis, may be important 
in determining the M1/M2 balance of macrophages in the interface tissue, and thus in the 
mode by which the host reacts to the inevitably forming wear particles (Pischon et al 
2007, Rocha et al 2009, Gregor et al 2011). Indeed, Gordon et al (2010) have 
demonstrated that peripheral blood monocytes isolated from subjects with previous aseptic 
THR loosening isplayed increased production of several inflammatory cytokines and thus 
a more M1-like phenotype in response to LPS stimulation than did monocytes isolated 
from subjects developing no hip replacement loosening. Gordon et al conclude that the 
innate immune system of patients experiencing aseptic THR loosening is genetically more 
reactive. An equally plausible explanation is that these results reflect the underlying 
inflammatory status of the system and a correspondingly increased macrophage-activation 
state. Yet another possibility is that the inflammation at a systemic level or in interface 
tissues leads to an increased proportion of circulating inflammatory CD14+CD16+ 
monocytes that, once migrated into interface tissue, preferably differentiate into 
inflammatory M1 macrophages. This systemic inflammation may be one answer as to why 
only a relatively small proportion of THR recipients eventually develop aseptic loosening. 
Similarly, controlling the systemic inflammation might be one means to limit wear-
particle-induced osteolysis. Indeed, HMG-CoA reductase inhibitors (statins) that, in 
addition to their intended effects on cholesterol metabolism have pleiotropic anti-
inflammatory properties, can reduce macrophage activation and wear-particle-induced 
osteolysis both in model systems and in clinical trials (von Knoch et al 2005, Laing et al 
2008, Thillemann  et al 2010). 
These phenomena may also provide some insight into the mechanisms of wear-
particle recognition and induced inflammation. SPIA analysis suggests that TLR- or 
NOD-like receptor signaling is involved in the wear-particle response of M1 
macrophages. This must  be interpreted cautiously, however, as only the end products 
(including inflammatory cytokines and chemokines  due to NF-?B and AP-1 activation) of 
these receptor-signaling pathways were enriched into GO and SPIA analyses. It is thus 
quite possible that activation of these transcription factors is mediated by some other, 
perhaps unknown, particle-recognition pathway. On the other hand, the up-regulation of 
the TLR system in M1 macrophages may well be one factor that enhances these cells’ 
wear-particle responses, although other IFN? effects, such as complex and various 
synergistic interactions between STAT1 and NF-?B pathways, or suppressed production 
of IL-10, may also explain the increased responsiveness of M1 macrophages to wear 
particles (Schroder et al 2006).  
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Assuming TLR involvement in wear-particle recognition, it is then interesting that 
wear-particle stimulation did elevate production of pro-inflammatory chemokines and 
cytokines; this suggests the activation of the MyD88-dependent signaling pathway and 
associated TLRs, culminating in the activation of AP-1 and NF-?B. In contrast, wear 
particle stimulus led neither to production of IFN-?2, nor to production of any other type-I 
interferon, thus excluding the TIRF-dependent pathway culminating in the activation of 
IRF3.  
In addition to these TLR-signaling pathways, the wear-particle-induced production 
of IL-1? suggests inflammasome activation, perhaps via particle-induced endosomal 
damage and cell stress as described previously (Maitra et al 2009, Burton et al 2012). One 
possibility is thus that, in addition to, or instead of TLR signaling, wear-particle-induced 
NF-?B activation is initially mediated via endosome damage, subsequent inflammasome 
activation, and the following auto- and paracrine IL-1? signaling.  
Suppression of the inflammatory response in M2 macrophages is likely mediated by 
general suppression of the TLR signaling and inflammatory response in these cells via 
inhibition of NF-?B and STAT signaling by the up-regulation and action of PPAR?. M2 
macrophages also effectively produced IL-10 and IL-1ra that likely further inhibited their 
wear-particle-induced responses. 
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10. Summary and conclusions 
 
During  the  previous  decade,  the  strict  dichotomy  between  the  two  major  
complications of otherwise very successful THR surgery, namely septic and aseptic hip 
replacement loosening, has been increasingly questioned. For instance, subclinical 
bacterial biofilms occur in at least in some cases of apparently aseptic implant loosening. 
Likewise, pro-inflammatory and osteolytic properties of wear particles depend at least 
partially on the presence of bacterial components adhering to their surfaces. These 
observations lead to the hypothesis that recognition of bacterial-product-coated wear 
particles and subsequent activation of interface tissue macrophages into the inflammatory 
phenotype might be mediated by macrophages’ TLRs. Thus, the extent to which the 
various TLRs are present and how they localize in the aseptic and septic interface tissues 
called for evaluation.  In addition, we evaluated the direct effect of wear particles on TLR 
levels in an animal model of wear-particle-induced inflammation and in a macrophage 
culture system. Moreover, in hopes of identifying cell populations potentially useful as 
diagnostic markers of subclinical implant-related infection, we evaluated cell populations 
present in typical septic and aseptic interface tissue. In addition, as immunological 
research indicates that the expression of TLRs and macrophages ability to produce 
inflammatory mediators is largely dependent on macrophage polarization, we further 
hypothesized that macrophage polarization might be an important determinant in the way 
that macrophages react to wear particles. 
 
The main conclusions of the study are: 
 
1) Macrophages of aseptic interface tissue express TLR1-9 and actively produce all of 
these  TLRs  except  TLR3  and  TLR7.  Based  on  the  literature,  what  seems  likely  is  that  
TLRs are involved in wear-particle recognition and subsequent macrophage activation. 
This may occur either by direct recognition of the particle’s polymeric surface or of metal 
ions released from the implant, but probably more often occurs via recognition of either 
exo-  or  endogenous  DAMP  molecules  adhering  to  the  particle  surface.  The  TLRs  most  
clearly implied are the ones recognizing bacterial and endogenous DAMP molecules, 
namely TLR2 and TLR2/1, TLR2/6 dimers, and TLR9, as well as TLR4. 
 
2) Comparison of inflammatory cell populations present in septic and aseptic interface 
tissues revealed that, in addition to neutrophils, B lymphocytes and plasma cells might be 
useful marker cells in the diagnosis of low-grade implant-related infection. Further studies 
are warranted to explore the possibility that analysis of lymphocyte subpopulations in 
either intraoperative histological samples or preoperative joint fluid aspirates might be a 
useful diagnostic tool for low-grade implant-related infection 
 
3) In a mouse model of particle-induced inflammation, wear particles led to down-
regulation rather than to up-regulation of TLR levels. They had no effect on TLR mRNA 
levels in a mouse macrophage culture system. The up-regulation of TLRs in aseptic 
interface tissue is thus likely mediated by factors other than the direct effect of wear 
particles on macrophages.  
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4) Macrophage polarization has a clear impact on macrophage wear-particle responses. In 
comparison to M0 macrophages, the inflammatory and chemotactic wear- particle 
response was enhanced in M1 macrophages but was effectively suppressed in M2 
macrophages which effectively contained particles in their intracellular compartments. 
Results suggest that in addition to wear-particle characteristics and DAMPs adhering to 
particle surfaces, the local cytokine milieu also determines the extent to which 
macrophages are activated by wear particles. This effect may be mediated by differing 
expression and regulation of TLRs or their signaling mechanisms among macrophage 
subtypes. The cytokine profile secreted by M1 macrophages implied a MyD88-dependent 
TLR-signaling pathway, suggesting the role of TLR2, TLR2/1, TLR2/6, or TLR9, rather 
than TLR4. The production of IL-1? implied inflammasome activation. A summary of the 
proposed mechanisms of aseptic ostelysis is presented in Figure 9. 
Figure 9. Proposed mechanisms of aseptic osteolysis. Wear particles are generated due to 
abrasion between THR components. Pressure waves of the pseudosynovial fluid 
effectively distribute these particles into surrounding interface tissue where they are 
phagocytosed by macrophages. Macrophages are activated to produce (1) pro-
inflammatory cytokines which directly enhance osteoclast formation and function. 
Furthermore, macrophage-derived inflammatory mediators enhance production of 
RANKL and suppress production of OPG from local fibroblasts and osteoblasts, so that 
the local RANKL/OPG ratio increases, favoring osteoclast formation and active bone 
resorption (2). Wear-particle-activated macrophages also produce (3) chemokines that 
recruit additional monocytes into interface tissue and (4) MMPs that degrade the local 
ECM. The extent to which wear particles cause macrophage activation appears to be 
dependent not only on wear-particle characteristics or DAMP molecules adhering to 
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particle surfaces but also on the local cytokine milieu determining the macrophage 
polarization state. PAMPs are released into the circulation from body surfaces, for 
example from chronic inflammation in periodontal tissue (5), and these hydrophobic 
molecules accumulate on wear particles, owing to their great surface area (6). Additional 
possible PAMP sources include subclinical bacterial colonization of the implant surface 
(7). Futhermore, endogenous alarmins released due to cell necrosis (8) and ECM damage 
(9) may adhere to wear-particle surfaces. DAMP-coated wear particles are then recognized 
by macrophages via TLRs. TLR signaling causes macrophage activation and possibly M1-
type macrophage polarization and production of pro-inflammatory cytokines, ultimately 
leading to osteoclastogenesis. Additionally, wear-particels can induce production of GM-
CSF that causes further M1-type macrophage activation. Limiting the action of M1-
polarizing factors and perhaps also promoting M2 macrophage polarization may be a 
means to control this sequence of events. The emerging hypothesis that low-grade 
inflammation at systemic level,  and the accompanying  release of low  levels of 
inflammatory cytokines from adipose tissue (10), atherosclerotic plaques (10), or 
periodontal tissue (10) may  be a determinant for  the general systemic M1-M2 balance of 
macrophages, or possibly for the levels of circulating monocyte subpopulations. Therefor 
they may influence the individual mode by which macrophages react to wear particles, a 
process that warrants further investigation. THR - total hip replacement; RANKL - 
receptor activator of nuclear factor kappa B ligand;  OPG - osteoprotegerin;  ECM - 
extracellular matrix;  MMP - matrix metalloproteinase; DAMP - danger-associated 
molecular pattern; PAMP - pathogen-associated molecular pattern; TLR - toll-like 
receptor;  GM-CSF - granulocyte-macrophage colony-stimulating factor. Illustration by 
Helena Schmidt. 
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